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Chapter 1:
COMPUTATIONAL METHODS &
LIFE SCIENCES
1.1. Introduction:
The convergence of Life Sciences and Informatics/Computer Science is rapidlytransforming our ability to understand and positively influence our lives and the worldaround us. The intertwining of basic science with applied fields such as biomedicalengineering and robotics is the first stage of a knowledge revolution that will lead toremarkable advances of great societal importance [1].
1.1.1 The Three Pillars of Computational and Life Sciences (CLS)CLS seeks to capture new intellectual frontiers by integrating three diverse pillars ofmodern scientific discovery [2-4]:
1.1.1.1 Computational Science & Informatics:Computational Science & Informatics modeling, simulation, high-endcomputing/data analysis, for information-based knowledge discovery and synthesis.Algorithms, database theory, statistics, numerical methods, and systems design form coreelements of CLS.
1.1.1.2 Synthetic Sciences:It’s combining design, construction and engineering in physical sciences withmolecular biology leads naturally to a synthetic biology; an approach that spans syntheticchemistry and condensed matter physics to exploit adaptive evolutionary principles for thegeneration of new functional materials, molecular machines and therapeutics.
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1.1.1.3 Systems Biology:It holistic exploration of living systems across multiple scales, from molecular tocellular, organ, individual and population. High-throughput, quantitative technologies willunderpin a network-level understanding of interacting components, enabling a predictivescience that unifies and enriches CLS.
1.2 Computational Science:
It is the field of study concerned with constructing mathematical models andnumerical solution techniques and using computers to analyze and solve scientific, socialscientific and engineering problems. In practical use, it is typically the application ofcomputer simulation and other forms of computation to problems in various scientificdisciplines.The field is distinct from computer science (the mathematical study of computation,computers and information processing). It is also different from theory and experimentwhich are the traditional forms of science and engineering. The scientific computingapproach is to gain understanding, mainly through the analysis of mathematical modelsimplemented on computers.Scientists and engineers develop computer programs, application software, whichmodel systems being studied and run these programs with various sets of input parameters.Typically, these models require massive amounts of calculations (usually floating-point)and are often executed on supercomputers or distributed computing platforms. Numericalanalysis is an important underpinning for techniques used in computational science [5].
1.2.1 Applications of Computer Science:Problem domains for computational science/scientific computing include[6-7]:
1.2.1.1 Numerical Simulations:Numerical simulations have different objectives depending on the nature of the taskbeing simulated:- Reconstruct and understand known events (e.g., earthquake, tsunamis and othernatural disasters).
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- Predict future or unobserved situations (e.g., weather, sub-atomic particlebehavior).
1.2.1.2 Model Fitting and Data Analysis:Appropriately tune models or solve equations to reflect observations, subject tomodel constraints (e.g. oil exploration geophysics, computational linguistics). Use graphtheory to model networks, especially those connecting individuals, organizations, andwebsites.
1.2.1.3 Optimization:Optimize known scenarios (e.g., technical and manufacturing processes, front endengineering).Programming languages commonly used for the more mathematical aspects ofscientific computing applications include Fortran, MATLAB, GNU Octave, and PDL.Computational science application programs often model real-world changingconditions, such as weather, air flow around a plane, automobile body distortions in a crash,the motion of stars in a galaxy, an explosive device, etc. Such programs might create a'logical mesh' in computer memory where each item corresponds to an area in space andcontains information about that space relevant to the model.For example in weather models, each item might be a square kilometer; with landelevation, current wind direction, humidity, temperature, pressure, etc. The program wouldcalculate the likely next state based on the current state, in simulated time steps, solvingequations that describe how the system operates; and then repeat the process to calculatethe next state.The term computational scientist is used to describe someone skilled in scientificcomputing. This person is usually a scientist, an engineer or an applied mathematician whoapplies high-performance computers in different ways to advance the state-of-the-art intheir respective applied disciplines in physics, chemistry or engineering. Scientificcomputing has increasingly also impacted on other areas including economics, biology andmedicine.Computational science is now commonly considered a third mode of science,complementing and adding to experimentation/observation and theory [1, 8].
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1.3 Formal Methods:
In computer science, formal methods are mathematically-based techniques for thespecification, development and verification of software and hardware systems. The use offormal methods for software and hardware design is motivated by the expectation that, asin other engineering disciplines, performing appropriate mathematical analyses cancontribute to the reliability and robustness of a design. However, the high cost of usingformal methods means that they are usually only used in the development of high-integritysystems, where safety or security is important [9-11].
1.3.1 TaxonomyFormal methods can be used at a number of levels:
1.3.1.1 Level 0:Formal specification may be undertaken and then a program developed from thisinformally. This has been dubbed formal methods life. This may be the most cost-effectiveoption in many cases.
1.3.1.2 Level 1:Formal development and formal verification may be used to produce a program in amore formal manner. For example, proofs of properties or refinement from the specificationto a program may be undertaken. This may be most appropriate in high-integrity systemsinvolving safety or security.
1.3.1.3 Level 2:Theorem proverb may be used to undertake fully formal machine-checked proofs.This can be very expensive and is only practically worthwhile if the cost of mistakes isextremely high (e.g., in critical parts of microprocessor design).
PDF Creator - PDF4Free v2.0                                                    http://www.pdf4free.com
Chapter 1: Computational Methods & Life Sciences 5
1.3.1.4 Lightweight Formal Methods:Some practitioners believe that the formal methods community has overemphasizedfull formalization of a specification or design. They contend that the expressiveness of thelanguages involved, as well as the complexity of the systems being modeled, makes fullformalization a difficult and expensive task. As an alternative, various lightweight formalmethods, which emphasize partial specification and focused application, have beenproposed. Examples of this lightweight approach to formal methods include the Alloy objectmodeling notation, Denney's synthesis of some aspects of the Z notation with use casedriven development, and the CSK VDM Tools.
1.3.2 Uses:Formal methods can be applied at various points through the development process.For convenience, we use terms common to the waterfall model, though any developmentprocess could be used. [12-15].
1.3.2.1 Specification:Formal methods may be used to give a description of the system to be developed, atwhatever level(s) of detail desired. This formal description can be used to guide furtherdevelopment activities; additionally, it can be used to verify that the requirements for thesystem being developed have been completely and accurately specified.The need for formal specification systems has been noted for years. In the ALGOL 60Report, John Backus presented a formal notation for describing programming languagesyntax (later named Backus normal form or Backus-Naur form (BNF)); Backus alsodescribed the need for a notation for describing programming language semantics. Thereport promised that a new notation, as definitive as BNF, would appear in the near future;it never appeared.
1.3.2.2 Development:Once a formal specification has been developed, the specification may be used as aguide while the concrete system is developed (i.e. realized in software and/or hardware).Examples:If the formal specification is in an operational semantics, the observed behavior ofthe concrete system can be compared with the behavior of the specification (which itself
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should be executable or simulateable). Additionally, the operational commands of thespecification may be amenable to direct translation into executable code.If the formal specification is in an axiomatic semantics, the preconditions and postconditions of the specification may become assertions in the executable code.
1.3.2.3 Verification:Once a formal specification has been developed, the specification may be used as thebasis for proving properties of the specification (and hopefully by inference the developedsystem).
Human-Directed Proof:Sometimes, the motivation for proving the correctness of a system is not the obviousneed for re-assurance of the correctness of the system, but a desire to understand thesystem better. Consequently, some proofs of correctness are produced in the style ofmathematical proof: handwritten (or typeset) using natural language, using a level ofinformality common to such proofs. A "good" proof is one which is readable andunderstandable by other human readers.Critics of such approaches point out that the ambiguity inherent in natural languageallows errors to be undetected in such proofs; often, subtle errors can be present in the low-level details typically overlooked by such proofs. Additionally, the work involved inproducing such a good proof requires a high level of mathematical sophistication andexpertise.
Automated Proof:In contrast, there is increasing interest in producing proofs of correctness of suchsystems by automated means. Automated techniques fall into two general categories:- Automated theorem proving, in which a system attempts to produce a formalproof from scratch, given a description of the system, a set of logical axioms, anda set of inference rules.- Model checking, in which a system verifies certain properties by means of anexhaustive search of all possible states that a system could enter during itsexecution.
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Neither of these techniques work without human assistance. Automated theoremprovers usually require guidance as to which properties are "interesting" enough to pursue;model checkers can quickly get bogged down in checking millions of uninteresting states ifnot given a sufficiently abstract model.Proponents of such systems argue that the results have greater mathematicalcertainty than human-produced proofs, since all the tedious details have beenalgorithmically verified. The training required to use such systems is also less than thatrequired producing good mathematical proofs by hand, making the techniques accessible toa wider variety of practitioners.Critics note that such systems are like oracles: they make a pronouncement of truth,yet give no explanation of that truth. There is also the problem of "verifying the verifier"; ifthe program which aids in the verification is itself unproven, there may be reason to doubtthe soundness of the produced results.
1.3.3 Criticisms:The field of formal methods has its critics. At the current state of the art, proofs ofcorrectness, whether handwritten or computer-assisted, need significant time (and thusmoney) to produce, with limited utility other than assuring correctness. This makes formalmethods more likely to be used in fields where the benefits of having such proofs, or thedanger in having undetected errors, make them worth the resources. Example: in aerospaceengineering, undetected errors may cause death, so formal methods are more popular thanin other application areas.At times, proponents of formal methods have claimed that their techniques wouldbe the silver bullet to the software crisis. Of course, it is widely believed that there is nosilver bullet for software development, and some have written off formal methods due tothose overstated, overreaching claims [16].
1.4 Formal System:
In logic and mathematics, a formal system consists of two components, a formallanguage plus a set of inference rules or transformation rules. A formal system may beformulated and studied for its intrinsic value, or it may be intended as a description (i.e. amodel) of external phenomena.
PDF Creator - PDF4Free v2.0                                                    http://www.pdf4free.com
Chapter 1: Computational Methods & Life Sciences 8
Each formal system has a formal language, which is composed by primitive symbols.These symbols act on certain rules of formation and are developed by inference from a setof axioms. The system thus consists of any number of formulas built up through finitecombinations of the primitive symbols—combinations that are formed from the axioms inaccordance with the stated rules. Formal systems in mathematics consist of the followingelements [17-18]:- A finite set of symbols (i.e. the alphabet), that can be used for constructingformulas (i.e. finite strings of symbols).- A set of axioms: each axiom must be well-formed formulas (WFF).- A set of inference rules.- A grammar, which tells how WFF are constructed out of the symbols in thealphabet. It is usually required that there be a decision procedure for decidingwhether a formula is well formed or not.- A formal system is said to be recursive (i.e. effective) if the set of axioms and theset of inference rules are decidable sets or semi decidable sets, according tocontext.
1.4.1 Formal Proofs:Formal proofs are sequences of WFFs. For a WFF to qualify as part of a proof, itmight either be an axiom or be the product of applying an inference rule on previous WFFsin the proof sequence. The last WFF in the sequence is recognized as a theorem.The point of view that generating formal proofs is all there is to mathematics isoften called formalism. David Hilbert founded metamathematics as a discipline fordiscussing formal systems. Any language that one uses to talk about a formal system iscalled a metalanguage. The metalanguage may be nothing more than ordinary naturallanguage, or it may be partially formalized itself, but it is generally less completelyformalized than the formal language component of the formal system under examination,which is then called the object language, that is, the object of the discussion in question.Once a formal system is given, one can define the set of theorems which can beproved inside the formal system. This set consists of all WFFs of which there is a proof for.Thus all axioms are considered theorems. Unlike the grammar for WFFs, there is noguarantee that there will be a decision procedure for deciding whether a given wff is atheorem or not. The notion of theorem just defined should not be confused with theorems
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about the formal system, which, in order to avoid confusion, are usually calledmetatheorems.
1.4.2 Formal Language:In mathematics, logic, and computer science, a formal language is a language that isdefined by precise mathematical or machine processable formulas. Like languages inlinguistics, formal languages generally have two aspects:- the syntax of a language is what the language looks like (more formally: the setof possible expressions that are valid utterances in the language)- the semantics of a language are what the utterances of the language mean(which is formalized in various ways, depending on the type of language inquestion)A special branch of mathematics and computer science exists that is devotedexclusively to the theory of language syntax: formal language theory. In formal languagetheory, a language is nothing more than its syntax; questions of semantics are not includedin this specialty.
1.4.3 Formal Grammar:In computer science and linguistics a formal grammar is a precise description of aformal language: a set of strings. The two main categories of formal grammar are that ofgenerative grammars, which are sets of rules for how strings in a language can begenerated, and that of analytic grammars, which are sets of rules for how a string can beanalyzed to determine whether it is a member of the language. In short, an analyticgrammar describes how to recognize when strings are members in the set, whereas agenerative grammar describes how to write only those strings in the set.
1.5 Computational Visualistics:
Images take a rather prominent place in contemporary life. Together with language,they have been connected to human culture from the very beginning. For about one century– after several millennia of written word’s dominance – their part is increasing againremarkably. Steps toward a general science of images, which we may call ‘general
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Visualistics’ in analogy to general linguistics have only been taken recently. So far, a uniquescientific basis for circumscribing and describing the heterogeneous phenomenon “image”in an interpersonally verifiable manner has still been missing while distinct aspects fallingin the domain of Visualistics have predominantly been dealt with in several otherdisciplines, among them in particular philosophy, psychology, and art history. Last (thoughnot least), important contributions to certain aspects of a new science of images have comefrom computer science.In computer science, too, considering pictures evolved originally along several moreor less independent questions, which lead to proper sub-disciplines: computer graphics iscertainly the most “visible” among them. Only just recently, the effort has been increased tofinally form a unique and partially autonomous branch of computer science dedicated toimages in general. In analogy to computational linguistics, the artificial expressioncomputational Visualistics is used for addressing the whole range of investigatingscientifically pictures “in” the computer [2, 7, 19-20].
1.5.1 Areas Covered:For a science of images within computer science, the abstract data type »image« (orperhaps several such types) stands in the center of interest together with the potentialimplementations. There are three main groups of algorithms for that data type to beconsidered in computational visualistics:
1.5.1.1 Algorithms from »image« to »image«:In the field called image processing, the focus of attention is formed by theoperations that take (at least) one picture (and potentially several secondary parametersthat are not images) and relate it to another picture. With these operations, we can definealgorithms for improving the quality of images (e.g., contrast reinforcement), andprocedures for extracting certain parts of an image (e.g., edge finding) or for stamping outpictorial patterns following a particular Gestalt criterion (e.g., blue screen technique).Compression algorithms for the efficient storing or transmitting of pictorial data also belonginto this field.
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1.5.1.2 Algorithms from »image« to “not-image”:Two disciplines share the operations transforming images into non-pictorial dataitems. The field of pattern recognition is actually not restricted to pictures. But it hasperformed important precursory work for computational Visualistics since the early 1950’sin those areas that essentially classify information in given images: the identification ofsimple geometric Gestalts (e.g., “circular region”), the classification of letters (recognition ofhandwriting), the “seeing” of spatial objects in the images or even the association of stylisticattributes of the representation.That is, the images are to be associated with instances of a non-pictorial data typeforming a description of some of their aspects. The neighboring field of computer vision isthe part of AI (artificial intelligence) in which computer scientists try to teach – looselyspeaking – computers the ability of visual perception. Therefore, a problem rather belongsto computer vision to the degree, to which its goal is “semantic”, i.e., the result approximatesthe human seeing of objects in a picture.
1.5.1.3 Algorithms from “not-image” to »image«:The investigation of possibilities gained by the operations that result in instances ofthe data type »image« but take as starting point instances of non-pictorial data types areperformed in particular in computer graphics and information visualization. The formerdeals with images in the closer sense, i.e., those pictures showing spatial configurations ofobjects (in the colloquial meaning of ‘object’) in a more or less naturalistic representationlike, e.g., in virtual architecture.The starting point of the picture-generating algorithms in computer graphics isusually a data type that allows us to describe the geometry in three dimensions and thelighting of the scene to be depicted together with the important optical properties of thesurfaces considered. Scientists in information visualization are interested in presentingpictorially any other data type, in particular those that consist of non-visual components ina “space” of states: in order to do so, a convention of visual presentation has firstly to bedetermined – e.g., a code of colors or certain icons. The well-known fractal images form aborderline case of information visualization since an abstract mathematical property hasbeen visualized.
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1.6 Computational Problem:
In theoretical computer science, a computational problem is a mathematical objectrepresenting a question that computers might want to solve. For example, "given anynumber x, determine whether “x is prime” is a computational problem. Computationalproblems are one of the main objects of study in theoretical computer science, becausenearly any task one would want to accomplish is an example of a computational problem. Inthe field of algorithms, we study methods of solving computational problems; in thecomplementary field of computational complexity theory, we organize computationalproblems based on how difficult they are to solve [21-23].
1.6.1 Problems and Instances:A computational problem encodes a general problem, independent of its specificinput. A problem with a specific set of inputs is called an instance. For example, "Given anytwo numbers x and y, find the sum of x and y" is a computational problem. A specificinstance of that computational problem would be "What is the sum of 13 and 28?".
1.6.2 Types of Computational Problems:Computational problems are organized in many different ways. They can beorganized by how they are defined, and by how many computational resources are neededto compute an answer. Computational problems that intuitively look very similar can varywildly in the amount of resources needed to compute them, and some computationalproblems are noncomputable, meaning that no possible algorithm could solve everyinstance.A computational problem which only returns a yes-or-no answer is called a decisionproblem. Examples of decision problems include "given an integer n, determine whether nis prime" and "given two numbers x and y, determine whether x evenly divides y". Decisionproblems are often used in computational complexity theory, because they are easier tostudy than other problems.Computational problems that are not restricted to yes-or-no answers are calledfunction problems. Examples of function problems include "given an integer n, list the primefactorization of n" and "given two numbers x and y, output x divided by y" [3, 24-25].
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Chapter 2:
BIOINFORMATICS:
CONCEPTS & APPLICATIONS
2.1. Introduction:
Bioinformatics is an exciting new discipline which applies computational techniquesto store, organize, generate, retrieve, analyze and share genomic, biological and chemicaldata to support the drug discovery process. With the high cost of drug discovery, risingcosts to the consumers, the product recalls being done and adverse side effects, all thistopped with more awareness and education on the part of the consumers, the industryimage has been battered. Thus it is imperative that the sector finds ways of reducing thecosts of drug discovery as well as the time it takes to get the medicine from the laboratoryto the patient and at the same time producing drugs which are target specific and withminimal side effects. Bioinformatics is one of the tools that industry has recently engaged toaid in the drug discovery process as well as to cut costs and the time-lines and indeed it wastime that the industry caught on with information technology. Computer-aided drugdiscovery (CADD) is an exciting and diverse discipline where various aspects of applied andbasic research merge and stimulate each other [1-5].Bioinformatics is a field which uses computers to store and analyze molecularbiological information. Using this information in a digital format, bioinformatics can thensolve problems of molecular biology, predict structures, and even simulate macromolecules.In a more general sense, bioinformatics may be used to describe any use of computers forthe purposes of biology, but the molecular biology specific definition is by far the mostcommon [6-9]. Bioinformatics is emerging trends and that helps in various fields like DrugDevelopment, Gene Therapy, Molecular Medicine, Waste Cleanup, Forensic Analysis ofMicrobes, Biotechnology, Personalized medicine, Antibiotic resistance, Bio-weaponcreation, Insect resistance, Veternity science, Crop Improvement and many others. Thiscategory of IT tool uses computers to store, organize, generate, retrieve, analyze and sharegenomic, biological and chemical data [3, 10-11].
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2.2. What is CADD?:
CADD stands for Computer-Aided Drug Design.The field of drug discovery is extremely complex and ever changing, with newmethodologies and technologies being introduced constantly. CADD methods are dependenton bioinformatics tools, applications and databases. The great aim of research inbioinformatics is to understand the functioning of living organisms in order to “improve the
quality of life” [18-20].Recently, one of the key trends in the pharmaceutical industry has been theintegration of what have traditionally been considered 'development' activities into theearly phases of drug discovery. The aim of this paradigm shift is the prompt identificationand elimination of candidate molecules that are unlikely to survive later stages of discoveryand development [21].
2.3. Hub of Bioinformatics:
Bioinformatics can be behaving as a central place that work with several branches,like scientific and support.On the scientific side of the Bioinformatics, bioinformatics methods are usedextensively in molecular biology, genomics, proteomics, and other emerging areas and inCADD research. On the support side of the Bioinformatics, Information Technology,Information Management, Software applications, databases and computation resources allprovide the infrastructure for bioinformatics.
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2.4. Objective of Bioinformatics:
An objective of bioinformatics is to extract useful knowledge from the flood of data,including biological texts, for the purpose of further analysis leading ultimately to drugdiscovery; in short, turning the flood of new bio-information into useable knowledge. Butthe data mining and knowledge management technologies that are being deployed today toassist researchers and regulators are unsuited to this task, for three reasons:
2.4.1. Ever-Expanding Information:The results of groundbreaking research are being published every day, at a ratefaster than any researcher or regulator can keep up with [79].
2.4.2. Ever-Expanding Sources:To make matters worse, updated bio-information resides in many differentlocations: print journals, web-based journals, chat rooms, and various intra- and internet
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data resources. With the sheer amount of new information out there, more than ever it isimperative to return search results that are relevant, so that time is not wasted sortingthrough irrelevant information [80].
2.4.3. Bioinformation Language:The language used in bioinformation texts presents unique challenges to anyinformation technology because of its proliferation of special terminology and symbols [81].
2.4.4. Conventional Search Technology:The technology underlying typical knowledge management applications is not up tothe task of dealing with these unique challenges, much less recognizing information that isrelevant to a particular researcher or research program [82].
2.5. Tools of Bioinformatics:
There are no standard protocols or formats to cross-examine or exchange biologicaldata. For this reason, there are various tools developed for different platforms in differentprogramming languages. Databases of existing sequencing data can be used to identifyhomologues of new molecules that have been amplified and sequenced in the lab [22].Examples of bioinformatics tools• Biotechnix 3d: The software offers standard tools for primary sequence analysis,including DNA restriction, PCR primer selection, base composition, DNA to proteintranslation and ORF identification and display. Secondary sequence analysis includesamino acid composition, estimations of hydrophobicity, flexibility, local structure [22].• StarDOM (Self-defining Text Archival and Retrieval – Document Object Model)StarDOM is a software package to transform data provided in the Self Defining TextArchival and Retrieval (STAR) format into XML. This opens new possibilities for visualediting, archiving, parsing and structured queries of structural biology data [18].• FASTAA database search tool used to compare a Nucleotide or peptide sequence to a sequencedatabase [14].• BLAST (Basic Local Alignment Search Tool)
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For comparing gene and protein sequences against others in public databases.Specialized BLASTs are also available for human, microbial, malaria and other genomes[15-16].• EMBOSS (The European Molecular Biology Open Software Suite)EMBOSS is "The European Molecular Biology Open Software Suite". EMBOSS is a freeOpen Source software analysis package specially developed for the needs of themolecular biology (e.g. EMBnet) user community. The software automatically copeswith data in a variety of formats and even allows transparent retrieval of sequence datafrom the web [19].• RasMol:RasMol is a molecular graphics program intended for the visualization of proteins,nucleic acids and small molecules [20].
2.6. Applications of Bioinformatics:
Applications of Bioinformatics are given below:
2.6.1. BioJavaBioJava is an open-source project dedicated to providing a Java framework forprocessing biological data. It include objects for manipulating sequences, file parsers, DASclient and server suport, access to BioSQL and Ensembl databases, and powerful analysisand statistical routines including a dynamic programming toolkit [77].
2.6.2. BioPerlBioperl is a collection of Perl modules that facilitate the development of Perl scriptsfor bioinformatics applications. [78].
2.7. Drug Discovery Pipeline:
The process by which a new drug is brought to market stage is referred to by anumber of names – most commonly as the development chain or “Pipeline” and consists of anumber of distinct stages. Drug discovery involves different stages, including: basic
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exploratory biology on target identification and validation; assay development; leadidentification, which usually requires access to high-throughput screening; medicinalchemistry and pharmaceutical lead optimization; and drug candidate selection [23-26].Following a successful Investigational New Drug application, the compound can undergo itsfirst entry into humans (Phase I). The next stage is Phase II, which focuses on determiningthe optimal dosing of the product, followed by a pivotal Phase III study against acomparator product [27-29].The significance of modern medicinal chemistry in both identifying an appropriatelead molecule and the iterative process of lead optimization is particularly poorlyunderstood outside the pharmaceutical industry and needs to be continuously emphasized.Optimization for pharmaceutical properties (adsorption, distribution, metabolism andexcretion, lack of overt toxicity, as well as for efficacy against the target organism, arecrucial30-31. Drug candidates fail to achieve registration for several reasons:biopharmaceutical properties such as oral bioavailability and formulation issues areresponsible for about 39% of failures, whereas toxicity constitutes about 21%. Thesefactors are as important as lack of efficacy, which is responsible for about 29% of failures[31-32].
2.8. Bioinformatics Key Areas:
2.8.1. High-Throughput Screening (HTS) in Drug Discovery:For those engaged in drug design, such as medicinal and computational chemists,the research phase can be broken down into two main tasks: identification of newcompounds showing some activity against a target biological receptor, and the progressiveoptimization of these leads to yield a compound with improved potency andphysicochemical properties in vitro, and, eventually, improved efficacy, pharmacokinetics,and toxicological profiles in vivo [33-34]. In recent years, this approach of structure-based
design has had a major impact on the rational design and optimization of new leadcompounds in those cases where the receptor structure is well-characterized [35-36]. HTSis now an essential component to identify leads [34, 37]. Virtual screening is increasinglygaining acceptance in the pharmaceutical industry as a cost-effective and timely strategy foranalyzing very large chemical data sets [33].
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2.8.2. Homology Modeling and Sequence Analysis:The basic Hidden Markov Models (HMM) quite rare in other fields but ubiquitous inbioinformatics; some recent papers are a fully Bayesian approach to sequence alignment[38] and a novel accuracy-based a posteriori decoding method [39]. The second area is theuse of probabilistic models for evolutionary tree analysis, concerning which there is a long-established research interest; some recent papers include the integration of an HMM withtree methods [40]. Some recent papers discuss the exciting ability to push into more-context-dependent grammars [41].Frequently, the quality of the target- template sequence alignment is non-uniformalong the sequence: parts can be modeled with a high confidence, whereas other parts differstrongly from the template. [42-43] one needs to evaluate a large number of possibleconformations.MODELLER [44] is used for homology or comparative modeling of protein three-dimensional structures [42]. MODELLER implements comparative protein structuremodeling by satisfaction of spatial restraints [42-43], and can perform many additionaltasks, including de novo modeling of loops in protein structures, optimization of variousmodels of protein structure with respect to a flexibly defined objective function, multiplealignment of protein sequences and/or structures, clustering, searching of sequencedatabases, comparison of protein structures [42, 45-46].
2.8.3. Sequence Similarity Searching:A natural question is whether there are other related sequences that share the samepattern. The most widely used tools for sequence similarity search allow matching betweenarbitrary regions of the query and database sequences [47-51]. In contrast, many motif-based search methods seek database sequences that match a pre-specified pattern [52-58].
2.8.4. Drug Lead Optimization:When a promising lead candidate has been found in drug discovery program, thenext step is to optimize the structure and properties of the potential drug. This usuallyinvolves a series of modifications to the primary structure and secondary structure of thecompound. This process can be enhanced using software tools that explore relatedcompounds to the lead candidate [59]. OpenEye’s WABE is useful for exploring the chemicalspace around a lead compound to elucidate candidates with improved drug profiles [60].
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2.8.5. PhysicoChemical Modeling:
The large number of components, the thermodynamic interactions among thesecomponents, the nonlinearity of the kinetic properties, the different time scales of variousprocesses, and the spatial organization of the cellular environment are some of thequalitative similarities between the biological processes and processes whose study iscentral to chemical engineering [61-62]. SWISS-PDB is a powerful modeling tool. It has thecapability to Searches of protein sequence databases, Mutation of side chains, and otherstructure alterations, Molecular dynamics minimizations, Calculation of electrostaticpotential surfaces [63].
2.8.6. Drug Bioavailability:The key characteristics for drugs are Absorption, Distribution, Metabolism, Excretion,Toxicity and Efficacy–in other words Bioavailability and Bioactivity. Although theseproperties are usually measured in the lab, they can also be predicted in advance withbioinformatics software [64-65]. Most drug candidates fail in phase III clinical trials aftermany years of research and millions of money has been spent on them. And most failbecause of toxicity or problems with metabolism.
2.8.7. High-Throughput Massively Parallel Applications:
Recent advances in genomic and proteomic techniques, coupled with significantresources devoted to this research, have resulted in the production of enormous amounts ofdata. The analysis and interpretation of these data have become an important and time-limiting step in biological research. The most popular way to handle these data analysisissues is to use massively parallel programs. Two general approaches exist for adapting acomputational biology tool to function as a massively parallel program: transform the toolinto a genuine parallel application or use it with a parallel wrapper program. Three verypopular tools BLAST and HMMER have been parallelized using the second approach, whilethe protein structure prediction program, LOOPP, is an example of rewriting the codeand/or altering algorithms to create a genuine parallel application [10-11].Bioinformatics seen as an emerging field with the potential to significantly improvehow drugs are found brought to clinical trials and eventually release to the marketplace.
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CADD methods are heavily dependent on bioinformatics tools, applications and databases.CADD and Bioinformatics together are a powerful combination in drug research anddevelopment. Bioinformatics clearly may be the answer to solve the drug discovery and costwoes of the pharmaceutical industry. Use of Bioinformatics in research in order to “improvethe quality of life”. By eliminating potential drug failures early on during the process, it alsohelps cut the time; scientists take to get a drug from the laboratory to the chemist’s shop asthey only concentrate their efforts on the leads which hold the greatest potential only. Thisimprovement will be achieved by many means including drug design, identification ofgenetic risk factors, gene therapy, and genetic modification of food, crops and animals.Clearly what is needed is a next-generation technology that is intelligent enough to readunstructured text and return only relevant information. In short, a technology that isintelligent enough to turn simple information into knowledge that researchers can useconfidently in the development of new bio-technologies. A challenge for computer scientistswho are involved in research in bioinformatics is to achieve results that make acontribution to computer science.
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Chapter 3:
BIOPHARMACEUTICS AND
PHARMACOKINETICS
3.1. Introduction:
3.1.1 Biopharmaceutics:In the world of drug development, the meaning of the term “Biopharmaceutics”often evokes confusion, even among scientists and professionals who work in the field.“Pharmaceutics” narrowly defined is a field of science that involves the preparation, use, ordispensing of medicine. Addition of the pre- fix “bio,” coming from the Greek “bios,” relatingto living organisms or tissues, expands this field into the science of preparing, using, andadministering drugs to living organisms or tissues. Inherent in the concept ofBiopharmaceutics as discussed here is the interdependence of biological aspects of theliving organism (the patient) and the physical–chemical principles that govern thepreparation and behavior of the medicinal agent or drug product.
3.1.1.1 Biopharmaceutics Classification System:The Biopharmaceutics Classification System is guidance for predicting the intestinaldrug absorption provided by the U.S. Food and Drug Administration. This system allowsrestricting the prediction using the parameters solubility and intestinal permeability. Thesolubility classification is based on a United States Pharmacopoeia (USP) aperture. Theintestinal permeability classification is based on a comparison to the intravenous injection.All those factors are highly important, since 85% of the most sold drugs in the USA andEurope are orally administered. According to the Biopharmaceutics Classification System,drug substances are classified as follows:
Class I - High Permeability, High Solubility:Those compounds are well absorbed and their absorption rate is usually higher thanexcretion.
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Class II - High Permeability, Low Solubility:The bioavailability of those products is limited by their salvation rate. A correlationbetween the in vivo bioavailability and the in vitro salvation can be found.
Class III - Low Permeability, High Solubility:The absorption is limited by the permeation rate but the drug is solvated very fast. Ifthe formulation does not change the permeability or gastro-intestinal duration time, thenclass I criteria can be applied.
Class IV - Low Permeability, Low Solubility:Those compounds have a poor bioavailability. Usually they are not well absorbedover the intestinal mucosa and a high variability is expected.
3.1.2 Pharmacokinetics:A young child given an injection might ask "How will that 'ouch' get from there tomy sore throat?". The answer to this question is the basis of pharmacokinetics. That is, howdrugs move around the body and how quickly this movement occurs. Pharmacokinetics isthe study of the time course of the drug concentration in the body, i.e., "what the body doesto the drug".Pharmacokinetics is a branch of pharmacology dedicated to the determination of thefate of substances administered externally to a living organism. In practice, this discipline isapplied mainly to drug substances, though in principle it concerns itself with all manner ofcompounds ingested or otherwise delivered externally to an organism, such as nutrients,metabolites, hormones, toxins, etc. Pharmacokinetics is often divided into several areasincluding, but not limited to, the extent and rate of Absorption, Distribution, Metabolismand Excretion. This sometimes is referred to as the ADME scheme.Absorption is the process of a substance entering the body. Distribution is thedispersion or dissemination of substances throughout the fluids and tissues of the body.Metabolism is the transformation of the substances and its daughter metabolites. Excretionis the elimination of the substances from the body. In rare cases, some drugs irreversiblyaccumulate in a tissue in the body. Pharmacokinetics is sometimes abbreviated as "PK".Pharmacokinetics is often studied in conjunction with pharmacodynamics. So while
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pharmacodynamics explores what a drug does to the body, pharmacokinetics explores whatthe body does to the drug.Pharmacokinetics is often studied using mass spectrometry because of the complexnature of the matrix (often blood or urine) and the need for high sensitivity to observe lowdose and long time point data. The most common instrumentation used in this application isLC-MS with a triple quadrupole mass spectrometer. Tandem mass spectrometry is usuallyemployed for added specificity. Standard curves and internal standards are used forquantitation of usually a single pharmaceutical in the samples. The samples representdifferent time points as a pharmaceutical is administered and then metabolized or clearedfrom the body. Blank or t=0 samples taken before administration are important indetermining background and insuring data integrity with such complex sample matrices.Much attention is paid to the linearity of the standard curve; however it is not uncommon touse curve fitting with more complex functions such as quadratics since the response of mostmass spectrometers is less than linear across large concentration ranges.
3.2 One Compartment I.V. Bolus:
Pharmacokinetics is the study of drug and/or metabolite kinetics in the body. Itdeals with a mathematical description of the rates of drug movement into, within and exitfrom the body. It also includes the study of drug metabolism or biotransformation rates.The body is a very complex system and a drug undergoes many steps as it is beingabsorbed, distributed through the body, metabolized or excreted (ADME).
Figure 3.2 (1) Drug Disposition
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The drug also interacts with receptors and causes therapeutic and/or toxicresponses. Although the details of drug kinetics are complicated it is fortunate that we canoften approximate drug kinetic processes using "simple" mathematical models.
3.2.1 Assumptions:According to this model we will consider the body to behave as a single well- mixedcontainer. To use this model mathematically we need to make a number of assumptions.
3.2.1.1 One Compartment:The drug in the blood is in rapid equilibrium with drug in the extravascular tissues.The drug concentration may not be equal in each tissue or fluid however we will assumethat they are proportional to the concentration of drug in the blood at all times. This is notan exact representation however it is useful for a number of drugs to a reasonableapproximation.
3.2.1.2 Rapid Mixing:We also need to assume that the drug is mixed instantaneously in blood or plasma.The actual time taken for mixing is usually very short, within a few of minutes, and incomparison with normal sampling times it is insignificant. We usually don't sample fastenough to see drug mixing in the blood.
3.2.1.3 Linear Model:We will assume that drug elimination follows first order kinetics. First orderkinetics means that the rate of change of drug concentration by any process is directlyproportional to the drug concentration remaining to undertake that process. If we have alinear if we double the dose, the concentration will double at each time point.
3.2.2 First-Order Kinetics:To illustrate first order kinetics we might consider what would happen if we were togive a drug by iv bolus injection, collect blood samples at various times and measure theplasma concentrations of the drug. We might see a steady decrease in concentration as thedrug is eliminated, as shown in below figure.
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Figure 3.2.2 (1). Linear Plot of Concentration versus Time
3.2.2.1 Rate versus Cp:If we measure the slope of this curve at a number of times we are actually
measuring the rate of change of concentration at each time point represented bythe straight line tangents in below figure.
Figure 3.2.2.1 (1). Rate versus Cp
Now if we plot this rate of change versus the plasma concentration, for each datapoint, we will get a straight line when first order kinetics is obeyed.
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Figure 3.2.2.1 (2). Plot of Cp/ t versus Cp for first order plot
This behavior can be expressed mathematically as:-
3.2.3 Plasma Data:
3.2.3.1 Scheme:The one compartment pharmacokinetic model can be represented schematically as:
Figure 3.2.3.1 (1). Scheme for a One Compartment Model,
Intravenous Bolus Administration
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3.2.3.2 Differential Equation:Going back to the slope calculations, if we measure the slope over small intervals weare calculating the tangent to the line. We can now say that the rate of elimination is thedifferential of the concentration with respect to time as t - - - > 0 then Cp/ t - - - >
dCp/dt which gives:It is a differential equation for the one-compartment model after IV bolusadministration. With the calculus term dCp/dt we are going from the gross or large timeinterval term Cp/ t to the continuously varying dCp/dt term.
3.2.3.3 Elimination Rate Constant, kel:We should now distinguish between the elimination rate and the elimination rateconstant. The rate (tangent or slope, dCp/dt) changes as the concentration changes,however, for a linear model the rate constant (kel) is constant, it does not change.
3.2.4 Area under the Curve:
Figure 3.2.4 (1). Linear Plot of Cp versus Time showing AUC and AUC segmentWe can continue by looking at two more parameters. These are the area under theplasma concentration time curve (AUC) and the half-life of elimination. First AUC. The AUCvalue is very useful for calculating the relative efficiency of different drug products. It willalso give us another method of calculating the apparent volume of distribution, not justfrom Cp0.The AUC is calculated by adding these segments together. Each very narrowsegment has an area = Cp*dt. Thus the total area has the area,
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calculus uses very narrow segments
then
at t = 0, e- kel*t = 1at t = , e- kel*t = 0
Therefore,
or
Analytical integration (exact solution, given exact values for V and kel).
Note: From t = 0 - > t = [[infinity]], AUC = Cp0/kel and for t = t - > t= [[infinity]] ,AUC = Cpt/kel]
Or
Usually we don't and have to calculate AUC directly from the Cp versus time data.We need then a different approach, which is called the trapezoidal rule.
Trapezoidal Rule:
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Figure 3.2.4 (2). Linear Plot of Cp versus Time showing Typical Data Points
We can calculate the AUC of each segment if we consider the segments to betrapezoids. [Four sided figures with two parallel sides].The area of each segment is then given by the average concentration x segmentwidth.
Figure 3.2.4 (3). Linear Plot of Cp versus Time showing One TrapezoidThe area from the first to last data point can then be calculated by adding the areastogether.
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Note: Summation of data point information (non-calculus)This gives:
Figure 3.2.4 (3). Linear plot of Cp versus time showing areas from data 1 to data n
We now have two more areas to consider. The first and the last. First if we give arapid I.V. bolus the zero plasma concentration Cp0 can be determined by extrapolation.Thus
The final segment can be calculated if we go back to the mathematical equation.
can be derived
Therefore the total AUC can be calculated as :-
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Time (hr)
Concentration
(µg/ml)
delta
AUC
AUC
(µg.hr/ml)
0 100
1 71 85.5 85.5
2 50 60.5 146.0
3 35 42.5 188.5
4 25 30.0 218.5
6 12 37.0 255.5
8 6.2 18.2 273.7
10 3.1 9.3 283.0
Total 8.9 291.9
Table 3.2.4 (1). Calculation of AUC
3.2.5 Half-life:Another important property of first order kinetics is the half-life of elimination, t1/2.The half-life is the time taken for the plasma concentration to fall to half its original value.Thus if Cp = concentration at the start and Cp/2 is the concentration one half-life later then:
ln 2 = kel * t1/2or
OR
These equations can be used as an approximate method of calculating kel. If we lookat a plot of Cp versus time on semi-log graph paper.
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Figure 3.2.5(1). Semi-log Plot of Cp versus Time with Some Data and a Line
The steps to take1) Draw a line through the points (this tends to average the data)2) Pick any Cp and t13) Determine Cp/2 and t24) Calculate t1/2 as (t2 - t1)Then kel = 0.693/t1/2Also consider determining Cp/4 or Cp/8 for two half-lives or three half-lives,respectively. The line smooths out the bumps. There may be bad data points, so by puttingin a line you 'sort of' average the data. The half-life is the same whether going from 40 to 20or from 10 to 5 mg/L. This is a property of the first order process.Cp - > Cp/2 in 1 half-life i.e. 50.0 % lost 50.0 %Cp - > Cp/4 in 2 half-lives i.e. 25.0 % lost 75.0 %Cp - > Cp/8 in 3 half-lives i.e. 12.5 % lost 87.5 %Cp - > Cp/16 in 4 half-lives i.e. 6.25 % lost 93.75 %Cp - > Cp/32 in 5 half-lives i.e. 3.125 % lost 96.875 %Cp - > Cp/64 in 6 half-lives i.e. 1.563 % lost 98.438 %Cp - > Cp/128 in 7 half-lives i.e. 0.781 % lost 99.219 %
Thus over 95 % lost or eliminated in 5 half-lives. Typically considered thecompletion (my definition unless told otherwise) of the process, although in theory it takesan infinite time. Others may wish to wait 7 half-lives where over 99% of the process iscomplete.
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3.3 Analysis of Urine Data:
So far we have looked at most of the information we can get from plasma data followinga rapid intravenous dose of a drug using a one compartment model. There is another part ofthe model which can be sampled. Sometimes it is not possible to collect blood or plasmasamples but we may be able to measure the amount of drug excreted into urine.
- we may not want to take repeated blood samples from certain patient populations,for example pediatrics;
- the apparent volume of distribution maybe so large that plasma concentrations aretoo small to measure.If we collect data for amount of drug excreted into urine it may be possible to determinethe elimination rate constant or half-life and other pharmacokinetic parameters.
3.3.1 Excretion Unchanged = No Metabolism:First we'll consider the case in which the drug is excreted totally as the unchangeddrug into urine. The scheme is then:
Figure 3.3.1 (1), Scheme for drug excreted into urine, one compartment
3.3.1.1 Differential Equation:Since the rate of elimination from plasma is the same as the rate of appearance ofdrug into urine.
Since according to this model, the drug is either in the body or has been eliminatedinto urine. Dose = Amount in body + Amount excreted = V * Cp + U
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3.3.2 Metabolism and Excretion – Parrallel Pathways:So far we have considered elimination by excretion into urine only. Usually drugsare eliminated by excretion AND metabolism, with possibly more than one metaboliteinvolved. Schematically this can be represented as:-
Figure 3.3.2(1). Schematic for drug eliminated by excretion and metabolism
ke is the excretion rate constant and km is the metabolism rate constant. Here wehave two parallel pathways for elimination (with others as a shadow). We can write thedifferential equations for the three components shown in this diagram. There could be morepathways. It may be appropriate to specify excretion by exhalation, in sweat, or as iscommonly the case, more than one metabolite.
3.3.3 Clearnace, CL:At this point we can define another pharmacokinetic parameter, clearance.Clearance can be defined as the volume of plasma which is completely cleared of drug perunit time. The symbol is CL and the units are ml/min, L/hr, i.e. volume per time. Anotherway of looking at Clearance is to consider the drug being eliminated from the body ONLY viathe kidneys.The amount cleared by the body per unit time is dU/dt, the rate of elimination (alsothe rate of excretion in this example). To calculate the volume which contains that amountwe can divide by Cp. That is the volume = amount/concentration. Thus:-
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As we have defined the term here it is the total body clearance. We have consideredthat the drug is cleared totally by excretion in urine. Below we will see that the total bodyclearance can be divided into a clearance due to renal excretion and that due to metabolism.
Figure 3.3.3(1). Representation of Renal Clearance
Clearance is a useful term when talking of drug elimination since it can be related tothe efficiency of the organs of elimination and blood flow to the organ of elimination. It isuseful in investigating mechanisms of elimination and renal or hepatic function in cases ofreduced clearance of test substances. Also the units of clearance, volume/time (e.g. ml/min)are easier to visualize, compared with elimination rate constant (units 1/time, e.g. 1/hr).Total body clearance, CL, can be separated into clearance due to renal elimination,CLr and clearance due to metabolism, CLm.CLr = ke * V (renal clearance)andCLm = km * V (metabolic clearance)NOTECL = CLr + CLmANOTHER METHOD of calculating CL can be derivedIntegrating
gives
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thus
also andThis equation uses the DATA only (without fitting a line through the data ormodeling the data) using the trapezoidal rule. Thus this is a model independent method.
thus a plot of dU/dt versus Cp will give a straight line through the origin with a slope equalto the clearance, CL.
3.4 Intravenous Infusion:
Commonly in a hospital setting a patient will receive a drug by intravenous infusion.The inconvenience of administering the drug over a long time is not a real problem withbedridden patients. Some may already be receiving intravenous fluids. If a drug ischemically stable and is compatible with the intravenous fluid it may be added to the fluidand thereby be given by slow infusion. Some drugs cannot be given by rapid intravenousinjection. Therefore they may be given by slower IV infusion over 15 or 30 minutes.
3.4.1 Continuous Infusion – Steady State:Giving the drug by infusion will alter the kinetics of the drug. Schematically:
Figure 3.4.1(1). Scheme for one compartment Intravenous Infusion
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Here we have added an infusion rate constant, k0 to the diagram presented earlier.This is a zero order process so the units of k0 would be amount per time; for example 25mg/min.
3.4.2 Combined Infusion and bolus administration:One reason we give a drug by IV infusion of course is because we need a quicktherapeutic response. One way to achieve a therapeutic concentration more quickly is togive a loading dose by rapid intravenous injection and then start the slower maintenanceinfusion.For example, theophylline again.To achieve Cpss = 14.1 mg/L; k0 = 60 mg/hr; V = 25 L; kel = 0.17 hr- 1.A loading dose can be calculated from
(Equation VI-4)thusDOSE = V * Cp0 = 25 x 14.1 = 353 mg
Figure 3.4.2(1). Linear Plot of Cp versus Time Showing Bolus, Infusion, and Combined Curves
An IV bolus and maintenance infusion is one way to achieve a steady state plasmaconcentration rapidly and maintain it. However, we may not be able to give a bolus doseintravenously...
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3.4.3 Combined Slow and Fast infusion:Alternately we can give a loading dose by rapid infusion and then give a slowermaintenance infusion once the plateau concentration is achieved.For example. Using the previous dataFor theophylline, kel = 0.17 hr-1; V = 25 L; with a required Cp = 14.1 mg/LIf we wish to give a loading infusion over 30 minutes we need to give the infusion ata rate which will produce Cp = 14.1 mg/L at 30 minutes. Therefore:-Cp30 min = 14.1 mg/L
(Equation VI-2 above)
thusk0 = 735 mg/hrTherefore we need to give a dose of 367 mg over 30 minutes to achieve a plasmaconcentration of 14.1 mg/L at 30 minutes. It is important to realize what the steady stateplasma concentration would be if we didn't turn this fast infusion off.
which would be quite toxic.
Figure 3.4.3(1). Linear Plot of Cp versus Time showing Combined and Separate
Curves for Both Infusions
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Consequently we would need to ensure that at 30 minutes the rapid infusion ratewas slowed from 735 mg/hr to 60 mg/hr. One way to do this is to only provide 367 mg (or360 mg) in the infusion syringe at first.The dosing regimen (or controlled sequence of drug administration) to achieve thedesired plasma concentration is:-a) a loading dose by IV infusion of 367 mg/30 minutes followed byb) a maintenance IV infusion of 60 mg/hr
3.4.4 Post infusion:Before moving on to discussing various routes of drug administration, we can lookat the equation for plasma concentration after an infusion is stopped. Remember that theequation for plasma concentration versus time during an IV infusion is:-
If the infusion is continued indefinitely then the plasma concentration approaches asteady state plasma concentration.
If however the infusion is stopped the plasma concentration can be expected to fall.
Figure 3.4.4(1). During and After an IV Infusion - One Compartment Model
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The scheme shown to represent 'after the infusion is stopped' is the same as that forthe bolus injection.
3.5 Routes of Drug Administration:
An alternate method of classifying these routes of administration is ENTERAL andPARENTERAL. Enteral means to do with the GI tract and includes oral, buccal, and rectal.Parenteral means not through the alimentary canal and commonly refers to injections suchas IV, IM, and SC; but could also include topical and inhalation. We can also distinguish IVfrom the rest, as with all others at least one membrane must be crossed, thus an absorptionprocess is involved in the administration and the pharmacokinetics.
3.5.1 Buccal / Sublingual:Some drugs are taken as smaller tablets which are held in the mouth or under thetongue. These are buccal or sublingual dosage forms. Buccal tablets are often harder tablets[4 hour disintegration time], designed to dissolve slowly. Nitroglycerin, as a softersublingual tablet [2 min disintegration time], may be used for the rapid relief of angina. ThisROA is also used for some steroids such as testosterone and oxytocin. Nicotine containingchewing gum may be used for cigarette smoking replacement.
3.5.1.1 Advantages:First pass - The liver is by-passed thus there is no loss of drug by first pass effect forbuccal administration. Bioavailability is higher.
Rapid Absorption - Because of the good blood supply to the area absorption isusually quite rapid.
Drug Stability - pH in mouth relatively neutral (cf. stomach - acidic). Thus a drugmay be more stable.
3.5.1.2 Disadvantages:Holding the dose in the mouth is inconvenient. If any is swallowed that portion mustbe treated as an oral dose and subject to first pass metabolism.Small doses only can be accommodated easily.
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3.5.2 Rectal:Most commonly by suppository or enema. Some drugs given by this route includeaspirin, theophylline, chlorpromazine and some barbiturates.
Figure 3.5.2(1). Showing IV, IM, and SC Injection
Drugs may be given into a peripheral vein over 1 to 2 minutes or longer by infusion.Rapid injections are used to treat epileptic seizures, acute asthma, or cardiac arrhythmias.Drugs may be given into a peripheral vein over 1 to 2 minutes or longer by infusion. Rapidinjections are used to treat epileptic seizures, acute asthma, or cardiac arrhythmias
3.5.2.1 Advantages:By-pass liver - Some of the veins draining the rectum lead directly to the generalcirculation, thus by-passing the liver. Reduced first-pass effect.Useful - This route may be most useful for patients unable to take drugs orally or withyounger children.
3.5.2.2 Disadvantages:Erratic absorption - Absorption is often incomplete and erratic. However for somedrugs it is quite useful. There is research being conducted to look at methods of improvingthe extent and variability of rectal administration.
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3.5.3 Itravenous:Drugs may be given into a peripheral vein over 1 to 2 minutes or longer by infusion.Rapid injections are used to treat epileptic seizures, acute asthma, or cardiac arrhythmias.
3.5.3.1 Advantages:
Rapid - A quick response is possible.
Total Dose - The whole dose is delivered to the blood stream. Large doses can begiven by extending the time of infusion.
Veins Relatively Insensitive - to irritation by irritant drugs at higher concentrationin dosage forms.
3.5.3.2 Disadvantages:
Suitable Vein - It may be difficult to find a suitable vein.
Maybe Toxic - Because of the rapid response, toxicity can be a problem with rapiddrug administrations, could then give as an infusion, monitoring for toxicity.
Requires Trained Personnel - Trained personnel are required to give intravenousinjections.
Expensive - Sterility, pyrogen testing and larger volume of solvent means greatercost for preparation, transport and storage.
3.5.4 Subcutaneous:This involves administration of the drug dose just under the skin.
3.5.4.1 Advantages:It can be given by patient, e.g. in the case of insulin.Absorption slow but usually complete.Improved by massage or heat.Vasoconstrictor may be added to reduce the absorption of a local anesthetic agent,thereby prolonging its effect at the site of interest.
3.5.4.2 Disadvantages:It can be painful.
PDF Creator - PDF4Free v2.0                                                    http://www.pdf4free.com
Chapter 3: Biopharmaceutics and Pharmacokinetics 51
Irritant drugs can cause local tissue damageMaximum of 2 ml injection thus often small doses limit use.
3.5.5 Intramuscular:
3.5.5.1 Advantages:Larger volume, than sc, can be given by IM.A depot or sustained release effect is possible with IM injections, e.g. procainepenicillin
3.5.5.2 Disadvantages:Trained personnel required for injections. The site of injection will influence theabsorption, generally the deltoid muscle is the best siteAbsorption is sometimes erratic, especially for poorly soluble drugs, e.g. diazepam,phenytoin. The solvent maybe absorbed faster than the drug causing precipitation of thedrug at the site of injection.
3.5.6 Inhalation:Local effect – bronchodilators.Systemic effect - general anesthesia.Rapid absorption, by-passing the liver.Absorption of gases is relatively efficient, however solids and liquids are excluded iflarger than 20 micron and even then only 10 % of the dose may be absorbed. Cromolyn istaken as a powder with 50 % of the particles within the range of 2 to 6 micron. Larger than20 micron and the particles impact in the mouth and throat. Smaller than 0.5 micron andthey aren't retained.
3.5.7 Topical:Local effect - eye drops, antiseptic, sunscreen, callous removal, etc.Systemic effect - e.g., nitroglycerin ointment.Absorption through the skin, especially via cuts and abrasions but also intact, can bequite marked. This can be a real problem in handling toxic materials in the laboratory orpharmacy.
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3.5.8 Other ROA’s:Other routes of administration include: intra-nasal, some systemic absorption hasbeen demonstrated for propranolol and some low dose hormones; intra-arterial for cancerchemotherapy to maximize drug concentrations at the tumor site; and intrathecal directlyinto the cerebrospinal fluid.
3.6 Pharmacokinetics of Oral Administration:
So far we have considered the pharmacokinetics of intravenously administereddrugs, either as a bolus or by infusion. If we know kel and V for a particular patient we cancalculate appropriate doses or dosing rates (infusion rates) to produce the necessarytherapeutic concentrations.Most of the routes of administration were extravascular; for example IM, SC, andmost importantly oral. With this type of drug administration the drug isn't placed in thecentral compartment but must be absorbed through at least one membrane. This has aconsiderable effect on drug pharmacokinetics and may cause a reduction in the actualamount of drug which is absorbed. Most commonly the absorption process follows firstorder kinetics. Even though many oral dosage forms are solids, which must dissolve beforebeing absorbed, the overall absorption process can often be considered to be a single firstorder process. At least that's the assumption we will use for now. Schematically this modelcan be represented as:
Figure 3.6(1). Representing Oral Administration, One Compartment Pharmacokinetic Model
Where Xg is the amount of drug to be absorbed, Xp is the amount of drug in thebody, and ka is the first order absorption rate constant.
3.6.1 Differential Equation:The differential equation for Xg is :-
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This is similar to the equation for after an IV bolus administration.The integrated equation is:-Xg = Xg0 * e-ka * t = F * Dose * e-ka * twhere F is the fraction of the dose which is absorbed, the bioavailability.We could therefore plot Xg (the amount remaining to be absorbed) versus time onsemi-log graph paper and get a straight line with a slope of -ka.For Xp ( = V * Cp) the amount of drug in the body, the differential equation is :-
The first term --> ka * Xg absorptionThe second term --> kel * V * Cp eliminationEven without integrating this equation we can get an idea of the plasmaconcentration time curve.
At the start Xg >> V * Cp therefore the value of is positive, the slope will bepositive and Cp will increase. With increasing time Xg will decrease, while initially Cp is
increasing, therefore there will be a time when ka * Xg = kel * V * Cp. At this timewill be zero and there will be a peak in the plasma concentration. At even later times Xg -->
0, and will become negative and Cp will decrease. The plasma concentration timecurve will look like below figure:
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Figure 3.6.1(1). Linear Plot of Cp versus Time after Oral Administration
Showing Rise, Peak, and Fall in Cp
3.6.2 Integrated Equation:We can calculate the line using the integrated form of the equation. Starting with thedifferential equation we can substitute Xg = Xg *e-ka * t. The integration process won't bedescribed here but a reference, which describes the Laplace transform method ofintegration can be presented. This method makes integration as easy as the logarithmictransform makes multiplication and division easier.If we use F * DOSE for Xg0 where F is the fraction of the dose absorbed, theintegrated equation for Cp versus time is :-
Notice that the right hand side of this equation is a constant multiplied by thedifference of two exponential terms. We can plot Cp as a constant times the differencebetween two exponential curve. If we plot each exponential separately.
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Figure 3.6.2(1). Linear Plot of e-ka x t versus Time for Two Exponential Terms
Notice that the difference starts at zero, increases, and finally decreases again.
Plotting this difference by gives Cp versus time.
Figure 3.6.2(2). Linear Plot of Cp versus TimeWe can calculate the plasma concentration at anytime if we know the values of allthe parameters of Equation.
We can also calculate the time of peak concentration using the equation:-
PDF Creator - PDF4Free v2.0                                                    http://www.pdf4free.com
Chapter 3: Biopharmaceutics and Pharmacokinetics 56
As an example we could calculate the peak plasma concentration given that F = 0.9,DOSE = 600 mg, ka = 1.0 hr-1, kel = 0.15 hr-1, and V = 30 liter.
= 2.23 hour
= 21.18 x [ 0.7157 - 0.1075] = 12.9 mg/LAs another example we could consider what would happen with ka = 0.2 hr-1 insteadof 1.0 hr-1
= 5.75 hour
= 72 x (0.4221 - 0.3166) = 7.6 mg/L lower and slower than before
Error Message Value is not a numeric literal probably means that one of theparameter fields is empty or a value is inappropriate.
3.6.3 Absorption Rate Constant, ka:
Figure 3.6.3(1). Linear Plot of Cp versus Time with ka = 3, 0.6, or 0.125 hr sup>-1
Before going on to calculate the parameters ka, kel, and F from data provided we canlook at the effect different values of F and ka have on the plasma concentration versus timecurve.tpeak = 1, 2.75, 6.25 hour.
PDF Creator - PDF4Free v2.0                                                    http://www.pdf4free.com
Chapter 3: Biopharmaceutics and Pharmacokinetics 57
Notice that with higher values of ka the peak plasma concentrations are higher andearlier.
3.6.4 Extent of Absorption:
Figure 3.6.4(1). Linear Plot of Cp versus Time with F = 1, 0.66, or 0.33
Changing F values is equivalent to changing the dose. Thus the higher the F value thehigher the concentration values at each time point. Since the values of kel and ka areunchanged the time of peak plasma concentration is unchanged.Thus, tpeak = 1, 1, and 1 hour. The same in each case.
3.6.5 Calculation of Bioavailability Parameters:On most occasions you will be able to get the parameter values from tables andreferences. However, you should also know how to get these values from the data. The twoparameters we will concentrate on are ka and F. These values can be used to comparedosage forms or brands. In the previous Chapter we saw the effect changing ka or F has onthe plasma concentration time curve.
3.6.6 Calculation of ka and F:Starting with the equation for Cp versus time
PDF Creator - PDF4Free v2.0                                                    http://www.pdf4free.com
Chapter 3: Biopharmaceutics and Pharmacokinetics 58
this can be written as Cp = A * e-kel * t - A * e-ka * t
where A =
Figure 3.6.6(1). Semi-log Plot of Cp versus Time Showing a Straight Line at Longer Time
If one of the rate constants (ka or kel) is much larger than the other, the methodworks best if the difference is at least five times, then the faster differential will approachzero more quickly, and at later times can be ignored. If we plot Cp versus time on semi-loggraph paper we will see that the slope will approach a straight line.The equation for this straight line portion can be obtained from the equation for Cpby setting the faster term (usually e-ka*t) to zero:
Figure 3.6.6(2). Semi-log Plot of Cp versus Time Showing Cplate, Slope, and Intercept
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Then Cplate = A * e-kel * t and plotting Cplate versus time gives a straight line on semi-loggraph paper, with a slope (ln) = -kel and intercept = A.Now
therefore
Plotting the ln (Residual) versus time should give another straight line graph with aslope (ln) equal to - ka and the same intercept as before, i.e. Aln (Residual) = ln (A) - ka * t
Figure 3.6.6(3). Semi-log Graph of Cp versus Time Showing Residual Line
This is the method of residual or "feathering". It can give quite accurate values ofkel, ka, and V/F if :
- One rate constant is at least five times larger than the other and
- Both absorption and elimination are first order processes.
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Time
(hr)
Plasma
Concentration
(mg/L)
Cp(late)
(mg/L)
Residual
[Col3 - Col2]
(mg/L)0.25 1.91 5.23 3.320.5 2.98 4.98 2.000.75 3.54 4.73 1.191.0 3.80 4.50 0.701.5 3.84 4.07 0.232.0 3.62 3.69 0.073.0 3.044.0 2.49 Residual5.0 2.04 Cplate = 5.5 * e 2.05 * t6.0 1.67 = 5.5 * e 0.2 * t7.0 1.37
Table 3.6.6(1). Cp and Residual versus Time
Figure 3.6.6(4). Plot of Cp and Residual versus Time
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3.7 Bioavailability Studies:
Studies, which are carried to evaluate different dosage forms, are the topic of thisChapter. These studies called bioavailability or drug product evaluation studies mightcompare:-i) one type of dosage form with another, e.g. regular tablet with sustained releasetablet. For this type of tablet ka values should be slower; but F values should besimilar orii) two (or more) dosage forms made by two different manufacturers.Second brand or generic drug manufacturers are required to prove that theirproduct is equivalent to previously marketed products which have demonstrated clinicallyefficacy. For most drugs, the second and subsequent manufacturer must show that theirproduct is bioequivalent, i.e. same ka and F, as the product(s) on the market. During thedevelopment of new drugs and drug products, the original manufacturer will also performbioavailability studies on new products, probably comparing the product to be marketedwith an intravenous dosage form if at all possible.
3.7.1 Definition:
3.7.1.1 Bioavailability:It indicates a measurement of the rate and extent (amount) of therapeutically activedrug which reaches the general circulation.
3.7.1.2 Bioequivalent Drug Products:
Bioequivalent Drug Products means pharmaceutical equivalents or pharmaceuticalalternatives whose rate and extent of absorption do not show a significant difference whenadministered at the same molar dose of the therapeutic moiety under similar experimentalconditions, either single dose or multiple doses.Some pharmaceutical equivalents or pharmaceutical alternatives may be equivalentin the extent of their absorption but not in their rate of absorption and yet may beconsidered bioequivalent because such differences in the rate of absorption are intentionaland are reflected in the labeling, are not essential to the attainment of effective body drugconcentrations on chronic use, or are considered medically insignificant for the particulardrug product studied.
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3.7.1.3 Bioequivalence Requirement:
Bioequivalence Requirement means a requirement imposed by the Food and DrugAdministration for the in vitro and/or in vivo testing of specified drug products which mustbe satisfied as a condition of marketing.
3.7.1.4 Brand Name:
Brand Name is the trade name of the drug.
3.7.1.5 Chemical Name:
Chemical Name is the name used by the organic chemist to indicate the chemicalstructure of the drug.
3.7.1.6 Drug Product:
Drug Product means a finished dosage form, e.g., tablet, capsule, or solution, thatcontains the active drug ingredient, generally, but not necessarily, in association withinactive ingredients.
3.7.1.7 Generic Name:
Generic Name is the established, non proprietary or common name of the activedrug in a drug product.
3.7.1.8 Pharmaceutical Alternatives:
Pharmaceutical Alternatives means drug products that contain the identicaltherapeutic moiety, or its precursor, but not necessarily in the same amount or dosage formor as the same salt or ester. Each such drug product individually meets either the identicalor its own respective compendial or other applicable standard of identity, strength, quality,and purity, including potency and, where applicable, content uniformity, disintegrationtimes and/or dissolution rates.
3.7.1.9 Pharmaceutical Equivalent:
Pharmaceutical Equivalent means drug products that contain identical amounts ofthe identical active drug ingredient, i.e., the salt or ester of the same therapeutic moiety, inidentical dosage forms, but not necessarily containing the same inactive ingredients, and
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that meet the identical compendial or other applicable standard of identity, strength,quality, and purity, including potency and where applicable, content uniformity,disintegration times and/or dissolution rate.
3.7.2 Past Bioavailability Problems:There are a number of examples of drugs products which have exhibitedbioavailability problems in the past. These examples are all pre-1976 and as mentioned inthe text were included in the earlier edition of the book with no further examples reported.This is an indication that more attention is now being given to formulation developmentduring drug development.
3.7.2.1 Chlorpropamide:
Chlorpropamide. With three products tested the peak plasma concentration afterone brand was less than 1/2 the peak after the other two products.
3.7.2.2 Digoxin:
Digoxin. The text reports a number of bioavailability problems with digoxin. Oneexample is particularly interesting. Doctors in Israel noticed 15 cases of digoxin toxicitybetween Oct/Dec 1975 with almost no reports for the same period the previous year. It wasfound that the local manufacturer had changed the formulation to improve dissolutionwithout telling the physicians. Urinary data suggested a two-fold increase in availability ofthe new formulation.
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Figure 3.7.3(1). Plot of Cp versus Time
3.7.2.3 Phenytoin:Again there are a number of examples in the text. One report described an incidenceof phenytoin intoxication in Australia in 1968 and 1969. Apparently the tablet diluent waschanged from calcium sulfate to lactose.
3.7.3 Reasons for Bioequivalence Requirements:The FDA may decide to require bioavailability studies for a variety of reasons including:
· Results from clinical studies indicate that different drug products produce differenttherapeutics results.
· Results from bioavailability studies indicate that different products are notbioequivalent.
· Drug has a narrow therapeutic range.
· Low solubility and/or large dose.
· Absorption is considerably less than 100%
3.7.4 Bioavailability Study Characters:With recently introduced products properly conducted bioavailability studies willhave been performed before the product is allowed to be marketed. However productswhich were approved some time ago may not have been tested as thoroughly. It is therefore
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helpful to be able to evaluate the testing which may have been undertaken. There are anumber of situations where a pharmacist is required to evaluate bioavailability studytesting. When selecting drug products for a prescription, product performance should bemost important criteria. Once it is established that two or more products are equivalent,then the choice of brand can be made on the basis of economic factors, cost etc.The evaluation of a drug product bioavailability study involves the consideration ofvarious factors.
3.7.4.1 Drug:The drug substance in each product must be the same. Bioavailability studies areconducted to compare two or more products containing the same chemical substance. Wecan't compare different chemical substances. The apparent volume of distribution and kelcan be quite different for different drug substances, thus no interpretation of the results ispossible. The first rule of bioavailability testing is that you compare the drug products withthe same drug in each dosage from.The only time that this rule is relaxed is in the case of pro-drug administration. Apro-drug is a compound which will form the drug of interest in the body. In this case it maybe appropriate to compare the delivery of a dosage form containing the drug with anotherdosage form containing a pro-drug. This testing is generally conducted to evaluate theusefulness of the pro-drug, rather than a strict comparison of the drug products. Once theusefulness of the pro-drug is demonstrated comparisons between dosage forms allcontaining the pro-drug should be undertaken to evaluate the drug product performance.
3.7.4.2 Drug Product:Usually the comparison is made between two (or more) similar products, containingexactly the same chemical substance. However, different dosage forms can be compared(when they contain the same drug). For example we could compare an IM dosage form withan IV one.By calculating the AUC values we can determine the absolute bioavailability of theIM dosage form. In this case it appears to be close to 100%. The rate of absorption for theIM dose can be determined also, but of course no comparison is possible.
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Figure 3.7.4.2(1). Plot of Cp versus Time after IV and IM Administration.
Figure 3.7.4.2(2). Plot of Cp versus Time for A and B with B having Slower Absorption
Alternately we could compare brand A tablet with brand B tablet or capsule. Bycomparing the AUC values and ka values we can make comparisons concerning both theextent and rate of absorption. In this case A appears to be faster than B but the extent ofabsorption doesn't appear to be all that different.
3.7.4.3 Subject:A number of factors are of concern; health, age, weight, enzyme status, number.
3.7.4.4 Health:Usually a study is designed so that each subject takes each product in turn. Thus theeffect of the individual subject can be eliminated or reduced. Such a study design is called a
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cross- over design. Even though each subject will act as their own control it is usually bestto have subjects of similar kinetic characteristic so that major variations are not introduced.Thus healthy volunteers are often preferred by drug product evaluation studies. Informedconsent should be obtained from each volunteer and some biochemical and medicalexamination will be used to confirm their medical state. For some drugs there may bespecial disease states which may cause the exclusion of some volunteers. For example, inone study we looked at propranolol products, and otherwise healthy volunteers with a pasthistory of asthma were excluded from this study.
3.7.4.5 Age:As you will see later, age can have a significant effect on drug pharmacokinetics.Elderly patients and young children can have quite different kinetics compared with youngadults. In the interest of a better matched group, subjects between the ages of 18 to 35 yearsare preferred. Kinetic changes usually aren't important until age greater than 60.
3.7.4.6 Weight:The apparent volume of distribution is usually proportional to weight in subjects ofnormal weight for height. However, in overweight (or underweight) subjects the V in L/kgmaybe somewhat different. Again to better match the subjects, normal weights arepreferred.
3.7.4.7 Enzyme Status:Smokers or subjects taking certain other drugs may have altered kinetics for thedrug of interest. This can be caused by alteration of enzyme activity or by drug-druginteractions. These effects add complications to a study and an attempt is usually made tominimize these factors.
3.7.4.8 Number:The number of subjects included in the study should be sufficient to see any real(maybe 20% variation) differences in bioavailability. Usually 10 - 20 subjects are used inthese studies. In clinical studies where the end-point is some clinical response, much largernumbers are required because of the greater variability in clinical response.
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3.7.4.9 Assay:The same assay method should be used for all phases of the study. It is not much useusing one assay for product A samples and another assay for product B samples. Thiswouldn't be done in a single study; however, if you were trying to compare the results fromone study with those from another, different assay methods may have been used. One assaymethod may pick up an interference which is not indicative of the drug concentration or thebioavailability. Also the assay method should be sensitive and specific.
3.7.4.10 Design:
Design: Usually a complete cross-over design is used. With this design each subjectreceives all products with a wash-out period between each dose administration.
Figure 3.7.4.10(1). Figure Showing Concentrations after two Separate Drug Administrations
Week 1 Week 2Group 1 A BGroup 2 B A for two products
Table 3.7.4(1). Two Product Example
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Week 1 Week 2 Week 3Group 1 A B CGroup 2 B C AGroup 3 C A BGroup 4 A C BGroup 5 C B AGroup 6 B A C for three products
Table 3.7.4(2). Three Product Examples
When more than 3 or 4 products are involved it has been suggested that a differentdesign is used whereby each subject will get maybe 3 or 4 products of a possible 8 to 12.This type of design, possibly an incomplete block design, usually requires more subjects toget the same information, but it does mean that each subject is not required to take as manydoses. It is harder to recruit subjects for longer studies.
3.7.4.11 Data Analysis:The rate of absorption can be characterized by the ka value and also the time ofpeak concentration. The extent of drug absorption is characterized by the F value or thepeak concentration or total AUC values. Any differences in the average values of theseparameters can then be analyzed statistically to determine the significance of thedifferences.The 5 % confidence level is usually used as the criteria of acceptance. The analysis ofvariance is a technique for separating the effect of product, subject, and sequence. Thesignificance of each of these factors can be tested.
Source of Variation d.f. SS MS F Significance Level
Total 35 44.6 - - -
Subject 11 28.3 2.58 10.1 p < 0.001
Week 2 0.14 0.068 0.27 n.s.
Treatment 2 11.0 5.55 21.8 P < 0.001
Residual 20 5.09 0.255 - -
Table 3.7.4(3). Analysis of Variance Table for Three-Way Cross-Over Study
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In this example two effects are significant. There appears to be a significant effectdue to treatment and subject. This would indicate that the subjects are significantlydifferent from each other and that the treatments are significantly different in terms of theparameter measured. It is quite common that Cp or AUC values are significantly different fordifferent subjects, because of their different weights or size. The different treatments wouldappear to be bio-inequivalent.
3.8 Physiological Factors Affecting Oral Absorption:
Looking briefly at the overall picture of drug absorption, distribution, andelimination.
Figure 3.8(1). Scheme of ADME processes
The ultimate goal is to have the drug reach the site of action in a concentrationwhich produces a pharmacological effect. No matter how the drug is given (other than I.V.)it must pass through a number of biological membranes before it reaches the site of action.
3.8.1 Membrane Physiology
3.8.1.1 Membrane Structure:In 1900 Overton performed some simple but classic experiments related tomembrane structure. By measuring the permeability of various types of compounds acrossthe membranes of a frog muscle he found that lipid molecules could readily cross thismembrane, larger lipid insoluble molecules couldn't and small polar compounds couldslowly cross the membrane.
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Figure 3.8.1.1(1). The Davson-Danielli Model
These results suggest that the biologic membrane is mainly lipid in nature butcontains small aqueous channels or pores. Other experiments involving surface tensionmeasurements have suggested that there is also a layer of protein on the membrane. Theseresults and others have been incorporated into a general model for the biologicalmembrane. This is the Davson-Danielli model.The membrane then acts as a lipid barrier with small holes throughout.
Figure 3.8.1.1(2). Simplified Model of Membrane
This is the general structure. Membranes in different parts of the body havesomewhat different characteristics which influence drug action and distribution. Inparticular, pore size and pore distribution is not uniform between different parts of thebody. Various examples of some membrane types are as below:
Blood-brain Barrier:The membranes between the blood and brain have effectively no pores. This willprevent many polar materials (often toxic materials) from entering the brain. However,
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smaller lipid materials or lipid soluble materials, such as diethyl ether, halothane, can easilyenter the brain. These compounds are used as general anesthetics.
Renal Tubules:In the kidney there are a number of regions important for drug elimination. In thetubules drugs may be reabsorbed. However, because the membranes are relatively non-porous, only lipid compounds or non-ionized species (dependent of pH and pKa) arereabsorbed.
Blood Capillaries and Renal Glomerular Membranes:These membranes are quite porous allowing non-polar and polar molecules (up to afairly large size, just below that of albumin, M.Wt 69,000) to pass through. This is especiallyuseful in the kidney since it allows excretion of polar (drug and waste compounds)substances.
3.8.1.2 Transport across the Membranes
Carrier mediated:
(1) Active
Figure 3.8.1.2(1). Carrier-Mediated Transport Process
The body has a number of specialized mechanisms for transporting particularcompounds; for example, glucose and amino acids. Sometimes drugs can participate in thisprocess. Active transport requires a carrier molecule and a form of energy.
· the process can be saturated
· transport can proceed against a concentration gradient
· competitive inhibition is possible
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(2) FacilitatedA drug carrier is required but no energy is necessary. e.g. vitamin B12 transport
· saturable if not enough carrier
· no transport against a concentration gradient, downhill but faster
(2) Passive:
Figure 3.8.1.2(2). Diagram of Passive Transport with a Concentration Gradient
Most drugs cross biologic membranes by passive diffusion. Diffusion occurs whenthe drug concentration on one side of the membrane is higher than that on the other side.Drug diffuses across the membrane in an attempt to equalize the drug concentration onboth sides of the membrane.If the drug partitions into the lipid membrane a concentration gradient can be established.The rate of transport of drug across the membrane can be described by Fick's first law ofdiffusion:-
Rate of diffusion =
Equation XI-1 Rate of Diffusion:The parameters of this equation are:-
D: diffusion coefficient. This parameter is related to the size and lipid solubility ofthe drug and the viscosity of the diffusion medium, the membrane. As lipid solubilityincreases or molecular size decreases then D increases and thus dM/dt also increases.
A: surface area. As the surface area increases the rate of diffusion also increase. Thesurface of the intestinal lining (with villae and microvillae) is much larger than the stomach.This is one reason absorption is generally faster from the intestine compared withabsorption from the stomach.
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x: membrane thickness. The smaller the membrane thickness the quicker thediffusion process. As one example, the membrane in the lung is quite thin thus inhalationabsorption can be quite rapid.
(Ch -Cl): concentration difference. Since V, the apparent volume of distribution, is atleast four liters and often much higher the drug concentration in blood or plasma will bequite low compared with the concentration in the GI tract. It is this concentration gradientwhich allows the rapid complete absorption of many drug substances.Normally Cl << Ch then:-
Thus the absorption of many drugs from the G-I tract can often appear to be first-order.
(3) PinocytosisFor example Vitamin A, D, E, and K.
(4) Ion pair transportFor example quaternary ammonium compounds
3.8.2 Gastrointestinal Physiology:
3.8.2.1 Characteristics of G- I physiology:
pH Membrane BloodSupply SurfaceArea TransitTime By-passliverBUCCAL approx 7 thin Good, fastabsorptionwith lowdose
small Shortunlesscontrolled
yes
ESOPHAGUS 5 – 6 Very thick,noabsorption
- small short -
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STOMACH 1 - 3decomposition,weak acidunionized
normal Good small 30 - 40minutes,reducedabsorption
no
DUODENUM 6 - 6.5 bileduct,surfactantproperties
Normal Good verylarge very short(6" long),windoweffect
no
SMALLINTESTINE 7 – 8 Normal Good verylarge10 - 14ft, 80cm 2/cm
about 3hours no
LARGEINTESTINE 5.5 – 7 - Good notverylarge 4- 5 ft
long, up to24 hr lowercolon,rectumyes
Table 3.8.2.1(1). GI Physiology and Drug Absorption
3.8.2.2 Gastric Emptying and Motility:
Figure 3.8.2.2(1). Showing Dependence of Peak Acetaminophen Plasma
Concentration as a Function of Stomach Emptying Half-life
PDF Creator - PDF4Free v2.0                                                    http://www.pdf4free.com
Chapter 3: Biopharmaceutics and Pharmacokinetics 76
Generally drugs are better absorbed in the small intestine (because of the largersurface area) than in the stomach, therefore increasing stomach emptying will increasedrug absorption. For example, a good correlation has been shown between stomachemptying time and peak plasma concentration for acetaminophen. The quicker the stomachemptying the higher the plasma concentration.
pH Membrane BloodSupply SurfaceArea TransitTime By-passliverBUCCAL approx 6 thin Good, fastabsorptionwith lowdose
small Shortunlesscontrolled
yes
ESOPHAGUS 6 Very thick,noabsorption
- small short -
STOMACH 1 - 3decomposition,weak acidunionized
normal good small 30 - 40minutes,reducedabsorption
no
DUODENUM 5 - 7bile duct,surfactantproperties
normal good verylarge very short(6" long),windoweffect
no
SMALLINTESTINE 6 -7 normal good V large10 - 14ft, 80cm 2 .
about 3hours no
LARGEINTESTINE 6.8 – 7 - good notverylarge 4- 5 ft
long, up to24 hr lowercolon,rectumyes
Table 3.8.2.2(2). Factors Affecting Gastric Emptying
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3.8.2.3 Influence of Food:
Figure 3.8.2.3(1). Showing the Effect of Fasting versus Fed on Propranolol Concentrations
Food can affect the rate of gastric emptying. For example fatty food can slow gastricemptying and retard drug absorption. Generally the extent of absorption is not greatlyreduced. Occasionally absorption may be improved. Griseofulvin absorption is improved bythe presence of fatty food. Apparently the poorly soluble griseofulvin is dissolved in the fatand then more readily absorbed.Propranolol plasma concentrations are larger after food than in fasted subjects. Thismay be an interaction with components of the food.
3.8.2.4 Other Factors:- Intestinal Motility and Transit Time- Food Retards transit
3.9 Physical-Chemical Factors affecting Oral Absorption:
There are two major headings, which can be used to discuss this material as it affectoral drug absorption. These are i) the pH -partition theory and ii) the dissolution of drugs.
3.9.1 pH – Partition:For a drug to cross a membrane barrier it must normally be soluble in the lipidmaterial of the membrane to get into membrane, also it has to be soluble in the aqueous
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phase as well to get out of the membrane. Most drugs have polar and non-polarcharacteristics or are weak acids or bases. For drugs which are weak acids or bases the pKaof the drug and the pH of the GI tract fluid and the pH of the blood stream will control thesolubility of the drug and thereby the rate of absorption through the membranes, lining theGI tract.Brodie et al. (in 1957) proposed the pH - partition theory to explain the influence ofGI pH and drug pKa on the extent of drug transfer or drug absorption. Brodie reasoned thatwhen a drug is ionized it will not be able to get through the lipid membrane, but only whenit is non ionized and therefore has a higher lipid solubility. Brodie tested this theory byperfuming the stomach or intestine of rats, in situ, and injected the drug intravenously. Hevaried the concentration of drug in the GI tract until there was no net transfer of drugacross the lining of the GI tract. He then determined the ratio D:-
D =
i.e. D =
Figure 3.9.1(1). Showing Transfer across Membrane
These values were determined experimentally, but we should be able to calculate atheoretical value if we assume that only non ionized drug crosses the membrane and thatnet transfer stops when [U]b = [U]gThe ratio [U]/[I] is a function of the pH of the solution and the pKa of the drug; asdescribed by the Henderson - Hasselbach equationFor weak acids:-
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pKa - pH =and for weak bases:-
pKa - pH =Brodie found an excellent correlation between the calculated D value and theexperimentally determined values.Even though the D values refer to an equilibrium state a large D value will mean thatmore drug will move from the GI tract to the blood side of the membrane. The larger the Dvalue, the larger the effective concentration gradient, and thus the faster the expectedtransfer or absorption rate.
Figure 3.9.1(2). Drug Distribution between Stomach and Blood
Compare D for a weak acid (pKa = 5.4) from the stomach (pH 3.4) or intestine (pH6.4), with blood pH = 7.4Stomach[U]/[I] = 10pKa - pH = 105.4 - 3.4 = 102 = 100i.e. [I] = 0.01 x [U]Blood[U]/[I] = 10pKa - pH = 105.4 - 7.4 = 10-2 = 0.01i.e. [I] = 100 x [U]Therefore the calculated D value would be
D =
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Figure 3.9.1(3). Drug Distribution between Intestine and Blood
By comparison in the intestine, pH = 6.4The calculated D value is (100+1)/(10+1) = 9.2From this example we could expect significant absorption of weak acids from thestomach compared with from the intestine. Remember however that the surface area of theintestine is much larger than the stomach. This approach can be used to compare a series ofsimilar compounds with different pKa values.We have applied the pH - partition theory to drug absorption, later we will use thistheory to describe drug re-absorption in the kidney.
Figure 3.9.1(4). Plot of ka versus fu
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With this theory it should be possible to predict that by changing the pH of the G-Itract that we would change the fraction non ionized and therefore the rate of absorption.This has some application in understanding drug absorption in overdose situations, butmore readily used in relation to renal excretion.Thus kaobserved = ku * fu assuming that the ionized species is not absorbed.
Figure 3.9.1(5). Plot of ka Versus fu for Sulfaethidole
For some drugs it has been found that the intercept is not zero in the above plot,suggesting that the ionic form is also absorbed. For example, results for sulfaethidole.May be the ions are transported by a carrier which blocks the charge, a facilitatedtransport process.
3.9.2 Drug dissolution:So far we have looked at the transfer of drugs in solution in the G-I tract, through amembrane, into solution in the blood. However, many drugs are given in solid dosage forms,and therefore must dissolve before absorption can take place.
Dissolution AbsorptionSOLID ----------------------> SOLUTION ------------------> BLOOD
G-I Tract
If absorption is slow relative to dissolution then all we are concerned with isabsorption. However, if dissolution is the slow, rate determining step (the step controlling
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the overall rate) then factors affecting dissolution will control the overall process. This is amore common problem with drugs which have a low solubility (below 1 g/100 ml) or whichare given at a high dose, e.g. griseofulvin.There are number of factors which affect drug dissolution and we can look at thisprocess as diffusion controlled.
Figure 3.9.2(1). Stagnant Layer
First we need to consider that each particle of drug formulation is surrounded by astagnant layer of solution.After an initial period we will have a steady state set-up where drug is steadilydissolved at the solid-liquid interface and diffuses through the stagnant layer. If diffusion isthe rate determining step we can use Fick's first law of diffusion to describe the overallprocess.
Figure 3.9.2(2). Plot of Concentration Gradient
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If we could measure drug concentration at various distances from the surface of thesolid we would see that a concentration gradient is developed.
3.9.2.1 Fick's First Law:By Fick's first law of diffusion then:-
Rate of solution =where D is the diffusion coefficient, A the surface area, Cs the solubility of the drug,Cb the concentration of drug in the bulk solution, and h the thickness of the stagnant layer.If Cb is much greater than Cs then we have so-called "Sink Conditions" and the equationreduces to
Rate of solution =with each term in this equation contributing to the dissolution process.
3.9.2.2 Surface area, A:The surface area per gram (or per dose) of a solid drug can be changed by alteringthe particle size. For example, a cube 1 cm on each side has a surface area of 6 cm2. If thiscube is broken into cubes with sides of 0.1 cm, the total surface area is 60 cm2. Actually if webreak up the particles by grinding we will have irregular shapes and even larger surfaceareas. Generally as A increases the dissolution rate will also increase. Improvedbioavailability has been observed with griseofulvin, digoxin, etc.Methods of particle size reduction include mortar and pestle, mechanical grinders,fluid energy mills, solid dispersions in readily soluble materials (PEG's).
3.9.2.3 Diffusion Layer Thickness, h:This thickness is determined by the agitation in the bulk solution. In vivo we usuallyhave very little control over this parameter. It is important though when we perform invitro dissolution studies because we have to control the agitation rate so that we get similarresults in vitro as we would in vivo.
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Figure 3.9.2.3(1). Plot of Concentration versus Distance for
Dissolution into a Reactive Medium
The apparent thickness of the stagnant layer can be reduced when the drugdissolves into a reactive medium. For example, with a weakly basic drug in an acidicmedium, the drug will react (ionize) with the diffusing proton (H+) and this will result in aneffective decrease in the thickness of the stagnant layer.The effective thickness is now h' not h. Also the bulk concentration of the drug iseffectively zero. For this reason weak bases will dissolve more quickly in the stomach.
3.9.2.4 Diffusion Coefficient, D:The value of D depends on the size of the molecule and the viscosity of thedissolution medium. Increasing the viscosity will decrease the diffusion coefficient and thusthe dissolution rate. This could be used to produce a sustained release effect by including alarger proportion of something like sucrose or acacia in a tablet formulation.
3.9.2.5 Drug Solubility, Cs:Solubility is another determinant of dissolution rate. As Cs increases so does thedissolution rate. We can now look at ways of changing the solubility of a drug.
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Salt form:
Figure 3.9.2.5(1). Plot of Concentration versus Time
Salts of weak acids and weak bases generally have much higher aqueous solubilitythan the free acid or base, therefore if the drug can be given as a salt the solubility can beincreased and we should have improved dissolution. One example is Penicillin V. If we lookat the dissolution profile of various salts.
Figure 3.9.2.5(2). Plot of Cp versus Time
This can lead to quite different Cp versus time results after oral administration.The t peak values are similar thus ka probably the same. C peak would show a goodcorrelation with solubility. Maybe site limited (only that in solution by the time the drug
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gets to the 'window' is absorbed). Use the potassium salt for better absorption orally. Usebenzathine or procaine for IM depot use.
Crystal form:
Figure 3.9.2.5(3). Plot of Cp versus Time for Three Formulations of
Chloramphenicol Palmitate
Some drugs exist in a number of crystal forms or polymorphs. These different formsmay well have different solubility properties and thus different dissolution characteristics.Chloramphenicol palmitate is one example which exists in at least two polymorphs. The Bform is apparently more bioavailable*.The recommendation might be that manufacturers should use polymorph B formaximum absorption. However, a method of controlling and determining crystal formwould be necessary in the quality control process.
3.10 Formulation Factors:
The role of the drug formulation in the delivery of drug to the site of action shouldnot be ignored. With any drug it is possible to alter its bioavailability considerably byformulation modification. With some drugs an even larger variation between a goodformulation and a bad formulation has been observed. Since a drug must be in solution tobe absorbed from the G-I tract, you may expect the bioavailability of a drug to decrease inthe order solution > suspension > capsule > tablet > coated tablet.
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This order may not always be followed but it is a useful guide. One example is theresults for pentobarbital. Here the order was found to be aqueous solution > aqueoussuspension = capsule > tablet of free acid form. This chapter will briefly discuss each ofthese formulation types particularly in regard to the relative bioavailability.
3.10.1 Solutions:Drugs are commonly given in solution in cough/cold remedies and in medication forthe young and elderly. In most cases absorption from an oral solution is rapid and complete,compared with administration in any other oral dosage form. The rate limiting step is oftenthe rate of gastric emptying.When an acidic drug is given in the form of a salt, it may precipitate in the stomach.However, this precipitate is usually finely divided and is readily redissolved and thus causesno absorption problems. There is the possibility with a poorly water soluble drug such asphenytoin that a well formulation suspension, of finely divided powder, may have a betterbioavailability.Some drugs which are poorly soluble in water may be dissolved in mixedwater/alcohol or glycerol solvents. This is particularly useful for compounds with tightcrystal structure, higher melting points that are not ionic. The crystal structure is broken bysolution in the mixed solvent. An oily emulsion or soft gelatin capsules have been used forsome compounds to produce improved bioavailability.
3.10.2 Suspensions:A well formulated suspension is second only to a solution in terms of superiorbioavailability. Absorption may well be dissolution limited; however a suspension of a finelydivided powder will maximize the potential for rapid dissolution. A good correlation can beseen for particle size and absorption rate.With very fine particle sizes the dispersibility of the powder becomes important.The addition of a surface active agent will improve dispersion of a suspension and mayimprove the absorption of very fine particle size suspensions otherwise caking may be aproblem.
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3.10.3 Capsules:In theory a capsule dosage form should be quite efficient. The hard gelatin shellshould disrupt rapidly and allow the contents to be mixed with the G-I tract contents. Thecapsule contents should not be subjected to high compression forces which would tend toreduce the effective surface area, thus a capsule should perform better than a tablet.This is not always the case. If a drug is hydrophobic a dispersing agent should beadded to the capsule formulation. These diluents will work to disperse the powder,minimize aggregation and maximize the surface area of the powder.
3.10.4 Tablets:The tablet is the most commonly used oral dosage form. It is also quite complex innature. The biggest problem is overcoming the reduction in effective surface area producedduring the compression process. One may start with the drug in a very fine powder, butthen proceeds to compress it into a single dosage unit.
3.10.4.1 Ingredients:Tablet ingredients include materials to break up the tablet formulation.
· Drug - may be poorly soluble, hydrophobic
· Lubricant - usually quite hydrophobic
· Granulating agent - tends to stick the ingredients together
· Filler - may interact with the drug, etc., should be water soluble
· Wetting agent - helps the penetration of water into the tablet
· Disintegration agent - helps to break the tablet apartCoated tablets are used to mask an unpleasant taste, to protect the tabletingredients during storage, or to improve the tablets appearance. Another barrier is placedbetween the solid drug and drug in solution. This barrier must break down quickly or it mayhinder a drug's bioavailability.
3.10.5 Sustained Release Tablets:Another form of coating is enteric coated tablets which are coated with a materialwhich will dissolve in the intestine but remain intact in the stomach. Polymeric acidcompounds have been used for this purpose with some success. This topic and the area ofsustained release products has been discussed in more detail in other courses.
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3.10.5.1 Benefits:
· for short half-life drugs, sustained release can mean less frequent dosing and thusbetter compliance.
· reduce variations in plasma/blood levels for more consistent result.
3.10.5.2 Problems:
· More complicated formulation may be more erratic in result. A sustained releaseproduct may contain a larger dose, i.e. the dose for two or three (or more) 'normal'dosing intervals. A failure of the controlled release mechanism may result in releaseof a large toxic dose.
· more expensive technology
3.10.5.3 Types of Products:
· erosion tablets
· waxy matrix
o matrix erodes or drug leaches from matrix
· coated pellets
o different pellets (colors) have different release properties
· coated ion exchange
· osmotic pump
o insoluble coat with small hole. Osmotic pressure pushes the drug out at acontrolled rate.
3.10.5.4 Results:Reduced side effects
3.10.6 In-vitro Dosage Form Testing:
3.10.6.1 Disintegration:Disintegration time is the time to pass through a sieve while agitated in a specifiedfluid. Indicates the time to break down into small particles. Not necessarily solution. In theprocess of tablet manufacturer the drug is often formulated into a granular state (that issmall but not fine) particles.
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This is done as the granule often has better flow properties than the a fine powderand there is less de-mixing leading to better uniformity. The granules are then compressedto produce the tablet. The disintegration test may lead to an end point of tablet to granuleonly.
3.10.6.2 Dissolution:The time is takes for the drug to dissolve from the dosage form. Numerous factorsaffect dissolution. Thus the dissolution medium, agitation, temperature are carefullycontrolled. The dissolution medium maybe water, simulated gastric juice, or 0.1M HCl. Thetemperature is usually 37 degree C.The apparatus and specifications may be found in the U.S.P. The U.S.P. methods areofficial however there is a wide variety of methods based on other apparatus. These areused because they may be faster, cheaper, easier, sensitive to a particular problem for aparticular drug, or developed by a particular investigator.Dissolution tests are used as quality control to measure variability between batcheswhich maybe be reflected by in vivo performance. Thus the in vitro test may be a quickmethod of ensuring in vivo performance. Thus there has been considerable work aimed atdefining the in vitro/in vivo correlation.
3.11 Multiple IV Bolus Dose Administration:This will consider drug pharmacokinetics after multiple dose drug administration.But, first review the equations for single dose drug administration.
3.11.1 Single Dose Summary:
3.11.1.1 IV Bolus:
IV Bolus
Figure 3.11.1.1(1). Scheme for IV Bolus
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Figure 3.11.1.1(2). Linear Plot of Cp versus Time
Figure 3.11.1.1(3). Semi-log Plot of Cp versus Time
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3.11.1.2 IV infusion
Figure 3.11.1.2(1). Scheme for IV Infusion
Differential Equations
o During:
Rate of Change of Cp
o After:
Cp versus Time
Integrated Equations:
o During
Cp versus Time During an IV Infusion
o At steady state
Cp at Steady State
o After
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Cp versus Time after the Infusion
·
Figure 3.11.1.2(2). Linear Plot of Cp versus Time
·
Figure 3.11.1.2(3). Semi-log Plot of Cp versus Time
3.11.1.3 Oral Administration:
Figure 3.11.1.3(1). Scheme for Oral Administration
Rate of Change of Cp
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Cp versus Time
Figure 3.11.1.3(2). Linear Plot of Cp versus Time
Figure 3.11.1.3(3). Semi-log Plot of Cp versus Time
With this refresher, drug pharmacokinetics after multiple dose administration maybe easier to understand.Aspirin given for a headache may be given as a single administration, whereasaspirin for arthritis will be given as a multiple dose. Antibiotics are usually given as amultiple dose regimen to produce and maintain effective plasma concentration. In fact,many drugs are given this way; anti-hypertensives, anti-epileptics etc.Multiple dose administration is a very common method of drug administration. Upto this point we can calculate the drug concentration in plasma at any time after a singledose, we will continue now by looking at the equations for multiple dose administration.
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3.11.2 Multiple IV Bolus:
3.11.2.1 Independent Doses:After a single dose administration we assume that there is no drug in the bodybefore the drug is administration and that no more is going to be administered. However, inthe case of multiple dose administration we are expected to give second and subsequentdoses before the drug is completely eliminated. Thus ACCUMULATION of the drug should beconsidered. On repeated drug administration the plasma concentration will be repeated foreach dose interval giving a PLATEAU or STEADY STATE with the plasma concentrationfluctuating between a minimum and maximum value.
Figure 3.11.2.1(1). Plot of Cp Versus Time Showing Cp0
We have already looked at the shape of the plasma concentration versus time curvefollowing a single intravenous administration. If we assume instantaneous mixing we start
off with an initial concentration Cp0, given by and then we have a fall inconcentration with time controlled by the elimination rate constant.
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Figure 3.11.2.1(2). Plot of Cp Versus Time after Two Separate Doses
If the doses are given far enough apart then the concentration will have fallen toapproximately zero before the next dose. There will then be no accumulation of drug in thebody.
3.11.2.2 Accumulating Doses:However if the second dose is given early enough so that not all of the first dose iseliminated then the drug will start to accumulate and we will get higher concentrations withthe second and third dose. As an example we could consider a drug with a half-life of 6hours. Giving a dose of 100 mg with an apparent volume of distribution of 25 liter the Cp0 =4 mg/liter.After six hours the plasma concentration will fall to 2 mg/liter. If we give the samedose again the plasma concentration will increase by 4 mg/liter from 2 mg/liter to 6mg/liter. Then after another half-life (6 hours) the plasma concentration will fall to 3mg/liter. Again, another dose will increase the plasma concentration by 4 mg/liter to 7mg/liter. After another half-life the plasma concentration will be 3.5 mg/liter. Afterrepeated drug administration every six hours the plasma concentration will accumulateuntil it fluctuates between a maximum and minimum value of 8 mg/liter and 4 mg/liter.
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Figure 3.11.2.2(1). Plot of Cp Versus Time Showing Doses Every Six Hours
With each dose, drug accumulated until the amount of drug eliminated during eachdosing interval was equal to the amount of the dose. In the first interval plasmaconcentrations fall from 4 to 2 mg/L. Continuing for a number of doses gives the followingtable.
Start End Concentration lost during dosage interval4 --> 2mg/L 2 mg/L6 --> 3 37 --> 3.5 3.57.5 --> 3.75 3.75...8 --> 4 4 <- which is the same as the concentrationincrease caused by each dose
Table 3.11.2.2(1). Concentration Lost During Dosage Interval
There is a limit to drug accumulation because as the plasma concentration increasedthe amount of drug eliminated during the dosing interval will also increase as the rate ofelimination is equal to the amount of the drug in the body multiplied by the rate constantfor a first order elimination. (Compare this with the case of a continuous infusion).
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So far we can see that if we give repeated doses before the body can eliminate theprevious doses then we will get accumulation of the drug. We have also seen that when wehave first order elimination this accumulation will not proceed indefinitely but will level off.
3.11.2.3 Development of General Equation:We can now consider a general equation which could describe the plasmaconcentration at any time after multiple IV. bolus drug administration.
Concentration at the end of the first dosing interval
Cp after the First Dose
where This gives the plasma concentrations at the end of first interval, where t is thedosing interval in hours.At the start of the second interval
then at the end of the second dose interval
and so on.It will help if we define the parameter
which is the fraction of the initial plasma concentration remaining at the end of thedosing interval. Then
This is a geometric series with each term R times the preceding term.
Start
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Cp Immediately after the nth Doses
End
Cp at the end of nth Dosing Interval
These two sums can be simplified to give
Start
Cp at the Beginning on the nth Dosing Intervaland
End
Cp at the End of the nth Dosing Interval
using the first equation (Equation XIV-14) we can calculate the concentration in plasma atany time following uniform multiple IV bolus administration.
where t = time since the last dose. Then
Cp at any Time after n Doses
3.11.2.4 Cpmax and Cpmin Equations:More useful equations can be derived from this general equation. These areequations to calculate the maximum and minimum plasma concentration after many doses.That is as n ---> and t = 0 or t = t. These are the limits of the PLATEAU CONCENTRATIONS.
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Cp Immediately after Many Dosesand
Cp Immediately before Many Doses
An example may be helpful: t1/2 = 4 hr; IV dose 100 mg every 6 hours; V = 10 literthen
What are the Cpmax and Cpmin values when the plateau values are reached
kel = = 0.17 hr-1R = e-kel * = e-0.17 x 6 = 0.35therefore
and
therefore the plasma concentration will fluctuate between 15.5 and 5.4 mg/liter duringeach dosing interval when the plateau is reached.We can now calculate the plasma concentration at any time following multiple IVbolus administration and we can calculate the Cpmax and Cpmin values.
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Figure 3.11.2.4(1). Plot of Cp Versus Time showing Time to Approach 50% of
Plateau during Multiple Dose Regimen
It can be shown that the time to reach a certain fraction of the plateau concentrationis dependent on the drug elimination half-life only, much the same as for the approach tosteady state during an IV infusion. Thus we may have a problem with an excessive timerequired to reach the plateau. Therefore we may want to determine a suitable loading doseto achieve steady state rapidly.In the previous example Cpmax = 15.5 mg/literA suitable loading dose would be Cpmax * V155 mg as a bolus would give Cp = 15.5 mg/liter, followed by 100 mg every 6 hoursto maintain the Cpmax and Cpmin values at 15.5 and 5.5 mg/liter respectively.In general:-The loading dose is Cpmax * VAnd since
(see Equation XIV-17, page XIV-11)
Loading Dose
or Maintenance DOSE = Loading DOSE * (1 - R)
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We can try another example of calculating a suitable dosing regimen.Consider V = 25 liter; kel = 0.15 hr-1 for a particular drug and we need to keep the plasmaconcentration between 35 mg/liter (MTC) and 10 mg/liter (MEC).What we need is the maintenance dose, the loading dose, and the dosing interval.Since
therefore
AlsoR = e-kel * = 0.2857then- kel * = -1.2528 or= 8.35 hour; the dosing interval.A dosing interval of 8 hours would be more reasonable. Thus with = 8 hr and kel = 0.15hr-1R = e-kel * = e-8 x 0.15 = 0.3012
If we use Cpmax =Maintenance dose = Cpmax * V * (1 -R) = 35 x 25 x (1 -0.3012) = 611 mgAgain a more realistic dose would be 600 mg every 8 hours.To check
Cpmax = = 34.3 mg/LandCpmin = Cpmax * R = 10.3 mg/L
This regimen would be quite suitable as the maximum and minimum values are stillwithin the limits suggested. All that remains is to calculate a suitable loading dose.Loading dose = Cpmax * V = 35 x 25 = 875 mg either 875, 850 or 800 mgThis answer can be expressed graphically.
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Figure 3.11.2.4(2). Plasma Concentration after Multiple IV Bolus Doses
3.12 Multiple Oral Dose Administration:
So far we have looked at multiple IV bolus administration. In an analogous fashion,equations can be developed which enable you to calculate the plasma concentrationachieved following multiple oral administration. To start the plasma concentration achievedfollowing a single oral dose can be given by:-
Cp after a Single Oral Dose
This can be converted to an equation describing plasma concentration at any timefollowing n equal doses with constant dosing interval t.
General Equation
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Figure 3.12(1). Plot of Cp Versus Time for Multiple Oral
Doses showing Cpmax and Cpmin
The plasma concentration versus time curve described by this equation is similar tothe IV curve in that there is accumulation of the drug in the body to some plateau level andthe plasma concentrations fluctuate between a minimum and a maximum value.The Cpmax value can be calculated at the time t = tpeak after many doses (n -> ) but it iscomplicated by the need to determine the value for tpeak.
3.12.1 Cpmin Equation:However Cpmin can be more easily determined at t = 0 or t = t. Thus at t = 0 and n ->.
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Figure 3.12.1(1). Plot Cp Versus Time after a Single Dose showing
Possible Time of Second Dose
This can be further simplified if we assume that the subsequent doses are givenafter the plasma concentration has peaked and e-ka * t is close to zero. That is the next dose isgiven after the absorption phase is complete.Cpmin then becomes:-
Cp Equation Simplified
Cp Equation Simplified Again
The relationship between loading dose and maintenance dose and thus drugaccumulation during multiple dose administration can be studied by looking at the ratiobetween the minimum concentration at steady state and the concentration one dosinginterval (t) after the first dose.
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Which can be simplified to give:-
Ratio Between Cp after First and Last Dose
This turns out to be the same equation as for the IV bolus. Therefore we cancalculate a loading dose just as we did for an IV multiple dose regimen.
Loading Dose Equation
This equation holds if each dose is given after the absorption phase of the previousdose is complete. We can further simplify Equation XV-4, if we assume that ka >> kel
then (ka - kel) approximatley equal to ka and thus approximately = 1.
Cp after Many Oral Doses (Uniform Dose and Interval)
It is an even more extreme simplification. However, it can be very useful if we don'tknow what the ka value is but can assume that absorption is reasonably fast. Equation 71will tend to give concentrations that are lower than those obtained with the full equation.Thus any estimated fluctuation between Cpmin and Cpmax will be overestimated using thesimplified equation.
3.12.2 Average Cp Equation:Another very useful concentration term for the calculation of oral dosing regimensis the average plasma concentration, , during the dosing interval at steady state.This term is defined as the area under the plasma concentration versus time curveduring the dosing interval at steady state divided by the dosing interval.
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Average Cp for a Dosing Interval at Steady State
Figure 3.12.2(1). Plot of Cp versus Time after Multiple Oral
Administration showing AUC at Steady State
By integrating the equation for plasma concentration at the plateau, between t = 0and t = t gives:-
Average Cp for a Dosing Interval at Steady State
An interesting result of this equation is that we get the same average plasmaconcentration whether the dose is given as a single dose every t dosing interval or issubdivided into shorter dosing intervals.For example 300 mg every 12 hours will give the same average plasmaconcentration as 100 mg every 4 hours. Of course, the difference between the maximum andminimum plasma concentration will be larger in the case of the less frequent dosing.For example F = 1.0; V = 30 liter; t1/2 = 6 hours or kel = 0.693/6 = 0.116 hr-1.We can now calculate the dose given every 12 hours required to achieve an average plasmaconcentration of 15 mg/L.
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=We could now calculate the loading doseR = e-kel * [[tau]] = e-0.116 x 12 = 0.25
To get some idea of the fluctuations in plasma concentration we could calculate theCpmin value. Assuming that ka >> kel and that e-ka * t --> 0, using Equation XV-8.
Therefore the plasma concentration would probably fluctuate between 7 and 23mg/L (very approximate) with an average concentration of about 15 mg/L. [23 = 15 + (15-7), i.e. high = average + (average - low), very approximate!].As an alternative we could give half the dose, 312 mg, every 6 hours give:-
The would be the same
Thus the plasma concentration would fluctuate between about 10.4 to 20 with anaverage of 15 mg/L.
3.12.3 Non-uniform Dosing Intervals:Applies when all disposition processes are linear. That is, distribution, metabolism,and excretion (DME) processes are linear or first order. Thus, concentrations after multipledoses can be calculated by adding together the concentrations from each dose.
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For example, calculate drug concentration at 24 hours after the first dose of 200 mg.The second dose of 300 mg was given at 6 hours and the third dose of 100 mg at 18 hours.
Graphically, this will look like the results in the figure below:
Figure 3.12.3(1). Drug Concentration after Three IV Bolus Doses
The calculations we have looked at consider that the dosing intervals are quiteuniform, however, commonly this ideal situation is not adhered to completely.Dosing three times a day may be interpreted as with meals, the plasmaconcentration may then look like the plot in Figure. The ratio between Cpmax and Cpmin isseven fold (8.2/1.1 = 7.45) in this example.
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Figure 3.12.3(3). Cp versus Time during Dosing at 8 am, 1 pm, and 7 pm
However this regimen may be acceptable if1) the drug has a wide therapeutic index2) there is no therapeutic disadvantage to low overnight plasma concentrations, e.g.,analgesic of patient stays asleep.
3.13 Non-Linear Pharmacokinetic Models:
All of the rate processes discussed so far in this course, except for the infusionprocess, follow first order kinetics. In particular the elimination process has been assumedto follow first order kinetics. However occasionally it is observed that the elimination of adrug appears to be zero order at high concentrations and first order at low concentrations.That is 'concentration' or 'dose' dependent kinetics are observed. That is at high doses,which produce higher plasma concentrations, zero order kinetics are observed, whereas atlower doses the kinetics are linear, that is first order.This occurs especially with drugs which are extensively metabolized. A typicalcharacteristic of enzymatic reactions and active transport is a limitation on the capacity ofthe process. There is only so much enzyme present in the liver, and therefore there is amaximum rate at which metabolism can occur. A further limitation in the rate ofmetabolism can be the limited availability of a co-substance or co-factor required in theenzymatic process. This might be a limit in the amount of glucuronide or glycine, forexample.
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Most of our knowledge of enzyme kinetics is derived from in vitro studies wheresubstrate, enzyme, and co-factor concentrations are carefully controlled. Many factors areinvolved in vivo so that each cannot be easily isolated in detail. However, the basicprinciples of enzyme kinetics have application in pharmacokinetics.Dose dependent pharmacokinetics can often be described by Michaelis-Menten kineticswith the RATE of elimination approaching some maximum rate, Vm.
with Km a Michaelis-Menten constant. Km is the concentration at which the rate ofmetabolism is 1/2 the maximum rate, Vm
3.13.1 Scheme:
Figure 3.13.1(1). Scheme for One Compartment Model with Michaelis-Menten Elimination
We can use above figure, when M-M kinetics is included in a one compartmentpharmacokinetic model as the only the route of elimination.
3.13.2 Differential equation:Thus:-
It is not possible to integrate this equation but by looking at low and highconcentrations we can get some idea of the plasma concentration versus time curve.
3.13.2.1 Low Cp approximation to first order:At low concentrations, where Km > Cp, Km + Cp is approximately equal to Km
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where the Vm/Km is a constant term and the whole equation now looks like that for firstorder elimination, with Vm/Km a first order elimination rate constant.Therefore at low plasma concentrations we would expect first order kinetics.Remember, this is the usual situation for most drugs. That is Km is usually larger than theplasma concentrations that are achieved.
3.13.2.2 High Cp approximation to Zero Order:For some drugs, higher concentrations are achieved, that is Cp > Km, then Km + Cpis approximately equal to Cp.
and we now have zero order elimination of drug. At high plasma concentrations we havezero order or concentration independent kinetics.
Figure 3.13.2.2(1). Linear Plot of Cp Versus Time Showing High Cp and
Low Cp - Zero Order and First Order Elimination
From the plot.High Cp, in the zero order part, the slope is fairly constant but steeper, that is, therate of elimination is faster than at lower concentrations.At higher concentrations the slope = -Vm. At lower concentrations we see anexponential decline in plasma concentration such as with first order elimination.On semi-log graph paper we can see that in the zero order region the slope is moreshallow, thus the rate constant is lower. The straight line at lower concentrations isindicative of first order kinetics.
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Figure 3.13.2.2(2) Semi-Log Plot of Cp Versus Time Showing High Cp and Low Cp
The presence of saturation kinetics can be quite important when high doses ofcertain drugs are given, or in case of over-dose. In the case of high dose administration theeffective elimination rate constant is reduced and the drug will accumulate excessively ifsaturation kinetics is not understood.
Figure 3.13.2.2(3). Linear Plot of Versus Dose Per Day
Phenytoin is an example of a drug which commonly has a Km value within or belowthe therapeutic range. The average Km value about 4 mg/L. The normally effective plasmaconcentrations for phenytoin are between 10 and 20 mg/L. Therefore it is quite possible forpatients to be overdosed due to drug accumulation. At low concentration the apparent half-life is about 12 hours, whereas at higher concentration it may well be much greater than 24hours. Dosing every 12 hours, the normal half-life, can rapidly lead to dangerousaccumulation.
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At concentrations above 20 mg/L elimination maybe very slow in some patients.Dropping for example from 25 to 23 mg/L in 24 hours, whereas normally you would expectit to drop from 25 -> 12.5 -> 6 mg/L in 24 hours. Typical Vm values are 300 to 700 mg/day.These are the maximum amounts of drug which can be eliminated by these patients per day.Giving doses approaching these values or higher would cause dangerous accumulation ofdrug. Figure 90 is a plot of versus dose for example.
3.13.3 Parallel Pathway:
Figure 3.13.3(1). Plot of Salicylate Amount in the Body Versus Time.
Similar t1/2 at Lower Concentrations Only
Another drug with saturable elimination kinetics is aspirin or maybe more correctlysalicylate. In the case of aspirin or salicylate poisoning the elimination maybe much slowerthan expected because of Michaelis-Menten kinetics.
Figure 3.13.3(2). Scheme for Aspirin/Salicylate Elimination
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In the case of aspirin we have parallel first order process with the Michaelis-Mentenkinetics. Therefore as dose increases proportionally more drug would be removed by thefirst order processes rather than the saturable one. This is shown in the figure below:
Figure 3.13.3(3). Plot of Apparent t1/2 Versus log(DOSE)
The phenomena of non-linear pharmacokinetics is of great importance in multipledose therapy in which more significant changes in the plateau levels are produced by theaccumulation of drug in the body than can be expected in single dose studies. Thisaccumulation will result in toxic responses especially when the therapeutic index of thedrug is low.
3.13.4 Dosing Approaches:
3.13.4.1 First Dose:One approach is to use the population values for phenytoin. With this method wewould use the population values of Vm = 7 mg/kg/day and Km = 5 mg/L. Aiming at 15 mg/Lfor with a patient weight of 80 kg, the equation
Probably better to start out low since toxicity is more probable above 20 mg/L.
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3.13.4.2 Second Dosing Regimen:That is after giving a continuous dose regimen to steady state, measure plasmaconcentration and adjust dose. For example if after 420 mg/day, is 20 mg/L then adownward adjustment would be necessary. If we assume that the Km is close to the averagevalue of 5 mg/L we can estimate Vm from the equation above
thus a new dose rate can be calculated
approximately 400 mg/day. Note: A reduction in dose of 20 mg/day (5 %) is calculated togive a 5 mg/L change (25 %) in . Another approach can be describe using the 'graph'(nomogram) shown below.Line A represents Cpss = 8 mg/L on 300 mg/day (70 kg = 4.3 mg/kg/day). Line Bwas drawn to achieve a new Cpss = 15 mg/L with a dose of 5.2 mg/kg/day (= 364 mg/day)The graph is used by plotting the line described by the current Cpss and R on thegraph, marking a point in the middle of the contour. From that point draw a line to thedesired Cpss, the value on the vertical axis gives the required dose rate, R.
3.13.4.3 Third Dosing Regimen:If we already have two plasma concentrations after two dose rates we can solve theequation
using simultaneous equations.With = 8.0 mg/L and = 27.0 mg/L for R1 = 225 mg/day and R2 = 300mg/day
225 * Km + 225 * 8 = 8 * Vm (1)and
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300 * Km + 300 * 27 = 27 * Vm (2)or multiplying (1) x 300300 * 225 * Km + 300 * 225 * 8 = 300 * 8 * Vm (3)and multiplying (2) x 225300 * 225 * Km + 300 * 225 * 27 = 225 * 27 * Vm (4)subtracting (4) - (3)300 * 225 * (27 - 8) = (225 * 27 - 300 * 8) * Vm
and
With these Vm and Km values we can now calculate the next dosing regimen to try.
3.14 Routes of Excretion:The major routes included will be renal, biliary, pulmonary, and salivary.
3.14.1 Renal Excretion:The major organ for the excretion of drugs is the KIDNEY. The functional unit of thekidney is the nephron in which there are three major processes to consider:-
Figure 3.14.1(1). One Nephron of the Kidney
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3.14.1.1 Glomerular Filtration:In the glomerular all molecules of low molecular weight are filtered out of the blood.Most drugs are readily filtered from the blood unless they are tightly bound to largemolecules such as plasma protein or have been incorporated into red blood cells. Theglomerular filtration rate varies from individual to individual but in healthy individuals thenormal range is 110 to 130 ml/min. About 10% of the blood which enters the glomerular isfiltered. This filtration rate is often measured by determining the renal clearance of inulin.Inulin is readily filtered in the glomerular, and is not subject to tubular secretion or re-absorption. Thus inulin clearance is equal to the glomerular filtration rate.Again, most drugs are filtered from blood in the glomerular, the overall renalexcretion however is controlled by what happens in the tubules. More than 90% of thefiltrate is reabsorbed. 120 ml/min is 173 L/day. Normal urine output as you may realize ismuch less than this, about 1 to 2 liter per day.
3.14.1.2 Tubular Secretion:In the proximal tubule there is re-absorption of water and active secretion of someweak electrolyte but especially weak acids. As this process is an active secretion it requiresa carrier and a supply of energy. This may be a significant pathway for some compoundssuch as penicillins. Because tubular secretion is an active process there may be competitiveinhibition of the secretion of one compound by another. A common example of thesephenomena is the inhibition of penicillin excretion by competition with probenecid. Whenpenicillin was first used it was expensive and in short supply, thus probenecid was used toreduce the excretion of the penicillin and thereby prolong penicillin plasma concentrations(PDR). Since then it has been shown that probenecid also alters the distribution ofpenicillins to various tissues causing more drug to distribute out of plasma, causing evenless to be eliminated.Drugs or compounds which are extensively secreted, such as p-aminohippuric acid(PAH), may have clearance values approaching the renal plasma flow rate of 425 to 650ml/min, and are used clinically to measure this physiological parameter.
3.14.1.3 Tubular Re-absorption:In the distal tubule there is passive excretion and re-absorption of lipid solubledrugs. Drugs which are present in the glomerular filtrate can be reabsorbed in the tubules.
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The membrane is readily permeable to lipids so filtered lipid soluble substances areextensively reabsorbed. A reason for this is that much of the water, in the filtrate, has beenreabsorbed and therefore the concentration gradient is now in the direction of re-absorption. Thus if a drug is non-ionized or in the unionized form it maybe readilyreabsorbed.Many drugs are either weak bases or acids and therefore the pH of the filtrate cangreatly influence the extent of tubular re-absorption for many drugs. When urine is acidicweak acid drugs tend to be reabsorbed. Alternatively when urine is more alkaline, weakbases are more extensively reabsorbed. These changes can be quite significant as urine pHcan vary from 4.5 to 8.0 depending on the diet (e.g. meat can cause a more acidic urine) ordrugs (which can increase or decrease urine pH).In the case of a drug overdose it is possible to increase the excretion of some drugsby suitable adjustment of urine pH. For example, in the case of pentobarbital ( a weak acid)overdose it may be possible to increase drug excretion by making the urine more alkalinewith sodium bicarbonate injection. This method is quite effective if the drug is extensivelyexcreted as the unchanged drug (i.e. fe -> 1). If the drug is extensively metabolized thenalteration of kidney excretion will not alter the overall drug metabolism all that much.The effect of pH change on tubular re-absorption can be predicted by consideration of drugpKa according to the Henderson-Hesselbalch equation.
3.14.1.4 Renal Clearance:One method of quantitatively describing the renal excretion of drugs is by means ofthe renal clearance value for the drug. Remember that renal clearance can be calculated aspart of the total body clearance for a particular drug. Renal clearance can be used toinvestigate the mechanism of drug excretion. If the drug is filtered but not secreted orreabsorbed the renal clearance will be about 120 ml/min in normal subjects. If the renalclearance is less than 120 ml/min then we can assume that at least two processes are inoperation, glomerular filtration and tubular re-absorption. If the renal clearance is greaterthan 120 ml/min then tubular secretion must be contributing to the elimination process. Itis also possible that all three processes are occurring simultaneously.Renal clearance is then:-
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Renal clearance values can range from 0 ml/min, the normal value for glucose whichis usually completely reabsorbed to a value equal to the renal plasma flow of about 650ml/min for compounds like p-aminohippuric acid.We can calculate renal clearance using the pharmacokinetic parameters ke and V.Thus CLrenal = ke * V. We can also calculate renal clearance by measuring the total amount ofdrug excreted over some time interval and dividing by the plasma concentration measuredat the midpoint of the time interval.
To continue we can briefly look at some other routes of drug excretion. We will thenreturn to the topic of renal excretion by considering drug dosage adjustments in patientswith reduced renal function.
3.14.2 Hemodialysis:Hemodialysis or `artificial kidney' therapy is used in renal failure to remove toxicwaste material normally removed by the kidneys, from the patient's blood. In the procedureblood is diverted externally and allowed to flow across a semi-permeable membrane that isbathed with an aqueous isotonic solution. Nitrogenous waste products and some drugs willdiffuse from the blood, thus these compounds will be eliminated. Therefore in patients withkidney failure, hemodialysis will be an important route of drug elimination.This technique is particularly important with drugs which:1) have good water solubility;2) are not tightly bound to plasma protein;3) are smaller (less than 500) molecular weight; and4) have a small apparent volume of distribution.Conversely drugs which are tightly bound or extensively stored or distributed intotissues are only poorly removed by this route, or process.
3.14.3 Biliary Excretion:The liver secretes 0.25 to 1 liter of bile each day. Some drugs and their metabolitesare excreted by the liver into bile. Anions, cations, and non-ionized molecules containingboth polar and lipophilic groups are excreted into the bile provided that the molecular
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weight is greater than about 300. Molecular weights around 500 appears optimal for biliaryexcretion in humans. Lower molecular weight compounds are reabsorbed before beingexcreted from the bile duct. Conjugates, glucuronides (drug metabolites) are often ofsufficient molecular weight for biliary excretion. This can lead to biliary recycling.Indomethacin is one compound which undergoes this form of recycling.
Figure 3.14.3(1). Enteroheptic Recycling
Figure 3.14.3(2). Cp versus Time showing a Second Peak
Other compounds extensively excreted in bile include cromoglycate (unchangeddrug), morphine, and chloramphenicol (as glucuronide). At least part of the biliary secretionis active since bile/plasma concentrations maybe as high as 50/1. There can also becompetition between compounds.
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The efficiency of this biliary excretion system can be assessed by use of a testsubstance, such as Bromsulphalein.
3.14.4 Pulmonary Excretion:The lung is the major organ of excretion for gaseous and volatile substances. Thebreathalyzer test is based on a quantitative pulmonary excretion of ethanol. Most of thegaseous anesthetics are extensively eliminated in expired air.
3.14.5 Salivary Excretion:This is not really a method of drug excretion as the drug will usually be swallowedand reabsorbed, thus a form of 'salivary recycling'. Drug excretion into saliva appears to bedependent on pH partition and protein binding. This mechanism appears attractive in termsof drug monitoring, that is determining drug concentration to assist in drug dosageadjustment. For some drugs, the saliva/free plasma ratio is fairly constant. Therefore drugconcentrations in saliva could be a good indication of drug concentration in plasma. Forsome drugs localized side effects maybe due to salivary excretion of the drug.
3.14.6 Renal Disease Considerations:
3.14.6.1 Dose Adjustment:Getting back to the renal excretion of drugs. If a drug is extensively excretedunchanged into urine, alteration of renal function will alter the drug elimination rate.Fortunately creatinine clearance can be used as a measure of renal function. For most drugswhich are excreted extensively as unchanged drug it has been found that there is a goodcorrelation between creatinine clearance and drug clearance or observed elimination rate(since V is usually unchanged).
Creatinine Clearance:Creatinine is produced in the body by muscle metabolism from creatine phosphate.Creatinine production is dependent on the age, weight, and sex of the patient. Elimination ofcreatinine is mainly by glomerular filtration with a small percentage by active secretion.With the patient in stable condition the production is like a continuous infusion to steadystate with the infusion rate controlled by muscle metabolism and the elimination controlledby renal function. Thus as renal function is reduced serum creatinine concentrations
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increases. Other compounds such as inulin are also used for GFR measurement. Althoughinulin GFR values are probably more accurate they involve administration of inulin andcareful collection of urine for inulin determination. The major advantage of creatinine isthat its formation is endogenous. Determination of creatinine clearance consists ofcollection of total urine and a plasma/serum determination at the mid-point time.
with serum creatinine expressed as mg/100 ml and creatinine clearance as ml/min. Normalinulin clearance values are 124 ml/min for men and 109 ml/min for women. Because ofsome small renal secretion of creatinine, normal values of creatinine clearance are slightlyhigher than GFR measured with inulin. Thus, normal creatinine clearance values are about120 to 130 ml/min.Various investigators have developed equations which allow calculation ofcreatinine clearance using serum creatinine values. Thus a single serum level can used. Forexample, the equation of Cockcroft and Gault.
Males:
Females: Use 85% of the value calculated for males. Lean body weight can be used inthis equation.
Estimation of kel in a Patient:The relationship between creatinine clearance and overall drug elimination can beeasily seen by looking at plots of kel observed versus creatinine clearance.
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Figure 3.14.6.1(1). Plot of kel versus CLCR (Dettli Plot)
These are often called Dettli plots. Above figure shows the situation withconsiderable excretion as unchanged drug. i.e. fe 0.5 <--> 0.9
Figure 3.14.6.1(2). Dettli Plot (fe = 1)
In above figure drug is excreted entirely as unchanged drug. i.e. fe = 1
Figure 3.14.6.1(3). Dettli Plot (fe = 0)
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In above drug is excretion only as metabolized drug. i.e. fe = 0. If we can determinethe relationship between CLcr and drug clearance or kel from a number of patients we canthen determine the creatinine clearance in a new patient and estimate the elimination rateconstant for the drug of interest in this patient. We can therefore calculate an optimum doseand dosing interval.
Figure 3.14.6.1(4). Dettli Plot Showing kel Observed Versus CLCR
The question now arises, how do we calculate kel for a particular drug and patient?For this we need to rely on data previously obtained and published in literature. With thisinformation we can construct a plot of kel versus CLcr. This plot maybe built into acomputer program or nomogram.This is the plot shown before. In the references given earlier there is informationuseful for calculating kel in patients with impaired renal function.
For example knr BKanamycin 0.01 0.0024Sulfadiazine 0.03 0.0005Tetracycline 0.008 0.00072
Table 3.14.6.1(1). Calculating kel in patients with impaired renal functionAs an example these data could be used to calculate the kel for a patient with a CLcrof 10 ml/min compared with normal renal function of 120 ml/minFor kanamycinkelpatient = knr + b * CLcr = 0.01 + 0.0024 x 10 = 0.01 + 0.024 = 0.034 hr-1cf: kel = 0.01 + 0.0024 x 120 = 0.298 hr-1
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For sulfadiazinekelpatient = 0.03 + 0.0005 x 10 = 0.03 + 0.005 = 0.035 hr-1cf: kel = 0.03 + 0.0005 x 120 = 0.09 hr-1For tetracyclinekelpatient = 0.008 + 0.00072 x 10 = 0.008 + 0.0072 = 0.0152 hr-1cf: kel = 0.008 + 0.00072 x 120 = 0.0944 hr-1
3.14.6.2 Average Cp calculations:For example consider the drug kanamycin. A patient of 70 kg with normal kidneyfunction may receive 250 mg IM every six hours (about 3 half-lives; t1/2 = 2.3 hours). If F =1.0 and V = 13.3 liter, kel = 0.693/2.3 = 0.30 hr-1.Then
=If ka >> kel then
Cpmin =R = e-0.3 * 6 = 0.165Cpmin = 3.7 mg/LThese are the results you should expect in a patient with a normal creatinineclearance value. However in a patient with a creatinine clearance of only 10 ml/min theelimination rate constant will be quite different and if the same dosage regimen were usedquite different plasma concentrations would be achieved.The elimination rate constant for this patient would be 0.034 hr-1 (t1/2 = 20 hr).Using the same dosing regimen:
This average plasma concentration is well above the 35 mg/L which should beavoided (in the PDR 89 p740). Clearly some dosage adjustment should be made to thedosage regimen.
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Figure 3.14.6.2(1). Linear Plot of Cp versus Time
We should considera) changing the doseb) changing the dosing intervalc) changing both the dose and the dosing interval.We can make these alterations easily using the equation
From this we can see that decreasing the dose or increasing the dosing interval willhave the desired response.
Altered Dose:Assuming that a Cp of 10.4 mg/L (the value obtained in the normal patient on anormal dosage regimen) is satisfactory we can calculate a dose to achieve this value by:-
=Assuming ka >> kel, R = 0.815 and Cpmin = 9.3 mg/LThus this new dosing regimen of 28 mg every 6 hours should work
Altered Dose Interval:
=Therefore giving 250 mg every 53 hours should achieve a satisfactory plasmaconcentration profile.
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R = 0.165; Cpmin = 3.7 mg/LWe would expect greater fluctuations with this method and dosing every 53 hours isnot all that convenient. Every 6 hours is not all that great either if a longer dosing intervalwould work. We might consider dosing every 24 hours.
Altered Dose and Interval:Using t = 24 hours
= = 113 mg every 24 hours (maybe 100mg every 24 hours)R = 0.442; Cpmin = 6.7 mg/L.
Figure 3.14.6.2(2). Plot of Cp versus Time
The lines in Figure were calculated to achieve a of 10.4 mg/L using 28 mg q6h,250 mg q54h, pr 113 mg q24h.
3.14.6.3 Cpmax/Cpmin Calculations:This is another approach, the steps to be taken include
a. Define Cpmin/Cpmax.:From information on the drug with reference to the patient's clinical requirements.For example the normal upper limit for gentamicin peak concentrations might be 6 mg/L,however in case of life-threatening infection higher levels may be approached. Initial
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calculation might be based on a peak of 6 mg/L and a trough below 1 mg/L. (Use 1 mg/L asthe trough and extend the interval when making the adjustment in .
b. Determine CLcr:Probably from serum creatinine levels using the Cockcroft-Gault equation.
c. Determine kel:Using the equation kel = km + b * CLCr with km and b values from the literature
d. Calculate Tau:
Since and we know Cpmin, Cpmax, and kel we can calculatetau, . Typically this will be some uneven time value.
e. Round Tau:A more usual dosing interval should now be chosen. For example a tau of 7.8 or 6.7hour could be rounded to 8 hours, thus dosing three times a day.
f. Recalculate R:A new value of tau results in a new value of R.
g. Calculate Maintenance Dose:The maintenance dose can be calculated from the minimum or the maximum plasmaconcentration. ThusMaintenance dose = Cpmax * V * (1 - R) OR = Cpmin * V * (1 - R)/R
h. Calculate Loading DOSE:The loading dose can be calculated directly (for an iv bolus) by equating Cp0 and theCpmax value. Thus, Loading dose = Cpmax * V
Example: A 75 kg, 65 year old male patient, serum creatinine concentration of 2.3mg/100 ml, is to be given gentamicin iv to achieve a peak plasma concentration of 6 mg/Land trough concentration below 1 mg/L. The apparent volume of distribution is reported tobe 0.28 L/kg. From table 16-3 (Niazi), km and b values are 0.02 and 0.0028, respectively.a. Cpmax = 6 mg/L and Cpmin = 1 mg/L
b. CLcr =c. kel = km + b * CLcr = 0.02 + 0.0028 x 34 = 0.115 hr-1
d. R = ln (0.1667) = -1.792 = -0.115 x
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= 15.6 houre. Since a longer dosing interval is needed to keep the trough level below 1 mg/L use a tauvalue of 18 hours.f. New R value. R = e-0.115 x 18 = 0.1262g. Calculate maintenance dose using Cpmax = 6 mg/L as reference point. ThusMaintenance dose = Cpmax * V * (1 - R) = 6 x 75 x 0.28 x (1 - 0.1262) = 110 mgThus use 100 mg iv every 18 hours
Cpmin = Cpmax * R = 5.45 x 0.1262 = 0.69 mg/Lh. The loading dose can be calculated as:-Loading dose = Cpmax * V = 6 x 75 x 0.28 = 126 mg. Using 125 mg would give a
Cpmax = = 5.95 mg/L.Thus a loading dose of 125 mg followed by 100 mg every 18 hours should besatisfactory.
Comparison with PDR recommendation.Usual dose for 75 kg patient is 75 mg q8h. With serum creatinine 2.3 mg/100 mlgive 40 percent of 75 mg q8h. That is 30 mg q8h (R = 0.399) giving 2.38 and 0.95 for Cpmaxand Cpmin, respectively.
3.15 Metabolism:
The body has another way of deactivating drugs in the body. This method ofelimination is metabolism or biotransformation. Metabolic processes, in general, have theoverall effect of converting drug molecules into more polar compounds. Again, in general,the effect of this should be to decrease tubular re-absorption in the kidney and thusincrease drug elimination.Generally, it also means an immediate loss of pharmacological activity becausetransport into the site of action is hindered (less lipid soluble) or the molecule no longer fitsinto the receptor site. There are exceptions however, and a number of `new' drugs havebeen discovered as active metabolites.Metabolism takes place by enzymatic catalysis. Most metabolism occurs in the liveralthough other sites have been described, such as intestinal wall, kidney, skin, blood.
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3.15.1 Metabolic Reactions:There are four main patterns of drug metabolism.These are:1) oxidation2) reduction3) hydrolysis4) conjugationThe first three are often lumped together as phase I reactions, while the fourthprocess, conjugation, is called phase II metabolism. A common scheme in the overallmetabolism of drugs is that metabolites are metabolized. In particular a drug maybeoxidized, reduced or hydrolyzed and then another group may be added in a conjugationstep.A common cause of capacity limited metabolism is a limit in the amount of theconjugate added in the conjugation step.
3.15.1.1 Phase I:
Oxidation:Oxidation is the addition of oxygen and/or the removal of hydrogen. Most oxidationsteps occur in the endoplasmic reticulum.Common reactions include :-
Alkyl group ----> alcohol
for example phenobarbitone
Aromatic ring ----> phenol
for example phenytoin
Oxidation at S or N
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sulfoxidefor example chlorpromazine
in two steps oxidative dealkylation is possible
for example phenacetinOutside the microsomes - in liver and brainMonoamineoxidaze
for example 5-hydroxytryptamineAlcohol dehydrogenase - in liver, kidney, lung
Reduction:Add a hydrogen or remove oxygenazo (-N=N-) or nitro groups (-NO2) -----> amines (-NH2)for example nitrazepam
Hydrolysis:Addition of water with breakdown of molecule. In blood plasma (esterases) andliverEsters ---> alcohol and acid
for example aspirin to salicylic acidAmides to amine and acid
for example procainamide
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3.15.1.2 Phase II:
Conjugation:Conjugation reactions involve the addition of molecules naturally present in thebody to the drug molecule. The drug may have undergone a phase I reaction.
Glucuronidation:This is the main conjugation reaction in the body. This occurs in the liver. Naturalsubstrates are bilirubin and thyroxine. Aliphatic alcohols and phenols are commonlyconjugated with glucuronide. Thus hydroxylated metabolites can also be conjugated. forexample morphine
Acylation:Acylation, especially acetylation with the acetyl group, e.g. sulfonamidesGlycine:Glycine addition (NH2CH2COOH) for example nicotinic acid
Sulfate:Sulfate (-SO4) for example morphine, paracetamol
In most cases the metabolite is formed by production of a more polar group, forexample C-H -> C-OH, or addition of a polar group, for example acetyl (CH3COO-). Generallythe resultant metabolite is more water soluble, and certainly less lipid soluble. Less drug isreabsorbed from the kidney.Occasionally the metabolite is less water soluble. A significant example is the acetylmetabolite of some of the sulfonamides. Some of the earlier sulfonamides are acetylated torelatively insoluble metabolites which precipitated in urine, crystalluria. The earlier answerthis was the triple sulfa combination, now the more commonly used sulfonamides havedifferent elimination and solubility properties and exhibit less problems.In most cases the metabolites are inactive, however, occasionally the metabolite isalso active, even to the extent that the metabolite may be the preferred compound to beadministered. The original drug may take on the role of a pro-drug. For example:-amitriptyline ---> nortriptylinecodeine ---> morphineprimidone ---> phenobarbitalDrug metabolism can be quantitatively altered by drug interactions. This alterationcan be an increase by induction of enzyme activity or a reduction by competitive inhibition.
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3.15.2 Induction:A large number of drugs can cause an increase over time in liver enzyme activity.This in turn can increase the metabolic rate of the same or other drugs. Phenobarbitone willinduce the metabolism of itself, phenytoin, warfarin, etc. Cigarette smoking can causeincreased elimination of theophylline and other compounds. Dosing rates may need to beincreased to maintain effective plasma concentrations.
3.15.3 Inhibition:Alternately some drugs can inhibit the metabolism of other drugs. Drug metabolismbeing an enzymatic process can be subjected to competitive inhibition. For example,warfarin inhibits tolbutamide elimination which can lead to the accumulation of drug andmay require a downward adjustment of dose.
3.15.4 Hepatic Clearance:The systemic clearance, CL, is a measure of the efficiency with which a drug isirreversibly removed from the body. Under first order conditions, clearance can becalculated as:-Single dose
Clearance after a Single Dose
During multiple dose regimens, clearance can be calculated under steady stateconditions as:-
Clearance at Steady Statewhere Cpss is the steady state plasma concentration and Cp is the average plasmaconcentration during the dosing interval .
3.15.4.1 Venous Equilibration Model Equation:The above equations apply to the overall clearance of drug from the body. We canalso consider the organ clearance as it may be measured in an isolated organ system. Here
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we would have for example an isolated liver, perfused with blood containing the drug ofinterest. By measuring the drug concentration in the blood entering and leaving the organ atsteady state, the organ clearance can be measured for the drug.
Figure 3.15.4.1(1). Blood Flow through the Liver
where Q is the blood flow rate to the organ, Ca is the concentration of drug in the bloodentering the organ, and Cv is the concentration of drug in the blood leaving the organ. Theterm E is the steady state extraction ratio. High E values mean high clearance by the liverand thus extensive metabolism.The sum of the individual organ clearance values are equal to the systemicclearance, CL. For a drug which is eliminated entirely via the liver, the hepatic clearance isequal to the systemic or total body clearance. From the equation above we can see that theorgan clearance is a function of the liver blood flow and the extraction ratio of the drug. Theliver blood flow is a physiological parameter which may be altered in disease states. Theextraction ratio, we shall see shortly is a parameter dependent not only of the condition ofthe liver but also the drug.Both the hepatic clearance and the extraction ratio are empirical parameters whichcan be used as measures of the efficiency of the elimination process. They are dependent onthree independent variables:-i) total hepatic blood flow (Q),ii) fraction unbound (fu) or the extent of drug binding to blood constituents. Thismay be saturable with high dose, polar compounds, andiii) the free intrinsic clearance (CLint) or the rate-limiting step in drug uptake fromblood, intracellular transport, metabolism, and where necessary biliary secretion. The freeintrinsic clearance may be thought of as the clearance of drug from liver plasma water,devoid of the influence of blood flow or binding. Since a major part of this parameter ismetabolism which is typically enzyme mediated this parameter may be saturated at higherdoses, for some drugs.
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The equation describing hepatic clearance in terms of these parameters using thevenous equilibration model can be defined as:
Clearance
CL = Q * EWith this equation it is possible to look at the influence of free intrinsic clearance,drug binding, and liver blood flow on the overall hepatic clearance of a drug. Drugs can beclassified into three types depending on the intrinsic clearance and binding. Flow limited,capacity limited, and others.
3.15.4.2 Flow Limited Drugs:
High fu * CLint ( ) value:For drugs with high total intrinsic clearance the extraction ratio, E, approaches100%, the hepatic clearance approximates and is dependent of hepatic blood flow. Hepaticclearance is said to be FLOW LIMITED. Also, we can note that the hepatic clearance is notdependent on moderate changes in free intrinsic clearance or binding to blood constituents.
Examples include:- lidocaine, propranolol, morphine.
3.15.4.3 Capacity Limited Drugs:
Very Low Total Intrinsic Clearance:With drugs having very low intrinsic clearance, hepatic extraction is inefficient andhepatic clearance becomes independent of hepatic blood flow. Now changes in free intrinsicclearance and/or binding to blood constituents becomes very important in determination ofthe overall hepatic clearance. Hepatic clearance is said to be CAPACITY LIMITED as theintrinsic capacity of the liver controls the drug clearance.
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Examples include: phenytoin, warfarin, and quinidine. For such drugs it is possiblethat liver disease will cause a decrease in CLint but also an increase in fu. In this case theoverall hepatic clearance doesn't reflect just the hepatic metabolic activity but also the drugbinding. This is illustrated with tolbutamide. In patients with hepatitis there is an increasein fu but no change in CLint. As a result CL is increased and the elimination half-lifedecreases. The change in elimination half-life reflects changes in binding and not changes indrug metabolizing activity.
3.15.4.4 Other Drugs:
Between these two extremes. Capacity-limited but binding-insensitive drugs:The three parameters; Q, fu, and CLint are important determinants of drug elimination.Examples include:- theophylline, antipyrine
3.15.5 Systemic Availability:Even if we can assume that a drug is completely absorbed across the G-I tract, aproportion of the dose may be eliminated by the liver before reaching the systemiccirculation because of the anatomical arrangement of the portal circulation. This pre-systemic or first-pass elimination can be determined from the extraction ratio, E, such thatthe fraction of the dose that is available to the central circulation is 1-E. This 1-E valuebecomes the maximum availability possible before allowing for reduced productperformance.For drugs which are extensively metabolized, first pass metabolism can be quiteimportant. It means that higher doses must be given orally compared with parenteraladministration.for example morphine p.o. 30 mg cf. IV. 5 mglidocaine not active p.o.In liver disease there is potential for changing the systemic availability of highextraction drugs and thereby affecting steady state concentrations.If liver disease causes a modest reduction in the extraction ratio, from for example0.95 to 0.9, the fraction of the orally administered drug reaching the systemic circulation (1-E) will be doubled. One of the consequences of the pathogenesis of chronic liver disease isthe development of porta-systemic shunts that may carry drug absorbed from the G-I tractthrough the mesenteric veins directly into the systemic circulation. Thus in a disease where
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biochemical hepatic function is relatively well maintained (e.g., schistosomiasis), oraltreatment with high clearance drugs such as morphine or propranolol can lead to highblood levels and an increase in adverse drug effects. For example, 30 mg morphine orallymay act like 30 mg IV. and lead to over dosage with respiratory depression.
3.16 Drug Distribution:
Drug distribution means the reversible transfer of drug from one location to anotherwithin the body. Once a drug has entered the vascular system it becomes distributedthroughout the various tissues and body fluids in a pattern that reflects the physiochemicalnature of the drug and the ease with which it penetrates different membranes. The ONECOMPARTMENT model assumes rapid distribution but it does not preclude extensivedistribution into various tissues.
3.16.1 Drug Distribution Patterns:Distribution can be thought of as following one of four types of patterns.1) The drug may remain largely within the vascular system. Plasma substitutes suchas dextran are an example of this type, but drugs which are strongly bound to plasmaprotein may also approach this pattern.2) Some low molecular weight water soluble compounds such as ethanol and a fewsulfonamides become uniformly distributed throughout the body water.3) A few drugs are concentrated specifically in one or more tissues that may or maynot be the site of action. Iodine is concentrated by the thyroid gland. The antimalarial drugchloroquine may be present in the liver at concentrations 1000 times those present inplasma. Tetracycline is almost irreversibly bound to bone and developing teeth.Consequently tetracyclines should only be given to young children or infants in extremeconditions as it can cause discoloration and mottling of the developing second set of teeth.Another type of specific concentration may occur with highly lipid soluble compoundswhich distribute into fat tissue.4) Most drugs exhibit a non-uniform distribution in the body with variations thatare largely determined by the ability to pass through membranes and their lipid/watersolubility. The highest concentrations are often present in the kidney, liver, and intestineusually reflecting the amount of drug being excreted.
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Pattern 4 is the most common being a combination of patterns 1, 2 and 3.
Figure 3.16.1(1). Representing Various Volumes Distribution Patterns
Drug Liters/Kg Liter/70 KgChloroquine 94 - 250 6600 - 17500Nortriptyline 21 1500Digoxin 7 500Lidocaine 1.7 120Theophylline 0.5 35Tolbutamide 0.11 8
Table 3.16.1(1). Apparent Volumes of Distribution
A useful indicator of the type of pattern that characterizes a particular drug is theapparent volume of distribution.A value of V in the region of 3-5 liter (in an adult) would be compatible with pattern1. This is approximately the volume of plasma. Pattern two would be expected to produce aV value of 30 to 50 liter, corresponding to total body water. Agents or drugs exhibitingpattern 3 would exhibit very large values of V if the drug concentration effect was acting onmost of the dose. Chloroquine has a V value of approximately 17,000 liter. Drugs followingpattern 4 may have a V value within a wide range of values. These patterns of variation havebeen used to determine body fluid volumes.
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Fluid substances Volume (liter) TestExtracellular Fluid 13-16 Inulin, Na23, Br-, I-Plasma 3-4 Evans blue, I131 albumin, dextransInterstitial fluids 10-13Intracellular fluids 25-28Total body water 40-46 Antipyrine, D2O, ethanol
Table 3.16.1(2). Volumes Measured by Various Test Materials
3.16.2 Factors affecting Drug Distribution
3.16.2.1 Rate of Distribution:
Rate of distribution - Membrane permeabilityBlood perfusionExtent of Distribution - Lipid SolubilitypH - pKaPlasma protein bindingIntracellular binding
Table 3.16.2.1(1). Rate of distribution
Membrane Permeability:We have already covered some material about membrane permeability. Thecapillaries are typically lined with endothelium whose cells overlap, though to a lesserdegree than epithelial cells. Also, the junctions between cells are discontinuous. Capillarywalls are quite permeable. Lipid soluble drugs pass through very rapidly. Water solublecompounds penetrate more slowly at a rate more dependent on their size. Low molecularweight drugs pass through by simple diffusion. For compounds with molecular diameterabove 100 Å transfer is slow.For drugs which can be ionized the drug's pKa and the pH of the blood will have alarge effect on the transfer rate across the capillary membrane.There are two deviations to the typical capillary structure which result in variationfrom normal drug tissue permeability.
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i) Permeability is greatly increased in the renal capillaries by pores in themembrane of the endothelial cells, and in specialized hepatic capillaries, known as sinusoidswhich may lack a complete lining. This results in more extension distribution of many drugsout of the capillary bed.ii) On the other hand brain capillaries seem to have impermeable walls restrictingthe transfer of molecules from blood to brain tissue. Lipid soluble compounds can be readilytransferred but the transfer of polar substances is severely restricted. This is the basis of the"blood- brain" barrier.Membrane permeability tends to restrict the transfer and distribution of drugs oncethey are delivered to the tissue. The other major factor which determines the rate of drugdistribution is blood perfusion.
Blood Perfusion Rate:The rate at which blood perfuses to different organs varies widely.
Organ Perfusion Rate (ml/min/ml of tissue) % of cardiac outputBone 0.02 5Brain 0.5 14Fat 0.03 4Heart 0.6 4Kidneys 4.0 22Liver 0.8 27Muscle 0.025 15Skin 0.024 6
Table 3.16.2.1(2). Blood Perfusion Rate
Total blood flow is greatest to brain, kidneys, liver, and muscle with highestperfusion rates to brain, kidney, liver, and heart. It would be expected that total drugconcentration would rise most rapidly in these organs. Certain organs such as the adrenals(1.2/0.2%) and thyroid (2.4/1%) also have large perfusion rates.
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Figure 3.16.2.1(1). Comparison between Drug transfer to Brain and Muscle
As an example; thiopental gets into the brain faster than muscle, whereas, penicillingets into muscle more quickly than it gets into brain.i) Thiopental is only partly ionized and passes into the brain or muscle easily.Perfusion limits the transport. Since brain has a higher perfusion rate the thiopental cantransfer in and out more quickly.ii) Penicillin is quite polar and is thus slowly permeable. Permeability limitedtransfer is faster in muscle as muscle capillaries are less restrictive. Thus transfer ofpenicillin is faster in muscle than brain.In brain, perfusion or membrane permeability limits drug transport or distribution.Thiopental diffuses readily, thus perfusion limits its distribution. Since perfusion is higherto the brain than to muscle, transport to the brain is faster. Penicillin less readily diffusesthus it is diffusion which limits penicillin distribution. Muscle diffusion is easier thusdistribution into muscle is faster for penicillin than distribution into brain.
3.16.2.2 Extent of Distribution:We can now consider factors which alter the extent of drug distribution
Plasma Protein Binding:Extensive plasma protein binding will cause more drugs to stay in the central bloodcompartment. Therefore drugs which bind strongly to plasma protein tend to have lowervolumes of distribution.
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Proteins Involved:Although drugs are bound to many macromolecules, binding to plasma protein isthe most common. Of these plasma proteins, albumin, which comprises 50 % of the totalproteins binds the widest range of drugs. Acidic drugs commonly bind to albumin, whilebasic drugs often bind to alpha1-acid glycoproteins and lipoproteins. Many endogenoussubstances, steroids, vitamins, and metal ions are bound to globulins.
Drugs Binding Sites for Acidic AgentsBilirubin, Bile acids, Fatty Acids,Vitamin C,Salicylates, Sulfonamides,Barbiturates,Phenylbutazone,Penicillins, Tetracyclines,Probenecid
Albumins
Binding Sites for Basic AgentsAdenisine, Quinacrine, Quinine,Streptomycin,Chloramphenicol,Digitoxin, Ouabain, Coumarin Globulins, alpha1, alpha2, beta1,beta2, gamma
Table 3.16.2.2(1). Proteins with Potential Binding Sites for Various Drugs
Forces involved:Groups on the protein molecules that are responsible for electrostatic interactionswith drugs include:the of lysine and N- terminal amino acids,the of histidine, the - S- of cysteine, andthe - COO- of aspartic and glutamic acid residues.In order to achieve reasonably stable complexes, however, it is likely that in mostcases the initial electrostatic attraction is reinforced at close range by van der Waal's forces(dipole-dipole; dipole-induced dipole; induced dipole-induced dipole) and hydrogenbonding. This is suggested by the frequently crucial role of protein configuration in thebinding phenomenon. Agents which denature protein may cause the release of bound drug.Often there may be competition between drugs, in which agents that are bound very tightly,such as coumarin anticoagulants, are able to displace less tightly bound compounds fromtheir binding sites.
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Drug Percent Unbound (100 * fu)Caffeine 90Digoxin 77Gentamicin 50Theophylline 85Phenytoin 13Diazepam 4Warfarin 0.8Phenylbutazone 5Dicumarol 3
Table 3.16.2.2(2). Percent Unbound for Selected Drugs
Slight changes in the binding of highly bound drugs can result in significant changesin clinical response or cause a toxic response. Since it is the free drug in plasma whichequilibrates with the site of pharmacological or toxic response, a slight change in the extentof binding, such as 99 to 98 % bound, which can result in an almost 100 % change in freeconcentration, can cause very significant alteration in response. For a large number ofdrugs, including warfarin and phenytoin, drug response will be dependent on free drugconcentration. Alteration of free concentration by drug interaction or disease state can alterthe intensity of action of these drugs. Examples include phenylbutazone and salicylatesdisplacing tolbutamide to give an increased effect, hypoglycemia.As you can see from Table XVIII-5, the extent of protein binding can varyconsiderably from one drug to another.
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Protein Binding Determination:
Spectral changes: Most drugs have distinct UV spectra because of the conjugatedchromophores in the molecule. When a drug interacts with a protein the UV or visiblespectrum may be changed because of alterations in the electronic configuration. Thesealterations can be quantitated and used to determine the extent of binding. Changes influorescence spectra can be used in the same way. Spectra for warfarin.
Gel filtration: This involves the use of porous gels that are molecular sieves. Theyseparate components on the basis of size. Low molecular weight drugs are held on the gelwhereas bound drug and protein are washed through.
Equilibrium dialysis:
Figure 3.16.2.2(1). Equilibrium Across a Semi-permeable Membrane
The protein solution (e.g. plasma) containing drug and a buffer solution are placedon opposite sides of a dialysis membrane.After a sufficient time (maybe 12- 24 hours), free drug concentration will be thesame on either side of the membrane. Protein binding can be determined by measuring theconcentration of drug on either side of the membrane. On left the concentration will involvefree and bound drug, whereas on the right there is no binding and the concentration willequal to the free drug concentration.
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Ultrafiltration:
Figure 3.16.2.2(2). Ultrafiltration as a Method of Measuring Protein Binding
A quicker method of separating free and bound drug is the ultrafiltration method.Drug and protein solution are placed in a filter membrane and liquid containing free drug isforced through the membrane by centrifugation.Protein binding equilibriaWith one type of binding site, protein binding can be described mathematically bythe equation:
With [D] free drug concentration, [P] total protein concentration with 'n' bindingsites per molecule, thus [nP] is the total concentration of protein binding sites and [rP] =[DP] is the concentration of bound drug or bound protein with r drug molecules bound perprotein molecule. Typically there may be 1 - 4 binding sites per protein molecule.
Ka = association constant
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Plots:
Figure 3.16.2.2(3). Plot of r/[D] Versus r
This can be rearranged to give thus plotting r/[D] versusr should give a straight line. This is called a Scatchard plot.
Figure 3.16.2.2(4). Plot of 1/r Versus 1/[D]
Alternate rearrangement gives
thus a plot of 1/r versus 1/[D] should also give a straight line. This thedouble reciprocal plot.With one type of binding site these plots produce straight lines which can be used todetermine Ka and n values. With more than one type of binding site, these plots are curved.
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Tissue localization of drugs:In addition to plasma protein binding, drugs may bind to intracellular molecules.Certain of these may be actual drug receptors, and the interaction that occurs mayrepresent the molecular basis of the pharmacological action.The affinity of a tissue for a drug may be for any of several reasons, includingbinding to tissue proteins (such as albumin) or to nucleic acids, or in the case of adiposetissue, dissolution in the lipid material.The concentration of chloroquine in the liver is due to the binding of the drug toDNA. Barbiturates distribute extensively into adipose tissue, primarily because of their highlipid solubility. Tetracyclines bind to bone thus should be avoided in young children ordiscoloration of permanent teeth may occur.Unlike plasma binding, tissue binding of a drug cannot be measured directly ashandling of the tissue results in disruption of the binding. This doesn't mean that tissuebinding and changes in tissue binding are not important.
3.16.3 Weight Considerations:The apparent volume of distribution will often be proportional to the total bodyweight of a patient. In fact many V values found in the literature will be given as so manyliter per kilogram total body weight. The assumption made is that the body composition isunchanged on a percentage basis, thus distribution will be identical no matter what thepatient weighs. This works within some limits.For example body composition of the very young and the very old may be quitedifferent from `normal', that is the average subject in whom the parameter values may havebeen originally determined.For example the apparent volume of distribution of antipyrine is 0.62 l/kg in normalweight subjects but 0.46 l/kg in obese patients. Other drugs such as digoxin and gentamicinare also quite polar and tend to distribute into water rather than adipose tissue.
3.16.4 Protein Binding Interactions:The role of protein binding in drug interactions can be quite involved. Althoughdrugs may well displace each other from common binding sites, the clinical (andpharmacokinetic) importance of these interactions may require considerable investigation.
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For these effects to be important one drug must be extensively protein bound, while thedisplacer must have a high affinity for the same binding site.Therapeutically the major criteria are the free drug concentration. One result of adrug interaction is to tend to produce an increase in free drug concentration, however, thatwill cause an increase in elimination and thus an overall reduction in total drugconcentration, potentially maintaining the free concentrations unchanged.
3.17 Multi-Compartment Pharmacokinetic Models:
So far we have talked about the pharmacokinetics of drugs in terms of a onecompartment model. We have assumed that the drug, once administered is mixedinstantaneously in the blood and that the drug distributes throughout the body rapidlyreaching equilibrium throughout the tissue into which the drug enters. We have in essenceconsidered that the body acts as a well mixed container.
Figure 3.17(1). Linear Plot of Cp Versus Time for a One-Compartment - IV Bolus
With first order drug elimination we found that the plasma concentration will fallmonoexponentially with time following IV bolus administration.
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Figure 3.17(2). Semi-Log Plot of Cp Versus TimeAnd the log of the plasma concentration will fall as a straight line.
Figure 3.17(3). Semi-Log Plot of Cp Versus Time. Two-Compartment - IV Bolus.
Commonly we find with real data, especially if we have a number of early datapoints, that the log Cp versus time plot is not a straight line. We see an initial early deviationfrom the straight line, followed by a log-linear phase. The initial phase is a more rapid dropin plasma concentration before settling into the log-linear fall in plasma concentration.This suggests that the body is not behaving as a single well mixed compartment.There appears, mathematically, to be distribution between two (or more) compartments.That is we don't have instantaneous equilibrium between the drug in all the various tissuesof the body. In the next approximation we can consider that the body is behaving as twodistinct compartments. These compartments can be called the central compartment and the
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peripheral compartment. Exact anatomical assignment to these compartments is not alwayspossible. However, generally the rapidly perfused tissues often belong in the centralcompartment.
3.17.1 Intravenous administration
3.17.1.1 Scheme or Diagram:
Figure 3.17.1.1(1). Two Compartment Pharmacokinetic Model
3.17.1.2 Differential Equation:The differential equation for drug in the central compartment following intravenousbolus administration is:-
The kel * X1 term describes elimination of the drug from the central compartment,while the k12 * X1 and k21 * X2 terms describe the distribution of drug between the centraland peripheral compartments.
3.17.1.3 Integrated equationIntegration of this equation (using Laplace transforms) leads to a biexponentialequation for plasma concentration as a function of time.Thus,Cp = A * e- * t + B * e- * t with > .The A, B, , and terms were derived from the microconstants during the integrationprocess. They are functions of the microconstant k12, k21, kel and V1+ = kel + k12 + k21* = kel * k21
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3.17.1.4 Parameter Determination:
Method of Residuals:Values for all these parameters can be determined by first calculating A, B, , and. For this we can use the method of residuals (in a similar fashion to determining ka andkel for the one compartment model after oral administration). By definition is greaterthan then as t --> , e- *t --> 0 faster than e- * t. Therefore if the ratio / is largeenough (greater than 5) the terminal data points will fall on the lineCplate = B * e- * tThis equation is similar to the equation for the late plasma concentration valuesafter oral administration with a one compartment model. This line will be linear if plottedon semi-log graph paper.From the slope of this line a value of can be determined. The t1/2 calculated as0.693/ is often called the biological half-life or terminal half-life. It is the half-lifedescribing the terminal elimination of the drug from plasma. [For the one compartmentmodel the biological half-life is equal to 0.693/kel].
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Figure 3.17.1.4(1). Semi-Log Plot of Cp Versus Time Showing Cplate Extrapolated Back to B
The difference between the Cplate values at early times and the actual data at earlytimes is again termed the 'residual'Residual = Cp - Cplate = A * e- *t
Figure 3.17.1.4(2). Semi-Log Plot of Cp Versus Time Showing Residual Line and Line
From the slope of the residual line the value of can be calculated with the A readoff the concentration axis. With A, B, , and calculated we can calculate themicroconstants given the formulas.
; ;
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3.17.1.5 Effect of k12 and k21:
Figure 3.17.1.5(1). Plot of Cp versus Time Showing the Effect of
Different k12/21 Ratio Values
From the k12 and k21 values we can assess the extent of distribution of drug intothe peripheral compartment. The higher the ratio k12/k21 the greater the distribution ofdrug into the peripheral compartment. The larger the individual values of k12 and k21 thefaster is the transfer between the central and peripheral compartments and the more thebody behaves as a single compartment.
Figure 3.17.1.5(2). Plot of Cp versus Time Showing the Effect of the
Magnitude of k12 and k21
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As the ratio increases the distribution phase is more pronounced. Conversely withthe ratio 1/4 there is very little distribution phase. Also note that the value or the slope ofthe terminal phase is changing even though the kel is fixed at 0.2 hr-1.With faster and faster distribution the initial drop in plasma concentration becomesquite rapid. If you were sampling every 30 minutes, the initial phase would be missed. Thedata would look just like a one compartment model. Redrawing the slow plot with k12/k21(0.5/0.25) over 24 hours and gives a plot that is definitely still biexponential.
3.17.1.6 Apparent Volumes of Distribution:The concentration of drug in the body is determined not only by the rate constantvalues but also by the apparent volume of distribution. In the case of the two compartmentmodel a number of volume terms can been defined.
V1:The apparent volume of the central compartment, V1 or Vc, can be calculated as:-
This parameter is important because it allows the calculation of the highest plasmaconcentration or Cp0 after an IV bolus administration. This concentration may result intransient toxicity. V1 can also be used in dose calculations.
Varea ( = Vß):Varea or Vß is defined as:-
= VßBecause of the relationship with clearance and and with V1 and kel this parameteris quite useful in dosing calculations. This parameter can be readily calculated via AUC andvalues from the 'raw' data and is therefore commonly quoted.
Vextrap:Vextrap calculated as:-
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This is the volume value calculated if the distribution phase is ignored. Generally notvery useful. However, you may see it used. You will be using this if the distribution phase isignored. (That is, it is the V calculated using a one compartment model with a twocompartment drug).
VssVss, V steady state defined as:-
This term relates the total amount of drug in the body at 'steady state' with theconcentration in plasma or blood
Figure 3.17.1.6(1). Plot of X1 (Plasma) and X2 (Tissue) Compartment Concentrations,
Showing ÔSteady StateÕ with Both Lines Parallel
The relationship between volume terms is that:Vextrap > Varea > Vss > V1 and for a one compartment model the values for all these parametersare equal.The first two columns are the time and plasma concentration which may becollected after IV bolus administration of 500 mg of drug. At longer times, after 4 hours, outto 12 hours the data appears to follow a straight line on semi- log graph paper. Since >this terminal line is described by B * e- *t.
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As an example we can look at the data in the table below.
Time
(hr)
Concentration
(mg/L)
Cplate
(mg/L)
Residual
(mg/L)0.5 20.6 8.8 11.81 13.4 7.8 5.62 7.3 6.1 1.23 5.0 4.7 0.34 3.7 3.7 -6 2.28 1.410 0.8212 0.50
Table 3.17.1.6(1). Two Compartment Pharmacokinetics
Figure 3.17.1.6(2). Plot of Cp versus Time Illustrating the Method of Residuals
Following it back to t = 0 gives B = 10 mg/L. From the slope of the line [ = 0.25 hr-1.Cplate values at early times are shown in column 3 and the residual in column 4. The residualvalues are plotted (o) also giving a value of A = 25 mg/L and = 1.51 hr-1Note that / = 6, thus these values should be fairly accurate.B = 10 mg/L, = (ln 10 - ln 0.5)/12 = 2.996/12 = 0.25 hr-1A = 25 mg/L, = (ln 25 - ln 0.27)/3 = 4.528/3 = 1.51 hr-1Therefore Cp = 25 * e-1.51 * t + 10 * e-0.25 * tWe can now calculate the microconstants.
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= 0.61 hr-1
k12 = + - k21 - kel= 1.51 + 0.25 - 0.61 - 0.62= 0.53 hr-1
The AUC by the trapezoidal rule + Cplast/ = 56.3 + 2.0 = 58.3 mg.hr.L-1, [Note theuse of ] thus
Notice that Vextrap > Varea > Vss > V1 [50 > 34.3 > 26.7 > 14.3]
3.17.1.7 Dosage Calculations:Dosage calculations are complicated by the extra terms in the equations howeversome calculations are still reasonably straightforward. The dose required for a particularinitial plasma concentration can be calculated if V1 is known.Thus: DOSE = V1 * Cp0(required)To achieve an initial Cp of 20 mg/L given V1 = 30 liter would require a DOSE = 20 *30 = 600 mg.Alternately if a dose of 500 mg is given and the V1 value is 16 L, the expected Cp0 canbe calculated.Cp0 = 500/16 = 31.3 mg/LIf the A, B, , and values are known or calculated, then the plasma concentrationat any time after a single IV dose can be calculated.The plasma concentration achieved after a continuous IV infusion is given by the sameequation described for the one compartment model, i.e.:-k0 = Cpss * clearance = Cpss * V1 * kel = Cpss * Varea *If a plasma concentration of 30 mg/L is required and V1 = 15 L and kel is 0.2 hr-1then the required infusion rate can be readily determined. k0 = 30 x 15 x 0.2 = 90 mg/hr
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Figure 3.17.1.7(1). Linear Plot of Cp Versus Time With IV Bolus and Infusion to Give 30 mg/L
Since the time to reach the steady state concentration is controlled by the valuethis could mean a slow approach to the desired value, thus an IV bolus loading dose may beuseful. Unfortunately this calculation is not straight forward as you found in the labexperiment.
Figure 3.17.1.7(2). Linear Plot with Higher and Lower Bolus Dose
With V1 = 15 L, kel = 0.2 hr-1, and required Cp = 30 mg/LBolus DOSE = 15 x 30 = 450 mg andInfusion Rate = k0 = 30 x 15 x 0.2 = 90 mg/hrAs you can see this gives quite a dip in the Cp versus time curve. With Bolus DOSEs,either 600 or 300 mg the curves may or may not be better depending on the therapeuticrange of the drug.
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Figure 3.17.1.7(3). Linear Plot of Cp Versus Time With Fast and Slow Infusion
Another alternative is to give a fast infusion followed by the maintenance infusion.Here 1200 mg was given over 4 hours (at 300 mg/hr) before switching to the slower 90mg/hr maintenance rate.
3.17.2 Oral Administration:Following oral administration of a drug with two compartment characteristics, Cp isdescribed by an equation with three exponential terms.
Figure 3.17.2(1). Scheme for Oral Two-Compartment Pharmacokinetic Model
The model is shown in above figure:
Differential equation
Cp = A.e-alpha.t + B.e-beta.t + C.e-ka.twhere A + B + C = 0
Integrated Equation
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Figure 3.17.2(2). Semi-Log Plot Showing Pronounced Distribution
Bioavailability calculations are the same as for the one compartment model, i.e., bycomparison of AUC or U . These apply for any linear system. Also if , , and ka aresufficiently separated the method of residuals can be applied to determine the three values.
Figure 3.17.2(3). Semi-Log Plot Without Distribution Phase Evident
The equation can also be used to calculate appropriate dosing regimens. Forexample if an average plasma concentration of 20 mg/L is required and V1 = 15 L, kel = 0.15hr-1, F = 0.9 and a dosing interval of 12 hours is to be used then the required dose is:-= 600 mg every 12 hours
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3.17.3 Non Compartmental Analysis:
Table 3.17.3(1). Typical Cp versus Time Data after IV Bolus Administration
Non compartmental methods can be used to determine certain pharmacokineticparameters without deciding on a particular compartmental model. The basic calculationsare based on the area under the plasma concentration versus times curve (zero moment)and the first moment curve (AUMC). The AUC can be calculated as before using by thetrapezoidal rule.The first moment is calculated as concentration times time (Cp * t). The AUMC is thearea under the concentration times time versus time curve. Maybe best covered with anexample. Consider a drug given both by iv and oral administration. Both the AUC and AUMCwere calculated using the trapezoidal rule without making any assumption concerning thenumber of compartments. The final segment of the AUC curve is calculated as Cp(last)/k,where k is the last exponential (the slowest). The last segment for the AUMC curve is:
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From the AUC and AUMC values we can calculate the mean residence time, MRT.This is the average time that the drug stays in the body (or plasma as measured here). It canbe related to the average elimination rate constant as 1/MRT. The values from the abovedata are MRT = 553.21/67.43 = 8.2 hr and k = 1/8.2 = 0.122 hr- 1. Remember we can alsocalculate the clearance, CL = Dose/AUC = 100/67.43 = 1.48 L.hr- 1. Finally a steady statevolume can be calculated as CL * MRT = 1.48 x 8.2 = 12.2 L.
Table 3.17.3(2). Typical Cp versus Time Data after Oral Administration
The following data were calculated after a 250 mg oral dose of the same drug. Fromthese data a MRT was calculated as 1360.98/149.78 = 9.08 hr. We can subtract from thisMRT(PO) the MRT(iv) to get an idea of the absorption process, the mean absorption time(MAT). That is MAT = MRT(PO) - MRT(iv) = 9.08 - 8.20 = 0.88 hr. From this we can calculatean average absorption rate constant = 1/MAT = 1/0.88 = 1.14 hr-1. Of course we cancalculate the bioavailability of the oral dosage form using the dose adjusted AUC ratio. ThusF = (149.78/67.43) x (100/250) = 0.89.
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Figure 3.17.3(1). Plot of Cp versus Time (IV)
Figure 3.17.3(2). Plot of Cp x Time versus Time (IV)
Figure 3.17.3(3). Plot of Cp versus Time (PO)
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Figure 3.17.3(4). Plot of Cp x Time versus Time (PO)
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Chapter 4:
DRUG DISSOLUTION
PARAMETERS COMPUTATIONS
4.1. Introduction:
Dissolution, or Solvation, in chemistry, the process of dissolving a solid substanceinto a solvent to yield a solution. Drug dissolution testing is an approach to evaluate drugrelease characteristics of a product (tablets/capsules) in vitro. The technique is very wellestablished and extensively used at every stage of product manufacturing. [1-2].Dissolution testing of pharmaceutical dosage forms is considered to be one of themost important quality control tests in the pharmaceutical industry for the characterizationof drug substance and solid dosage forms. It is also a useful tool in correlation offormulation / process variables to the rate and extent of release of the drug from the dosageform. The optimization of formulation parameters such as particle size, amount and type ofsurfactant, disintegrates and lubricants incorporated, compressional forces applied totablets, coatings employed to extend release, and other factors to produce desired releasecharacteristics for a drug product are conveniently monitored by dissolution techniques.Dissolution has been accepted as an important quality control test for oral solid dosageforms for over 20 years. Though not often validated by in vivo studies, the results of a well-designed dissolution test generally offer a sense of assurance for product quality that isneeded for proper in vivo performance. [3-5]Drug dissolution (or release) testing is an analytical technique used to assess releaseprofiles of drugs in pharmaceutical products, generally solid oral products such as tabletsand capsules. This test gains its significance from the fact that if a drug from a product is toproduce its effect; it must be released from the product and should generally be dissolved inthe fluids of the gastrointestinal (GI) tract. Thus, a drug dissolution test may be consideredas an indicator of potential drug release and absorption characteristics of a product inhumans as well as in animals. Therefore, a dissolution test is often considered a surrogatefor the assessment of availability of drugs in the body, generally termed bioavailability. This
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link of dissolution (in vitro) to drug release in the body (in vivo) as commonly determinedby bioavailability assessment is formally referred to as in vitro–in vivo correlation(IVIVC).This concept of IVIVC, in a quantitative and/or qualitative format, provides the basisfor the assessment of quality of the products. Thus, the dissolution test is not only aprocedure for product development but is also extensively used as a quality controltechnique because of this in vitro–in vivo association. [5-8]
4.1.1 Dissolution Profiles:The ideal immediate release profile goes through 5 main stages. While many ofthese actions are occurring through out the profile, these named are the primary factoraffecting the shape of the profile. It is a term used to describe the diminishing light of a staras a celestial body slowly blocks it from view. The fifth term is a borrowed medical termused to describe the complete blockage of an artery, no longer able to deliver any moreblood. [9-11]
Figure 4.1.1(1): Plot of Concentration and Time
A: DisintegrationB: DeaggegationC: ReleaseD: OccultationE: Occlusion
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4.1.2 Dissolution Profiling:Dissolution profile of two products (12 units each) of the test and referenceproducts. To use the mean dissolution values from both curves, the percent coefficient ofvariation at the earlier time points should not be more than 20% and at other time pointsshould not be more than 10%. Only one measurement should be considered after 85%dissolution of both of the products. The dissolution measurements of the test and referencebatches should be made under exactly the same conditions. [12-13].
4.1.3 Dissolution and Particle Size:In order for a drug to have its effect after oral administration it must go into solutionand then diffuse through the gut wall into the body. The first step in that process is thedisintegration of the dosage form followed by dissolution of the active ingredient.Dissolution of a pure substance follows the Noyes Whitney Equation.              Where,     is the rate of dissolution,k is the dissolution rate constant,S is the surface area of the dissolving solid,Cs is the saturation concentration of drug in the diffusion layer andCt is the concentration of drug in dissolution media (or the bulk).One way to increase dissolution rate of poorly soluble drugs is to increase thesurface available for dissolution. This is done by reducing particle size or by dividing thedosage form into two smaller tablets or capsules, with a larger combined surface area. Otherways include increasing the disintegration rate and deaggregation. [14]A wide range of principles and methods is available for the purpose of enhancingdissolution and/or dissolution rate of 'low-solubility' substances, for example: selection ofsalt form for weak acids and bases, reduction of particle size and, thereby, increased specificsurface area, use of surfactants for increased wettability, complex formation withexcipients, e.g. hydrophilic polymers or cyclodextrins, preparation of solid dispersions,change of crystal form by precipitation with hydrophilic polymers, lipophilic formulations,i.e. emulsions, microemulsions etc. [14-15].To reflect drug absorption behavior in vivo or, more accurately drug release in vivo,drug dissolution tests are conducted in vitro, mimicking the physiological environment of
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the GI tract. The GI tract environment is represented by mild stirring of drug products inaqueous-based solutions, such as 0.1 N HCl or buffers having pH values in the range of 4–7.5. The cumulative percentage of a drug dissolved at a number of time points is determinedand may be reported as a plot of % drug dissolved versus sampling times. The resultinggraph is commonly referred to as a “dissolution profile” and provides a means ofcomparison with in vivo drug release to establish absorption characteristics of drugs fromproducts in humans. [16].
Figure 4.1.3(1):Possible testing outcome scenarios, as drug dissolution (release) profiles, of
products with in vivo similar (bioequivalent) and dissimilar (bioinequivalent) release
characteristics.
Further, because of the above-mentioned in vitro–in vivo association, it is generallyconsidered that if a dissolution profile of a test product matches that of a reference product,then the test product should behave similarly to the reference product in vivo (i.e., both willhave similar bioavailability and will be considered as bioequivalent). Conversely, if theprofile of the test product is different from that of the reference product, then the testproduct might behave differently in humans. This practice of describing dissolution resultsor profiles is commonly referred to as providing discriminating dissolution profiles, and thetest as a discriminatory test. That is, a dissolution test is expected to discriminate whetherdissimilar products are from different manufacturing batches of the same product or from
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different products such as generics. It is most important to note that the terminology of“discrimination” should be related to and based on similarity or dissimilarity of in vitroresults to in vivo results only. It is further important to note that a test should only beconsidered discriminatory if dissolution profiles obtained are dissimilar for dissimilar invivo profiles (i.e., products should be bioinequivalent). [17-19].If different dissolution profiles are obtained for products with the same or differentformulations or manufacturing attributes but with similar in vivo characteristics, they maynot be considered as discriminating profiles, and the test that produces such profiles shouldnot be considered as a discriminatory test. The differences in profiles for products havingsimilar release characteristics in vivo (i.e., for bioequivalent products) should be consideredas an expected and acceptable variation in dissolution results from acceptable productswithout any negative therapeutic consequences. Such differences in dissolution profilesshould form the basis of setting tolerances for quality control purposes for acceptableproducts and not for establishing discrimination or differences. Dissolution is the processby which a solid or liquid enters its aqueous phase (solution) [20-21].
4.2 Mechanism of Drug Dissolution:
So far we have looked at the transfer of drugs in solution in the G-I tract, through amembrane, into solution in the blood. However, many drugs are given in solid dosage forms,and therefore must dissolve before absorption can take place. [22].
Figure 4.2(1) Dissolution and Absorption
If absorption is slow relative to dissolution then all we are concerned with isabsorption. However, if dissolution is the slow, rate determining step (the step controllingthe overall rate) then factors affecting dissolution will control the overall process. This is amore common problem with drugs which have a low solubility (below 1 g/100 ml) or whichare given at a high dose, e.g. griseofulvin.
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There are number of factors which affect drug dissolution. One model that iscommonly used is to consider this process to be diffusion controlled through a stagnantlayer surrounding each solid particle.
Figure 4.2(2) Diagram Representing Diffusion through the Stagnant Layer
A physical model is shown in Figure 4.2(1).First we need to consider that each particle of drug formulation is surrounded by astagnant layer of solution.After an initial period we will have a steady state set-up where drug is steadilydissolved at the solid-liquid interface and diffuses through the stagnant layer. If diffusion isthe rate determining step we can use Fick's first law of diffusion to describe the overallprocess.
Figure 4.2(3) Plot of Concentration Gradient
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If we could measure drug concentration at various distances from the surface of thesolid we would see that a concentration gradient is developed. [23-25].
4.2.1 Fick's First Law:
By Fick's first law of diffusion applied to dissolution:
where D is the diffusion coefficient, A the surface area, Cs the solubility of the drug, Cb theconcentration of drug in the bulk solution, and h the thickness of the stagnant layer. If Cb ismuch smaller than Cs then we have so-called "Sink Conditions" and the equation reduces to
with each term in this equation contributing to the dissolution process.
4.2.1.1 Surface area, A:The surface area per gram (or per dose) of a solid drug can be changed by alteringthe particle size. For example, a cube 1 cm on each side has a surface area of 6 cm2. If thiscube is broken into cubes with sides of 0.1 cm, the total surface area is 60 cm2. Actually if webreak up the particles by grinding we will have irregular shapes and even larger surfaceareas. Generally as A increases the dissolution rate will also increase. Improvedbioavailability has been observed with griseofulvin, digoxin, etc.Methods of particle size reduction include mortar and pestle, mechanical grinders,fluid energy mills, solid dispersions in readily soluble materials (PEG's).
4.2.1.2 Diffusion layer thickness, hThis thickness is determined by the agitation in the bulk solution. In vivo we usuallyhave very little control over this parameter. It is important though when we perform invitro dissolution studies because we have to control the agitation rate so that we get similarresults in vitro as we would in vivo.
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Figure 4.2.1.2(1) Plot of Concentration versus Distance for Dissolution into a Reactive Medium
The apparent thickness of the stagnant layer can be reduced when the drugdissolves into a reactive medium. For example, with a weakly basic drug in an acidicmedium, the drug will react (ionize) with the diffusing proton (H+) and this will result in aneffective decrease in the thickness of the stagnant layer.The effective thickness is now h' not h. Also the bulk concentration of the drug iseffectively zero. For this reason weak bases will dissolve more quickly in the stomach.
4.2.1.3 Diffusion Coefficient, DThe value of D depends on the size of the molecule and the viscosity of thedissolution medium. Increasing the viscosity will decrease the diffusion coefficient and thusthe dissolution rate. This could be used to produce a sustained release effect by including alarger proportion of something like sucrose or acacia in a tablet formulation.
4.2.1.4 Drug Solubility, CsSolubility is another determinant of dissolution rate. As Cs increases so does thedissolution rate. We can now look at ways of changing the solubility of a drug.
Salt Form:If we look at the dissolution profile of various salts.
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Figure 4.2.1.4(1) Plot of Dissolved Drug Concentration versus Time
Salts of weak acids and weak bases generally have much higher aqueous solubilitythan the free acid or base, therefore if the drug can be given as a salt the solubility can beincreased and we should have improved dissolution. One example is Penicillin V.
Figure 4.2.1.4(2) Plot of Cp versus Time
Crystal Form:
Figure 4.2.1.4(3) Plot of Cp versus Time for Three Formulations of Chloramphenicol Palmitate
PDF Creator - PDF4Free v2.0                                                    http://www.pdf4free.com
Chapter 4: Drug Dissolution Parameters Computations 177
This can lead to quite different Cp versus time results after oral administration. Thetpeak values are similar thus ka probably the same. Cpeak would show a good correlation withsolubility. Maybe site limited (only that in solution by the time the drug gets to the 'window'is absorbed). Use the potassium salt for better absorption orally. These results mightsupport the use benzathine or procaine for IM depot use.Some drugs exist in a number of crystal forms or polymorphs. These different formsmay well have different solubility properties and thus different dissolution characteristics.Chloramphenicol palmitate is one example which exists in at least two polymorphs. The Bform is apparently more bioavailable.The recommendation might be that manufacturers should use polymorph B formaximum solubility and absorption. However, a method of controlling and determiningcrystal form would be necessary in the quality control process. Shelf-life could be a problemas the more soluble (less stable) form may transform into the less soluble form. In time thesuspension may be much less soluble with variable absorption. [26-27]
4.3 Dissolution Testing Parameters:
Dissolution tests in vitro measures the rate and extent of dissolution of a drug inaqueous medium from a dosage form. Extensive research work on in vitro dissolution andin vivo availability of drugs revealed the fact that in vitro dissolution test can be used topredict the in-vivo performance of the dosage form. There are number of parameters thatmust be considered when performing dissolution test. [28-31].
4.3.1 Apparatus:The most commonly employed dissolution test methods are (1) the basketmethod (Apparatus 1) and (2) the paddle method (Apparatus 2). The basket and thepaddle methods are simple, robust, well standardized, and used worldwide. Thesemethods are flexible enough to allow dissolution testing for a variety of drugproducts. For this reason, the official in vitro dissolution methods described in U.S.
Pharmacopeia (USP), Apparatus 1 and Apparatus 2 should be used unless shown tobe unsatisfactory. The in vitro dissolution procedures, such as the reciprocatingcylinder (Apparatus 3) and a flow-through cell system (Apparatus 4) described in
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the USP, may be considered if needed. These methodologies or other alternatives/modifications should be considered on the basis of their proven superiority for aparticular product. Because of the diversity of biological and formulation variablesand the evolving nature of understanding in this area, different experimentalmodifications may need to be carried out to obtain a suitable in vivo correlationwith in vitro release data. Dissolution methodologies and apparatus described in theUSP can generally be used either with manual sampling or with automatedprocedures. [32-33].
4.3.2 Dissolution Medium:Dissolution testing should be carried out under physiological conditions, ifpossible. This allows interpretation of dissolution data with regard to in vivoperformance of the product. However, strict adherence to the gastrointestinalenvironment need not be used in routine dissolution testing. The testing conditionsshould be based on physicochemical characteristics of the drug substance and theenvironmental conditions the dosage form might be exposed to after oraladministration. [34].The volume of the dissolution medium is generally 500, 900, or 1000 mL.
Ø Generally as dissolution media following are used:
Ø 0.1N HCL
Ø 0.01N HCL
Ø 0.06N HCL
Ø 0.05M Potassium Phosphate pH 6.8
Ø 0.05M Potassium Phosphate pH 7.2
Ø 0.05M Potassium Phosphate pH 7.4
Ø 0.05M Acetate Buffer pH
Ø 4.5 Simulated Gastric Fluid
Sink conditions are desirable but not mandatory. An aqueous medium withpH range 1.2 to 6.8 (ionic strength of buffers the same as in USP) should be used. Tosimulate intestinal fluid (SIF), a dissolution medium of pH 6.8 should be employed. Ahigher pH should be justified on a case-by-case basis and, in general, should not
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exceed pH 8.0. To simulate gastric fluid (SGF), a dissolution medium of pH 1.2should be employed without enzymes. The need for enzymes in SGF and SIF shouldbe evaluated on a case-by-case basis and should be justified.Use of water as a dissolution medium also is discouraged because testconditions such as pH and surface tension can vary depending on the source ofwater and may change during the dissolution test itself, due to the influence of theactive and inactive ingredients. For water insoluble or sparingly water soluble drugproducts, use of a surfactant such as sodium lauryl sulfate is recommended. Theneed for and the amount of the surfactant should be justified. [35-37].All dissolution tests for IR dosage forms should be conducted at 37±0.5°C.The basket and paddle method can be used for performing dissolution tests undermultimedia conditions (e.g., the initial dissolution test can be carried out at pH 1.2,and, after a suitable time interval, a small amount of buffer can be added to raise pHto 6.8). Alternatively, if addition of an enzyme is desired, it can be added after initialstudies (without enzymes).Use of Apparatus 3 allows easy change of the medium. Apparatus 4 can alsobe adopted for a change in dissolution medium during the dissolution run. Certaindrug products and formulations are sensitive to dissolved air in the dissolutionmedium and will need deaeration. In general, capsule dosage forms tend to floatduring dissolution testing with the paddle method. [38].The apparatus suitability tests should be carried out with a performancestandard (i.e., calibrators) at least twice a year and after any significant equipmentchange or movement. However, a change from basket to paddle or vice versa mayneed recalibration. The equipment and dissolution methodology should include theproduct related operating instructions such as deaeration of the dissolution mediumand use of a wire helix for capsules. Validation of automated procedures comparedto the manual procedures should be well documented. [39].
4.3.3 Types of Dosage Form: [40]Dissolution testing is a useful tool for evaluation and testing of various dosageforms. Dosage forms are the means by which drug molecules are delivered to sites of action
PDF Creator - PDF4Free v2.0                                                    http://www.pdf4free.com
Chapter 4: Drug Dissolution Parameters Computations 180
within the body. The different forms in which drugs may be supplied to a patient aredescribed briefly:
4.3.3.1 Implants:These are sterile disks or cylinders introduced surgically into body tissues anddesigned to release one or more medicaments over an extended period of time.
4.3.3.2 Insufflations:These are medicated powders designed to be blown into the ear, nose, throat orbody cavities by means of a device known as an insufflator. Bulk insufflation has largelydisappeared and has been replaced by individual doses of powdered drugs supplied in hardcapsules and inhaled from a device which breaks the capsule and allows the patient toinhale the powder. This type of insufflation is used mainly for drug delivery into therespiratory tract by inhalation.
4.3.3.3 Irrigation Solutions:These are sterile, pyrogen-free solutions usually intended for irrigation of bodycavities, operation cavities, wounds or the urogenital system.
4.3.3.4 Linctuses:Linctuses are viscous, liquid oral preparations that are usually prescribed for therelief of cough. They usually contain a high proportion of syrup and glycerol which have ademulcent effect on the membranes of the throat. The dose volume is small (5ml) and, toprolong the demulcent action, they should be taken undiluted.
4.3.3.5 Liniments:Liniments are fluid, semi-fluid or, occasionally, semi-solid preparations intended forapplication to the skin. They may be alcoholic or oily solutions or emulsions. Most aremassaged into the skin but some are applied on a warm dressing or with a brush (analgesicand soothing types). Liniments should not be applied to broken skin.
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4.3.3.6 Lozenges:Lozenges are solid preparations consisting of sugar and gum, the latter givingstrength and cohesiveness to the lozenge and facilitating slow release of the medicament.They are used to medicate the mouth and throat and for the slow administration ofindigestion or cough remedies.
4.3.3.7 Lotions:These are fluid preparations for external application without friction. They areeither dabbed on the skin or applied on a suitable dressing and covered with a waterproofdressing to reduce evaporation.
4.3.3.8 Mixtures:Mixtures are liquid oral preparations consisting of one or more medicamentsdissolved or suspended in an aqueous vehicle. Official mixtures are not usually formulatedfor a long shelf-life.
4.3.3.9 Mouthwashes:These are similar to gargles but are used for oral hygiene and to treat infections ofthe mouth.
4.3.3.10 Ointments:Ointments are semi-solid, greasy preparations for application to the skin, rectum ornasal mucosa. The base is usually anhydrous and immiscible with skin secretions.Ointments may be used as emollients or to apply suspended or dissolved medicaments tothe skin. Ointments intended for application to large open wounds should be sterile.
4.3.3.11 Oral Emulsions:The term 'oral emulsion' as an oral dosage form may be defined as 'a fine dispersionof droplets of an oily liquid in an aqueous liquid which forms the continuous phase'. Drugsmay be dissolved in either of the phases or suspended in the emulsion.
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4.3.3.12 Nasal Drops and Sprays:Drugs in solution may be instilled into the nose from a dropper or from a plasticsqueeze bottle. The drug may have a local effect, e.g. antihistamine, vasoconstrictor,decongestant. Alternatively the drug may be absorbed through the nasal mucosa to exert asystemic effect, e.g. the peptide hormones oxytocin and vasopressin. The use of oily nasaldrops should be avoided because of possible damage to the cilia of the nasal mucosa.Prolonged use of nasal vasoconstrictors may result in rebound vasodilatation and furthernasal congestion.
4.3.3.13 Oral Liquids:Oral Liquids are homogeneous preparations containing one or more activeingredients dissolved or suspended in a suitable vehicle. Elixirs, linctuses, mixtures, oraldrops, oral emulsions, oral solutions and oral suspensions are included in the generalcategory of oral liquids.
4.3.3.14 Parenteral Preparations (Injectable Preparations):These are sterile dosage forms containing one or more medicaments and designedfor parenteral administration.
Injections are sterile solutions, suspensions or emulsions in a suitable aqueous ornon-aqueous vehicle and are usually classified according to their route of administration.
Powders for injections are sterile solid substances to be dissolved or suspended byadding a prescribed volume of the appropriate sterile fluid. The solution or suspension isusually prepared immediately prior to use to avoid deterioration of the product on storage.
Intravenous infusions are sterile aqueous solutions or emulsions, free from pyrogens andusually made isotonic with blood. they do not contain added antimicrobial preservatives orbuffering agents and are designed for intravenous administration in volumes usuallygreater than 10-15 ml.
4.3.3.15 Pastes:Pastes are semi-solid preparations for external application that differ from similarointments and gels in that they contain a high proportion of finely powdered medicaments.The base may be anhydrous (liquid or soft paraffin) or water soluble (glycerol or a
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mucilage). Their stiffness makes them useful protective coatings. Pastes intended forapplication to large open wounds should be sterile.
4.3.3.16 Paints:Paints are liquids for application to the skin or mucous membranes. Skin paintsoften have a volatile solvent that evaporates quickly to leave a dry resinous film ofmedicament. Throat paints are more viscous due to a high content of glycerol, designed toprolong contact of the medicament with the affected site.
4.3.3.17 Pills:Pills are oral dosage forms which consist of spherical masses prepared from one ormore medicaments incorporated with inert excipients. Pills are now rarely used. The term'pill' is used colloquially (yet incorrectly) as a synonym for oral contraceptive tablets whichare actually prepared by compression.
4.3.3.18 Poultices:Poultices are paste-like preparations used externally to reduce pain andinflammation because they retain heat well. After heating, the preparation is spread thicklyon a dressing and applied as hot as the patient can bear, to the affected area.
4.3.3.19 Powders (Oral):There are two kinds of powder intended for internal use.
Bulk Powders usually contain non-potent medicaments such as antacids since thepatient measures a dose by volume using a 5ml medicine spoon. The powder is then usuallydispersed in water or, in the case of effervescent powders, dissolved before taking.
Divided Powders are packaged individually - each dose is seperately wrapped inpaper or sealed into a sachet.
4.3.4 Dissolution Rate:
Dissolution rate Measurement of the intrinsic dissolution rate of materials to aid theselection of the best form of the API for progression. Examples of test materials include:Salts, Polymorphs, Amorphous, Hydrates and Formulations. [41].
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Dissolution rate of a material is a much better parameter for correlation with thelikely in-vivo performance of an oral formulation compared to thermodynamic solubility.
Figure 4.3.4(1) Dissolution Rate
4.3.5 Solubility:
Solubility is a characteristic physical property referring to the ability for a givensubstance, the solute, to dissolve in a solvent. It is measured in terms of the maximumamount of solute dissolved in a solvent at equilibrium. The resulting solution is called asaturated solution. Certain liquids are soluble in all proportions with a given solvent, suchas ethanol in water. This property is known as miscibility. Also, the equilibrium solubility
Tablets
Capsule Drug in
Solution
Drug in Blood
Dissolution
Disintegration
Granules or aggregates
Fine particles
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can be exceeded under various conditions to give a so-called supersaturated solution, whichis metastable.A supersaturated solution will often lose the excess solute immediately if a suitablesite on which to do so, such as a scratched beaker wall, a gas bubble, or a crystal of solute, isintroduced into the solution.
Ø Very Soluble < 1
Ø Freely Soluble between 1 and 10
Ø Soluble between 10 and 30
Ø Sparingly Soluble between 30 to 100
Ø Slightly Soluble between 100 to 1000
Ø Very Slightly Soluble between 1000 to 10000
Ø Practically insoluble > 10000
4.3.6 Type of Dissolution Apparatus:
Varying the test apparatus and conditions is the first step in defining an in vitromethod that is sufficiently discriminatory for evaluating bioavailability and/or controlmanufacturing variables. This is especially true for modified-release oral solid dosage forms.For immediate-release oral solid dosage forms such as tablets, chewable tablets, and hardand soft gelatin capsules, however, needless proliferation of methods that often do not haveany distinct advantages over simple United States Pharmacopeia (USP) methods is notdesirable. In test medium selection, physiological relevance should always be the primaryconsideration.The most commonly used USP basket (Method I) and paddle (Method II) methodsfirst appeared in USP XIII in early 1970. These methods are referred to as closed systemmethods in which a fixed volume of dissolution medium is used. In practice, a rotatingbasket or paddle provides a steady stirring motion in a large vessel with 500â€“ 1000 mlfluid that is immersed in a temperature-controlled water bath. The devices are very simple,robust, and can be easily standardized. The descriptions for apparatus specifications aredetailed in chapter 711 of USP XXIII. When properly calibrated, USP methods I and II havebeen the methods of choice for dissolution testing of immediate release oral solid dosageforms. [42].
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4.3.7 Stirrer Type:Dissolution Testers for USP method 1 (Basket), 2 (Paddle), 5 (Paddle over Disc) and6 (Rotating Cylinder). A stirrer is a type of laboratory equipment consisting of a rotatingmagnet or stationary electomagnets creating a rotating magnetic field. The stirrer is used tocause a stir bar, immersed in a liquid to be stirred, to spin very quickly, stirring it. Often, thestirrer can provide heating.Stirrers are often used in laboratories, especially in the field of chemistry. They arepreferred over gear-driven motorized stirrers in chemical research because they arequieter, more efficient, and have no moving parts to break or wear out (other than thesimple bar magnet itself). Due to the small size, the stirring bar is more easily cleaned andsterilized than other stirring devices. [43].
4.3.8 Dissolution Media:The nature and quantity of the dissolution medium will also affect the dissolutiontest. Dissolution medium selected for the study must be able to show the in vitro and in vivocorrelation. [44].According to the nature of the drug product and the location in the body where thedrug is expected to dissolve, which medium is best is a matter of considerable controversy.Various investigators have used dissolution media are as following:
Ø 0.1N Hydrochloric Acid
Ø Phosphate Buffer (pH 4)
Ø Phosphate Buffer (pH 6.8)
Ø Phosphate Buffer (pH 7)
Ø Phosphate Buffer (pH 7.4)
Ø Phosphate Buffer (pH 8)
4.3.9 Volume of Dissolution Media:In selecting the volume of dissolution medium, the solubility as well as the amountof drug in the dosage form must be considered. Usually a volume of dissolution mediumlarger then the amount of solvent needed to completely dissolved the drug is used in suchtest. Generally used the volume is 250 ml, 500 ml, 900 ml and 1000 ml. [45].
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4.3.10 Temperature (Degree Centigrade):The temperature of dissolution medium must also be controlled and variation intemperature must be avoided. Most of dissolution tests are performed at 370 c, the bodytemperature. [46].
4.3.11 Resolution per Min (rpm):The rotational speed is selected and maintained according to the monographspecified in the individual monograph. For many drugs dissolution rates can be higher withthe paddle method so according to it resolution of basket and paddle method is preferred.
4.3.12 Assay Method:
4.3.12.1 UV:A wide range of spectrophotometers is now available for dissolution applications.The choice of spectrophotometer will depend to a large extent on cost and the degree ofsophistication required i.e., single beam, double beam, etc. All of UV-VIS on-line systemsare based on the â€˜continuous flowâ€™ method which is understandably the most popularapproach to automated Tablet Dissolution Testing. Such systems are simple, clean, easy toset up and maintain. UV visible spectrometers measures the absorbance at the wavelengthand it helps to find in vitro release of drug.
4.3.12.2 HPLC:It is known as high performance liquid chromatography. It is based on methods ofseparation pharmaceutical companies have automated testing options when working withsolid dosage forms. Dissolution testing using HPLC offers high-quality results.(Chromatography). (high-performance liquid chromatography)
4.3.12.3 IR:Infrared Spectroscopy involving the determination of dissolution profiles inpharmaceutical tablets is IR Fourier transform infrared (FT-IR) imaging was used to studydissolution of VARIOUS dosage forms. Infra red spectroscopy to measure the percentagedrug dissolution from a dosage forms. [47-48].
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4.3.13 Transitional Diffusion Layer Thickness (Microns):Good simulation of powder dissolution data has been achieved by assuming that thehydrodynamic diffusion layer thickness is equal to the drug particle radius for particlesbelow a certain radius and equal to a constant value for all larger particles. As a default, thisvalue is 30 µm on the interface. Given all other parameters constant, changing this valueallows for different dissolution rates due to changes in the stirring rate. Smaller values forthe transitional diffusion layer thickness will result in a faster rate of dissolution.
Figure 4.3.13(1) Plot of Diffusion Layer Thickness and Particle RadiusThe above group of drug particle size parameters allows the simulation of apolydisperse drug powder as a log-normal mass distribution shown above and to the right.The following equations are used to calculate the minimum and maximum particlediameters, which are updated automatically anytime a change is made to either the mean orstandard deviation:
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Figure 4.3.13(2) Plot of Mass and Particle RadiusA geometric standard deviation of one yields a monodisperse distribution whileincreasing its value widens the distribution. In the figure below, the number of particle sizefractions is 15. Mechanistically, treating a polydisperse powder as a collection ofmonodisperse fractions of various sizes is more realistic and simulates dissolution better.The choice of the number of particle size fractions is a tradeoff between a better simulationof the dissolution data versus the increased time required to complete the simulation.
4.3.14 Simulation Time:Simulation Time is the desired duration of the simulation entered in units ofminutes. For example, if one wished to simulate the dissolution of a drug powder for onehour, 60 should be entered for the simulation time. The actual time to complete thesimulation will only be a small fraction of real time.
4.3.15 Dilution Factor (DF):It is the factor which helps in calculation of percentage release of drug in vitromethod.diltion can be carrid out for measurement of absorbance or for assay methodacording to which instrument is used.
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4.3.16 Withdrawal Volume of Dissolution Media (ml):
Withdrawal volume of dissolution media has been done according to the releaserate of drug in the body and for in vitro dissolution preffered withdrawal volume accordingto dilution and described in assay method.
4.3.17 Dose (mg):It is the quantity of something that may be eaten by or administered to an organ.Dose is the initial mass of solid drug in mg used in the simulation. The dose will bedistributed by mass into the various particle size fractions oi X according to the geometricmean drug particle diameter and standard deviation, or if desired, according to the actualexperimental particle size distribution.
4.3.18 Print Frequency (mg/cc):During a simulation run, a Microsoft Excel spreadsheet will be created to store thesimulated data for future viewing and graphing. Simulated data is calculated approximatelyevery second of simulated time. However, to save every calculated time point would resultin an extremely long spreadsheet. The Print Frequency allows the user to select the intervalbetween simulated data saved to the spreadsheet.
4.3.19 Use Experimental Drug Particle Size:Checking this box allows the use of experimental drug particle size data. Whenselected, all other drug particle size inputs on the user interface will be ignored except thenumber of particle size fractions. When the simulation is initiated, an Excel spreadsheet willappear to allow the user to enter particle size data either manually or by pasting from theclipboard.Particle diameter in micrometers must be entered in column 1 and the associatedpercent volume or mass must be entered in column 2. The number of rows of data enteredinto the spreadsheet must also equal the number of drug particle size fractions entered inthe main user interface.
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4.3.20 Drug Density (mg/cc):Drug Density is the true density of the drug and is a necessary conversion factorbetween drug particle size (volume) and drug mass. Typically, a gas pycnometer would beused to measure the true density of a drug powder.
4.3.21 Diffusion Coefficient (cm2/min):Diffusion coefficient is a parameter expressing the transfer rate of a substance byrandom molecular motion. Mathematically, it is defined as the specific transfer rate under aunit driving concentration gradient.
4.3.22 Human or Animal Body Weight (Kg):Clearance and Volume of Distribution are inputted on a per kilogram basis. Inequation 18, it can be seen that because clearance is divided by the volume of distribution,the body weight will cancel out as both clearance and volume of distribution are divided bybody weight. However, when calculating blood/plasma concentration of drug, the mass inthe central blood/plasma is divided by the volume of distribution in L/kg multiplied by thebody weight in kg.
4.3.23 Bioavailability:Bioavailability is entered in fractional form ranging from 0 to 1. As seen in equation18, it reduces the amount of drug reaching the systemic circulation. Bioavailability does notaffect the calculation of the amount of drug absorbed as shown in equation 14. As a result, itis possible to have a drug that is well absorbed, that is, it crosses the intestinal membranerapidly compared to other drugs, but does not completely reach the systemiccirculation due to metabolism by the liver or by the intestinal enterocytes.
4.3.24 Clearance (ml/min/kg):Clearance is the rate drug removal from the central blood/plasma compartmententered in units of ml/min/kg. The Clearance (Cl) of a drug is the volume of plasma fromwhich the drug is completely removed per unit time. The amount eliminated is proportionalto the concentration of the drug in the blood.
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4.3.25 Volume of Distribution (L/Kg):Volume of Distribution is the hypothetical volume of the central blood/plasmacompartment and is entered in units of L/kg. The Volume of Distribution (Vd) is the amountof drug in the body divided by the concentration in the blood. Drugs that are highly lipidsoluble, such as digoxin, have a very high volume of distribution (500 litres). Drugs whichare lipid insoluble, such as neuromuscular blockers, remain in the blood, and have a low Vd.
4.3.26 K12 (1/min) & K21 (1/min):K12 and K21 are first order rate constants used to calculate the rate of drug transferin and out of the peripheral compartment respectively (see Figure 1). Setting K12 equal tozero reduces the pharmacokinetic model shown in Figure 1 to a one-compartmentpharmacokinetic model.
4.3.27 Metastable Factor:During the simulation of drug dissolution, either in vitro or in vivo, it is possible thatdrug solubility could decrease, most likely for a basic drug exiting the stomach and enteringthe higher pH environment of the small intestine. As a result, the concentration of drugdissolved in solution could be higher than the solubility of the drug. If this happens, theoverall sign of the following term in equations 12 and 13 becomes negative:
If not all of the solid drug has dissolved, there will be crystalline drug surface onwhich crystal growth can occur, or at least, a very high concentration of supersaturateddrug near the solid/liquid interface where nucleation and crystal growth would likely occur.In this case, precipitation will be simulated automatically as the reverse of dissolution usingequations 12 and 13. It is also possible that the entire drug powder has dissolved, leaving nosolid surface for crystal growth. In this case, the metastable factor provides options forinitiating nucleation for further precipitation. The metastable factor is defined as follows:
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If conditions are such that the metastable factor is exceeded, then nucleation will beinitiated to allow for precipitation. For example, if the metastable factor were one,nucleation and precipitation would occur as soon as the solubility fell below theconcentration of drug in solution. If the metastable factor were 10, the solubility would haveto be more than 10 times smaller than the concentration of drug in solution beforenucleation and precipitation would occur. This allows the existence of a metastablesupersaturated state if so desired.The figure below shows a simulation of precipitation in an in vitro situation.Dissolution is complete by 90 minutes when solubility is decreased from 0.1 to 0.01 mg/ml.As soon as solubility falls below the concentration of dissolved drug, precipitation occursand the amount of dissolved drug decreases with the concomitant increase in the amount ofsolid drug. In the illustration below, the metastable factor was one, so that precipitationoccurred immediately. Increasing the metastable factor would delay precipitation. At somepoint, continuing to increase the metastable factor further will prevent precipitationentirely.
Figure 4.3.27(1) Simulation of precipitation in an in vitro situation
4.4 Tables
4.4.1 Cumulative Percentage Release:
4.4.1.1 Absorbance:In spectroscopy, the absorbance A is defined as
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               where I is the intensity of light at a specified wavelength ë that has passed through asample (transmitted light intensity) and I0 is the intensity of the light before it enters thesample or incident light intensity. Absorbance measurements are often carried out inanalytical chemistry, since the absorbance of a sample is proportional to the thickness of thesample and the concentration of the absorbing species in the sample, in contrast to thetransmittance I / I0 of a sample, which varies logarithmically with thickness andconcentration.Outside the field of analytical chemistry, e.g. when used with the Tunable DiodeLaser Absorption Spectroscopy (TDLAS) technique, the absorbance is sometimes defined asthe natural logarithm instead of the base-10 logarithm, i.e. as            The S.I. units for absorbance are absorptions (ab). No customary units exist.
4.4.1.2 Time:Time is a basic component of the measuring system used to sequence events, tocompare the durations of events and the intervals between them, and to quantify themotions of objects.
4.4.1.3 Concentration:Concentration is the measure of how much of a given substance there is mixed withanother substance. This can apply to any sort of chemical mixture, but most frequently theconcept is limited to homogeneous solutions, where it refers to the amount of solute in asubstance.Concentration is the strength of a solution; number of molecules of a substance in agiven volume (expressed as moles/cubic meter). If the concentration of the drug increasesin the body then the concentration gradient decreases leading to a decreases rate of thedissolution of the drug.
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4.4.2 Cumulative Percentage:Calculated by dividing the cumulative release by the number of observations andmultiplying it by 100. The last value will always be equal to 100%. This allows for easiercomparison of the data. Cumulative percentage release is the cumulative release of drugfrom the dosage form into the solution.
4.4.3 Calibration Curve:In analytical chemistry, a calibration curve is a general method for determining theconcentration of a substance in an unknown sample by comparing the unknown to a set ofstandard samples of known concentration.Here, the calibration curve is used for measurement of concentration from the dataof time and absorbance. So it can be used for calculation of concentration for dissolutiontesting and help in finding release of the drug
4.4.3.1 How to Create Calibration Curve:To find the best-fit straight line we use linear regression analysis. From the equationy = mx + c you substitute in the y value (response) and solve for x. Many different variablescan be used as the analytical signal, in Figure 1 analysis was of Chromium(III) bychemiluminescence. The detector (PMT) detects light, voltage increases with intensity oflight, this creates a peak and the peak area is the analytical signal. For most analyticaltechniques, the ultimate goal is to obtain a calibration curve; and there are a number ofadvantages to this method:The calibration curve not only gives you your answer it also gives you an idea abouthow good that answer is. Provided you are operating in the linear response range the plotshould be a straight line, deviations from this straight line give a good indication about theprecision of the result. That is to say, if the data points are spread out, there is less certaintyin the result.The calibration curve provides you with an empirical relationship, as opposed to atheoretical one. Instrumental response is usually highly dependent on the condition of theanalyze, solvents used and impurities it may contain; it could also be affected by externalfactors such as pressure and temperature. Many theoretical relationships, such asfluorescence, require the determination of an instrumental constant anyway; in which casea calibration curve is the only way to do the determination. By making standards as similar
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as possible to the unknown and creating the calibration curve, what is created is a customrelationship, which takes into account all the above factors and many others for the specificconditions of the experiment. The disadvantages are that a set of standards needs to bemade, for which you must have a source of analyte material of known composition. This is atime-consuming process, may use significant quantities of expensive chemicals, and resultsin an increased amount of waste for disposal. Also, you need to make a rough estimate of thecomposition of your unknown sample, in order to enable interpolation the concentrationsof the standards should fall above and below the expected unknown concentration.In short, there is a lot of information about the analysis in a calibration curve and itis a simple way to account for all the influencing factors that could change the analyticalsignal.
4.4.3.2 Applications of Calibration Curve:
Ø Analysis of concentration
Ø Verifying the proper functioning of an analytical instrument or a sensor device suchas an ion selective electrode
Ø Determining the basic effects of a control treatment (such as a dose-survival curvein clonogenic assay)
Figure 4.4.3.1(1) Calibration Curve
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4.4.4 Controlled Release Rate:The controlled release rate determines the amount of drug that is released everyminute, either as a solid powder when running in the controlled release mode, or asdissolved drug when running in the controlled release no dissolution mode. The release ratecan either be constant or change with time.Due to the complexity of simulating the controlled release of a polydisperse powder,running in the controlled release mode can take several hours, depending on the length ofthe simulation. This time can be reduced by decreasing the number of drug particle sizefractions.Running in the controlled release no dissolution mode is very fast and can be usedto quickly determine the release rate needed to achieve a desired drug plasmaconcentration. Once the target release rate has been determined, running the same releaserate in the controlled release rate mode will give insight into whether solubility and/or drugparticle size will have an impact on the desired drug plasma concentration profile. [49-50].
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Chapter 5:
INTEGRATED PROTOTYE
SOFTWARE DESIGN,
IMPLEMENTATION & RESULT
ANALYSIS
5.1 Introduction:
Dissolution testing plays an important role in pharmaceutical quality control and inthe development of solid, semi-solid, and transdermal pharmaceutical forms. Thedissolution kinetic is reexamined under simulated physiological conditions, which arespecified in both the U.S. Pharmacopeia (USP) and the European Pharmacopeia (EP)dissolution testing regulations. As such, these analytics are performed in a highly regulatedGood Manufacturing Practice (GMP) environment, and present particular challenges forrelated software applications. The role of computer based information systems hasconsiderably increased in pharmacy as well as clinical practice in the last decade. However,the use of such systems in dissolution test is still not widespread. Several mathematicalsystems are commercially available for dissolution parameters computations. In addition,comprehensive systems customized to specific needs have also been developed. The use ofsuch systems in dissolution parameters calculations, questions regarding the role ofstructured data versus free text input, standardization of nomenclature, and compatibilitywith other systems, are hotly debated. We describe the development of simple software fordissolution parameters computations records, which attempts to resolve some of theseissues. The prototype described herein was specifically designed to meet the requirementsof the dissolution parameters calculations programme of a tertiary referral and teachingwith a high volume of procedures. After appropriate coding, for storage and subsequentanalysis at a later date, and (b) to the report generator. An additional module was includedto allow modification and update of previously recorded data. A unique number assigned toeach test record was to be used as a primary identifier throughout the record.
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The method implemented as this software provides Graphical User Interface (GUI)interface to the user for taking input for the drug concentration, instrument response andtime data. After taking input it display list where user can opt for specific set ofcomputations and can get the results for desired set of computation. The softwaresupplements visualization along with computation. The user can opt for reports to beprovided by the software.It generate calibration curve, cumulative percentage release, dissolution efficiency,comparison of any number of drug profiles through similarity and dissimilarity factors. It isalso facilitate to work with various steps before comparing number of drug profiles, whichincludes bioavailability, Mean Residence Time (MRT), Volume of Distribution, Clearance,Dissolution Efficiency from this prototype. The prototype has various modules for input andmodification of data, computation of various parameters and visualization with facilities togenerate reports of dissolution parameters.The use of interface is designed for work with much ease in respecting. With littlepractice, scientists soon became adept at entering details correctly and quickly. The slightlyincreased time of data entry into the computer was more than made up by uniform andcomplete report generation. A user-friendly prototype providing computation andvisualization parse drug dissolution parameters. The analytical scientists can utilize theprototype for intensive research as wide variety of parameter computation at simple keystroke.
5.2 Materials & Method:
5.2.1 Requirements:The central objective of this project was to create a data model capable of accuratelyrepresenting the calculations for dissolution parameters computations in a computer-suitable format. Our main requirements included that the system should (a) be simpleenough to be directly operated by the analytical scientist(s) in analytical researchlaboratory, (b) run on personal computers, (c) allow comprehensive data entry conformingto well recognized procedures which are currently carried out, (d) generate a printedreport, (e) allow modification and update of data at a later date, and (f) permit subsequentstatistical analysis of records in a tabular format. As dissolution data were to be handled by
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analytical scientists with minimal previous computer experience, an emphasis was laid on auser-friendly interface.
5.2.2 Software Construction:The software was written in Visual Basic.NET 2005 and MATLAB 7 and generated aseries of successive screens for data entry. Two screens, relating to (a) Various tables dataand (b) Parameters. Data flow was designed in two directions: (a) to a database, afterappropriate coding, for storage and subsequent analysis at a later date, and (b) to the reportgenerator. An additional module was included to allow modification and update ofpreviously recorded data. Another module was designed for filling test reports onspecimens obtained during the procedure, as and when these results became available. Aunique identifier assigned to each test record was to be used as a primary identifierthroughout the record.
5.2.3 Data Entry:Modules were developed to allow easy user access and facilitate data entry. Oncompletion of one module, automatic transfer to the subsequent module was envisaged. Thebasic module was structured as a large window, with smaller sub-windows appearing onlyon demand. The entire software was kept menu driven, with a simple and consistenthierarchical structure.This system will enable us to have Data acquisition from remote places like drugdissolution machine or remote computer that attached directly to the drug dissolutionmachine. There may be number of places where human presence is not desirable or humaninvolvement is not desirable and for that this data acquisition system is useful for thisdeveloped prototype.All the industry will find this product useful for them, as it covers basic dataacquisition system which regulates basic parameter measurement like Calibration Curve,Cumulative Percentage Release, Dissolution Volume etc with having fast response, highlyuser interactive console and easy to use,
5.2.3.1 Serial Communications:Serial is a very common protocol for device communication that comes standard onjust about every PC.
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5.2.3.1.1 Data Entry through Communication Device:There are two basic types of serial communications synchronous and asynchronous.With synchronous communications, the two devices initially synchronize themselves toeach other, and then continually send characters to stay in sync. Even when data is notreally being sent, a constant flow of bits allows each device to know where the other is atany given time. That is, each character that is sent is either actual data or an idle character.Synchronous communications allows faster data transfer rates than asynchronous methods,because additional bits to mark the beginning and end of each data byte are not required.The serial ports on IBM-style PCs are asynchronous devices and therefore only supportasynchronous serial communications.Asynchronous means "no synchronization", and thus does not require sending andreceiving idle characters. However, the beginning and end of each byte of data must beidentified by start and stop bits. The start bit indicates when the data byte is about to beginand the stop bit signals when it ends. The requirement to send these additional two bitscauses asynchronous communication to be slightly slower than synchronous however it hasthe advantage that the processor does not have to deal with the additional idle characters.An asynchronous line that is idle is identified with a value of 1. By using this value toindicate that no data is currently being sent, the devices are able to distinguish between anidle state and a disconnected line. When a character is about to be transmitted, a start bit issent. A start bit has a value of 0 (also called a space state). Thus, when the line switchesfrom a value of 1 to a value of 0, the receiver is alerted that a data character is about to besent. Most computers include two RS-232 based serial ports. Serial is also a commoncommunication protocol that is used by many devices for instrumentation; numerous GPIB-compatible devices also come with an RS-232 port. Furthermore, serial communication canbe used for data acquisition in conjunction with a remote sampling device.The concept of serial communication is simple. The serial port sends and receivesbytes of information one bit at a time. Although this is slower than parallel communication,which allows the transmission of an entire byte at once, it is simpler and can be used overlonger distances. For example, the IEEE 488 specifications for parallel communication statethat the cabling between equipment can be no more than 20 meters total, with no morethan 2 meters between any two devices; serial, however, can extend as much as 1200meters.
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Typically, serial is used to transmit ASCII data. Communication is completed using 3transmission lines: (1) Ground, (2) Transmit, and (3) Receive. Since serial is asynchronous,the port is able to transmit data on one line while receiving data on another. Other lines areavailable for handshaking, but are not required. The important serial characteristics arebaud rate, data bits, stop bits, and parity. For two ports to communicate, these parametersmust match.
a) Baud rate:A speed measurement for communication. It indicates the number of bit transfersper second. For example, 300 baud is 300 bits per second. When we refer to a clock cycle wemean the baud rate. For example, if the protocol calls for a 4800 baud rate, then the clock isrunning at 4800Hz. This means that the serial port is sampling the data line at 4800Hz.
Fig. 5.2.3.1.1(1) Braud Rate
b) Data bits:A measurement of the actual data bits in a transmission. When the computer sends apacket of information, the amount of actual data may not be a full 8 bits. Standard values forthe data packets are 5, 7, and 8 bits. Which setting you choose depends on what informationyou are transferring. For example, standard ASCII has values from 0 to 127 (7 bits).Extended ASCII uses 0 to 255 (8 bits). If the data being transferred is simple text (standardASCII), then sending 7 bits of data per packet is sufficient for communication. A packetrefers to a single byte transfer, including start/stop bits, data bits, and parity. Since the
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numbers of actual bits depend on the protocol selected, the term packet is used to cover allinstances.
c) Stop bits:It is used to return the signal for end of communication of a single packet. Typicalvalues are 1, 1.5, and 2 bits.
d) Parity:A simple form of error checking that is used in serial communication. There are fourtypes of parity: even, odd, marked, and spaced. For even and odd parity, the serial port willset the parity bit (the last bit after the data bits) to a value to ensure that the transmissionhas an even or odd number of logic high bits.
5.2.3.1.2 Rs-232 Standard For Communication:The example serial waveforms in above figure show the waveform on a singleconductor to transmit a byte (0x41) serially. The upper waveform is the TTL-levelwaveform seen at the transmit pin of 8051. The lower waveform shows the same waveformconverted to RS232C levels. The voltage level of the RS232C is used to assure error-freetransmission over greater distances than would be possible with TTL levels.It is first step to collect values for computations. Its also help to scientist toautomation of fetching the values from the machine.Free text was allowed in some fields, such as the information beyond the fixedchoices available to the user. To allow complete data acquisition in each test, all data fieldswere marked mandatory, and the user was not allowed to proceed to a subsequent fieldwithout recording data in such fields.
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Fig. 5.2.3.1.2(1) Input form for Batch Data Profiles
Fig. 5.2.3.1.2(2) Batch Data Profiles Parameters
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5.2.4 Debugging and Modification:After initial development, the software was tested over a four-week period by inputof data. An attempt was made to rectify problems faced initially by the users. Opinion wassought from faculty members regarding possible modifications and improvements.Inconsistencies in the programming script, which gave rise to error messages duringoperation of software, were corrected.
5.2.5 Software Validation:To evaluate the actual utility of the software, all consecutive test records wereentered using this computer software. Analytical scientists were asked to assess the overallquality of the reports and the content of information. After entry of data for 60 consecutivetest procedures, these details were subjected to statistical analysis to evaluate therobustness of the database component.
5.2.6 Linearity or calibration curve:The linearity of an analytical procedure is its ability (within a given range) to obtaintest results, which are directly proportional to the concentration (amount) of analyze in thesample. A linear relationship should be evaluated across the range of the analyticalprocedure. It may be demonstrated directly on the drug substance (by dilution of a standardstock solution) and/or separate weighing of synthetic mixtures of the drug productcomponents, using the proposed procedure. The latter aspect can be studied duringinvestigation of the range.Linearity should be evaluated by visual inspection of a plot of signals as a function ofanalyze concentration or content. If there is a linear relationship, test results should beevaluated by appropriate statistical methods, for example, by calculation of a regression lineby the method of least squares. In some cases, to obtain linearity between assays andsample concentrations, the test data may need to be subjected to a mathematicaltransformation prior to the regression analysis. Data from the regression line itself may behelpful to provide mathematical estimates of the degree of linearity.The correlation coefficient, y-intercept, slope of the regression line and residual sumof squares should be submitted. A plot of the data should be included. In addition, ananalysis of the deviation of the actual data points from the regression line may also be
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helpful for evaluating linearity. For the establishment of linearity, a minimum of 5concentrations is recommended. For the dissolution calculation concentrations werecalculated from the respective calibration curve.
Fig. 5.2.6(1) Calibration Curve
Fig. 5.2.6(2) Curve Area Calculations
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5.2.7 Dissolution Study:In vitro dissolution specifications are established to guarantee batch-to-batchconsistency and to indicate potential bioavailability problems. For new drug products,dissolution specifications must be based on data obtained from the batch used in thebioavailability assay (bio-batch). For generic drugs, the dissolution specifications aregenerally the same of the reference drug product. These specifications are confirmed bytesting the performance of the bio-batch dissolution. If the generic drug dissolution issubstantially different from the reference drug product dissolution, and the in vivo studyhad proved the bio-equivalence between them, a different dissolution specification for thegeneric drug can be established, provided it is based upon a validated IVIVC. In that case,the specification must be fulfilled throughout the permanence of the generic drug in themarket. The specifications must be based on the bio-batch dissolution characteristics. If theformulation developed for commercialization differs significantly from the bio-batch, thecomparison of the dissolution profiles and the bio-equivalence study between these twoformulations is recommended.The dissolution tests must be undertaken under such conditions as: basket methodat 50/100 rpm or paddle method at 50/75/100 rpm. To generate a dissolution profile, atleast five sampling points must be obtained of which a minimum of three must correspondto percentage values of dissolved drug lower than 65% (when possible) and the last pointmust be relative to a sample period of time equal to, at least, the double of the former periodof time. For drug products of rapid dissolution, samples at shorter intervals (5 or 10minutes) may be necessary. For drug products with highly soluble drugs that present rapiddissolution (cases I and III of BCS), a dissolution test of a single point (60 minutes or less)that proves a dissolution of, at least, 85% is sufficient for batch to batch uniformity control.For drug products containing drugs poorly soluble in water, which dissolve very slowly(case II of BCS), a two points dissolution test, that is, one at 15 minutes and another at 30,45 or 60 minutes, to ensure 85% of dissolution is recommended.
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Fig. 5.2.7(1) Curve Parameters
Fig. 5.2.7(2) Cumulative Percentage Release
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5.2.8 Dissolution Efficiency:Khan16 suggested Dissolution Efficiency (D.E.) as a suitable parameter for theevaluation of in vitro dissolution data. D.E. is defined as the area under dissolution curve upto a certain time ‘t’ expressed as percentage of the area of the rectangle described by 100%dissolution in the same time. T50 and D.E. 120 min values were calculated from thedissolution data.Dissolution efficiency (D.E.) = 100
100
.0
x
y
dty
t
tò
Fig. 5.2.8(1) Dissolution Efficiency
5.2.9 Comparison of dissolution profiles by similarity and
dissimilarity factor:To avoid the requirement of bioequivalence studies of the immediate releasepharmaceutical forms of lower dosage, when several presentations with the same
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formulation exist, the dissolution profiles must be compared and must be identical amongall dosages.Until recently, single point dissolution tests and specifications have been employedto evaluate scale-up and post-registration changes. When minor alterations are carried out,the single point dissolution test may be adequate to ensure drug product quality andperformance. For major alterations, the comparison of dissolution profiles obtained inidentical conditions between the altered formulation and original one, is recommended. Inthis comparison, the curve is considered as a whole, in addition to each sampling point ofthe dissolution media, by means of independent model and dependent model methods.Independent Model Method employing the Similarity factor. A simple independent modelmethod employs a difference factor (f1)
Fig. 5.2.9(1) Similarity/Dissimilarity Factor - 1
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Fig. 5.2.9(2) Similarity/Dissimilarity Factor –2
Fig. 5.2.9(3) Similarity/Dissimilarity Factor - 3
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Fig. 5.2.9(4) Similarity/Dissimilarity Factor - 4
Fig. 5.2.9(5) Similarity/Dissimilarity Factor –5
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and a similarity factor (f2) to compare dissolution profiles. Factor f1 calculates thepercentage difference between two the profiles at each sampling point and corresponds to arelative error measure between the profiles:
where:n = number of sampling pointsRt = value dissolved in time t (percentage), obtained with the reference product or with theoriginal formulation (before the alteration)Tt = percentage value dissolved from the altered formulation, in time t.
Factor f2 corresponds to a similarity measure between the two curves:
The procedure is described as follows:
· Determine the dissolution profile of products, test and reference, using twelve unitsof each.
· Calculate factors f1 and f2 using the equations presented previously.
· Criteria for two dissolution profiles to be considered similar. The nominal range of f1and f2 values are 0 to 15 and 50 to 100, respectively.
The procedure is also to be considered:
· Use a minimum of five sampling points;
· Consider only one point above 85% of dissolution for both products;
· To allow use of averages, the coefficients of variation for the first points (15minutes, for example) should not exceed 20%. For the remaining points a maximumof 10% is allowed;
· The average values of Rt may derived from the last reference batch, withoutalteration, or from two or more consecutive batches, without alteration.
· In cases where dissolution is very quick, presenting a value equal to or higher than85% of the drug dissolved in 15 minutes, factors f1 and f2 loose their distinguishingpower and therefore it is not necessary to calculate them.
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5.3 Bioavailability:
Bioavailability is entered in fractional form ranging from 0 to 1. As seen in equation18, it reduces the amount of drug reaching the systemic circulation. Bioavailability does notaffect the calculation of the amount of drug absorbed as shown in equation 14. As a result, itis possible to have a drug that is well absorbed, that is, it crosses the intestinal membranerapidly compared to other drugs, but does not completely reach the systemiccirculation due to metabolism by the liver or by the intestinal enterocytes.
Fig. 5.3(1) Bioavailability
5.4 Clearance (ml/min/kg):
Clearance is the rate drug removal from the central blood/plasma compartmententered in units of ml/min/kg. The Clearance (Cl) of a drug is the volume of plasma from
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which the drug is completely removed per unit time. The amount eliminated is proportionalto the concentration of the drug in the blood.
Fig. 5.4(1) Clearance
5.5 Volume of Distribution (L/Kg):
Volume of Distribution is the hypothetical volume of the central blood/plasmacompartment and is entered in units of L/kg. The Volume of Distribution (Vd) is the amountof drug in the body divided by the concentration in the blood. Drugs that are highly lipidsoluble, such as digoxin, have a very high volume of distribution (500 litres). Drugs whichare lipid insoluble, such as neuromuscular blockers, remain in the blood, and have a low Vd.
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Fig. 5.5(1) Volume of Distribution
5.6 Mean Residence Time (MRT):
Equations for the mean residence time (MRT) of drug in the body and relatedfunctions are derived for drugs which are intravenously administered into a one- or two-compartment system with Michaelis-Menten elimination. This MRT is a function of thesteady-state volume of distribution and time-average clearance obtained from the dose andarea under the curve (dose/AUC). The differences between the MRT calculated by theproposed method and by using the moment theory method (AUM/AUC) are demonstratedboth mathematically and by computer simulations.
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Fig. 5.6(1) Mean Residence Time (MRT)
5.7 Compare Dissolution Profiles:
The Center for Drug Evaluation and Research (CDER) at the Food and Drug Ad-ministration (FDA) recently released a guidance which set forth application informationthat should be provided to CDER to assure continuing product quality and performancecharacteristics of immediate release oral solid dosage formulations for specific post-approval changes. Commonly called SUPAC IR, this guidance has the major intent to reducethe number of manufacturing changes that require preapproval by FDA. Consequently,dissolution testing is a prominent feature of SUPAC IR requirements. In order for apharmaceutical sponsor to take advantage of the benefits offered in the SU-PAC IR guidancewhere Case B or Case C dissolution testing is required, a sponsor will need to demonstratethat the dissolution profiles of the product pre-change and post-change are “similar.” Theobjective of the work was to apply several profile comparison approaches to dissolution
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data of tablet formulations in order to quantify each method’s metric for comparingdissolution profiles.
5.7.1 Model-independent Methods:The methods investigated to compare profiles can be classified into two categories:model-independent approaches and model-dependent approaches. The percent dissolved at60 and 90 minutes for the fast test formula, and the medium test formula were assignedvalues of 100% for each sample.Model-independent approaches can be further differentiated as ANOVA-based pro-cedures, ratio test procedures, or pair-wise procedures. Two ANOVA-based procedureswere evaluated: ANOVA on the percent dissolved at each time point and the level and shapeapproach. For the ANOVA testing of the percent dissolved data, one-way ANOVA plusTukey’s test for times 5–45 minutes were conducted. For 60 and 90 minute data, the one-sample t-test, which compared the percent dissolved of the slow formula against 100%, wasconducted. Each of the “level” and “shape” portions of the lev and shape approach wereperformed. Prior to analysis by the level and shape approach, the data were transformed interms of first difference.
5.7.2 Model-dependent Methods:The model-dependent approaches included zero-order, first-order, Hixson-Cro-well,Higuchi, quadratic, Weibull, Gompertz, and logistic models. The procedure to compare twodissolution profiles using a model-dependent approach follows and resembles the aboveratio test procedures since a 90% confidence interval is ultimately constructed. For each ofthe two formulations being compared, the model under study was fitted to each individualdissolution profile using our prototype. From the mean ratio of the model parameter andthe SE of the mean ratio, a 90% confidence interval was constructed.The result of the one-way ANOVA for each time point from 5–60 minutes was a p-value <0.001. The results of the one-sample t- test at 60 and 90 minutes were p-values of0.389 and 0.560. While these results are informative, ANOVA may serve as a conservativemethod. The level and shape approach appeared to possess the same limitation as ANOVAof the percent dissolved at each time point, in that the level and shape approach addresses aquestion concerning the statistical sameness rather than pharmaceutical sameness. Whendissolution data out to 30, 45, and 60 minutes were considered, the p-values for the “level”
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test statistic and th “shape” test statistic were always<0.0002. When dissolution out to 90minutes was considered, the level and shape p-values were 0.467 and <0.0002, respectively.
Fig. 5.7.2(1) Ratio of mean percent dissolved for closed circle versus open circle.
Error bars denote SE from n = 6.
Throughout the dissolution, the ratio of the percent dissolved from the fastformulation was always within 90%. During the first 10 minutes, the medium dissolvingtest formula was less than half of that; but by 25 minutes it was about 90% and by 45minutes it was fully dissolved. The ratio was below 0.8 for the first 45 minutes; only until 60minutes did the ratio reach a value greater than 0.8. The 90% confidence intervals for themean ratio of percents dissolved were about twice as wide as the SE bars [10-13].
5.8 Results:
In the calibration curve module, the number identifies each test record uniquely.The date of procedure is automatically derived from the system date maintained by thecomputer clock, but can be changed manually. The user has to enter the number ofobservations of concentration and instrumental response. The possible locations in the
PDF Creator - PDF4Free v2.0                                                    http://www.pdf4free.com
Chapter 5: Integrated Prototype, Software Design….. 224
dissolution parameters tree are represented by a cascading hierarchy of tables. Anadditional table listing the appropriate divisions/ segments appears.On completion of data entry, the user is transferred to the print module, where hecan preview the report prior to printing. The printed report contains all the informationentered in the database. It also contains standard set post- procedure instructions for thetest, and also has space for signatures for the analytical scientist carrying out the procedure.Problems initially faced by users were primarily related to data entry. Scientists, not havingany working knowledge of computers, encountered problems such as a slow speed of dataentry and failure to enter data in mandatory fields (with a consequent error message thatdid not allow the user to proceed further without rectifying the mistake).With little practice, they became adept at entering details correctly and quickly.Almost all the analytical scientists reported a slightly increased time of data entry into thecomputer, in comparison to writing reports on a standard printed Performa. However, allagreed that the report and data generated through the software were uniformly complete,and more than made up for the extra time spent. The new report has a uniform and easilyunderstood structure, and is free of any inadvertent omissions.The database component was evaluated by analyzing 60 consecutive recordsentered over a 4-month period. Statistics were generated on the demographic variables andcomplications. Data access and analysis were easily and quickly performed. Data werefound to have been completely transferred from data entry screens to the database and nomissing values were encountered.
5.9 Discussion:
Structured input and free-text input represent two fundamentally different ways ofentering data into a computer. Initial reports of test databases relied heavily on text basedtools. Such input facilitates personalized style and flexibility in description of test records,and generates a well readable report. However, free-text input weakens the utility of thedatabase, as it is not suited to subsequent analysis. Structured input and the resultingcategorical data offer an important advantage in this regard. Data thus entered is morelikely to be complete and is well suited for research and analysis, as well as for thegeneration of administrative reports and for quality control. It has been estimated that useof computerized test records improves completeness of data entry by more than 50 per
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cent5. However, a major trade-off for structure is flexibility. We therefore used a basicstructured data entry protocol, supplemented by use of free text only under specialsituations. Experience with previously designed bronchoscopes software has shown thatthe reporting procedure is slightly lengthened using computerized data entry3. Thisincrease in time is variable. Besides operator related factors, it is related to the amount offree text entered and the number of tables accessed during structured data entry4. However,the additional effort is rewarded by a more comprehensive and accurately documentedreport, and constant availability and better management3-4.A major feature of the software is the powerful database component. We had laidparticular stress on this aspect in view of the stress on academic and research activities.This portion of the software has been built as a set of two interrelated databases inMicrosoft Access, which can easily handle large databases (and is thus suited to the volumeof test procedures performed at our department) and also offers a wide range of analyticaltools through a versatile query system. We have evaluated the robustness of this module ofthe software through an analysis of 60 consecutive test records.Although such analysis requires some working knowledge of the database system, itis easy of learn. No data was lost and statistical analysis could be easily performed. Bothuser-friendliness of the software and completeness of data entry are critical to the successand acceptance of such software. We allowed easy integration of buttons, text boxes, checkboxes and fields for free text to achieve this end. The format for data input was optimizedthrough continuous interaction between scientists and the programmer. Scientists andother faculties were involved early and frequently during the development of the software,so that they were able to contribute ideas and advice. The software has now been underroutine use for over a year, and has performed well in areas of data entry, report generationand data analysis. Successful development and routine application of the database is,however, only a short-term achievement. More importantly, continuous improvementsneed to be made as and when new areas emerge. The system is adaptable and capable ofkeeping pace with new technological advances.
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Chapter 6:
Contribution of the Research Work
& Suggested Future Work
6.1 Contribution of the Research Work: A Discussion
Software Technologies are providing reduced drug dissolution computation time e-process solutions for accelerating global pharmaceutical development. Software developersthus far believe that they have the potential to cut 1 to 2 years off the current 7 to 9 years ittakes to bring new drugs to market, enabling them to increase their revenue potential. Manyof them use Internet technologies to conduct and manage dissolution testing andcomputation efficiently and effectively. They are providing service solutions to allowsponsors of drug dissolution computation to eliminate the need to transcribe and processtraditional paper data forms, to access global drug dissolution testing data in real-time, andto begin data analysis.Now that drug dissolution of drug profiles and bioinformatics associatedcomputational methods are reality. Somehow, the resulting compounds still have to bedelivered in the most effective manner. An injectible or solid oral immediate or sustainedreleased are “no brainers” for pharma in terms of dosage form selection. Now go have funwith solubility and stability, and its headache time, depending where you are in the worldand your choice of vice. To combine the right chemical ingredients in the right proportions,driving the right reactions under the right conditions to achieve the right end product withthe right properties requires an incredible amount of information and an incredible amountof knowledge. All this information and knowledge has to be available at the point offormulation as well as at the analysis stage to find whether particular drug batches areefficient of drug or not. Managing the formulation process without iteration is the secret toreducing development time. Having software to provide the right information at the rightplace at the right time and you avoid costly, embarrassing mistakes and eliminate duplicatework. Today, a drug dissolution testing could even identify promising leads, store, andmanage a pharma company’s testing portfolio or library. Modeling and simulation software
PDF Creator - PDF4Free v2.0                                                    http://www.pdf4free.com
Chapter 6: Contribution & Suggested Future Work 229
can now allow researchers to screen a wide variety of materials and process variables insilico, fail early, and focus on the most promising lead candidates for further experimentalwork. Such methods enable substantial time and cost savings.Drug dissolution testing and informatics software platforms also provide greatscience from easy-to-use desktop environments that interact with the databases throughouta corporate IT infrastructure. They can combine high-quality modeling and visualizationwith powerful methods to analyze and predict the parameters and behavior of chemical andbiological systems. These powerful methods include molecular mechanics, quantummechanics, mesoscale modeling, instrument simulation, and statistical correlations. Thisnew trend is being reinforced by many of scientific papers and has been successfullyapplied across industry and academia.With the convergence of drug dissolution testing and IT, there clearly will begrowing pains. Despite the challenges ahead, the union of high-tech and Pharma is sure tounleash novel tools and products that today can’t be envisioned. As drug dissolution testingcompanies struggle to understand and use numerous data points and bits of informationthey are generating, IT companies are eager to meet the demands of this new marketopportunity. Future computing solutions will require the capability to store vast quantitiesof data. In this evolving area, the ability to avoid chasing down a dead-end street willbecome increasingly important. To quickly discard all but the leading options andeliminating time wasted on low probability routes while identifying the best and leastexpensive ingredient mix can save money and time. In the final analysis, this will allow drugdissolution testing companies to be in a greater position of strength.The resulting speed-to-market advantage they can offer will take them beyond theinnovation of their testing systems alone and become integral with their strategies.Positioning will be easy and feed into the “you can have it now” instead of in 18 months.And, by getting their drug company prospects to market sooner, drug dissolution testingcompanies can improve their odds of solidifying licensing and development deals on betterterms The anticipated prototype is to provide both scientific computational power andvisualization power particularly with use of tools such as MATLAB, .NET and set ofbioinformatics tools and database. The environment brings ease to use to get desiredcomputation, data analysis with visualization.
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The main objective of this work was to apply several drug profiles comparisonapproaches to one dissolution data set in order to quantify each method’s metric forcomparing dissolution profiles through the developed prototype. In spite of the need tocompare dissolution profiles, methods to compare dissolution profiles are well developed.This work was conducted with the intent to compare all batch profiles and to gainfamiliarity with the numerical values of those methods. It is concluded that the ratio testprocedures, the pair-wise procedures, and several of the model-dependent approachesyielded numerical results which can possibly serve as objective and quantitative metrics forcomparing entire dissolution profiles.
6.2 Suggested Future Work:
Growth will become the result of the intersection of life sciences and IT period. SunMicrosystems, for example, has major research programs on informatics. Merck scientistsare becoming computer experts themselves. Oracle developed a database capable oforganizing tons of drug information moving from research through the drug dissolutiontesting process. And, this is just the beginning. They can now assure that vast quantities ofdata generated from experiments can be rapidly studied and correlated with billions ofother data bits streaming from Merck’s other labs. Looking at data in real time permitscompany scientists to make fast calls about which compounds to push into development.Information technology provides the only means for drug companies to automate andtruncate the development process. Drug companies spend huge amount per year on IT.The future application of Drug Dissolution Parameters Computations (DDPC) willbecome more important when the present framework gains increased recognition, whichwill probably be the case if the DDPC borders for certain Class II (high permeability, lowsolubility) and Class III (low permeability, high solubility) drugs are extended. Revision ofthe DDPC guidelines by the regulatory agencies in communication with academic andindustrial scientists is exciting and will hopefully result in an increased applicability in drugdevelopment.Finally, scientists in this field emphasize the usefulness of DDPC as a simple tool inearly drug development to determine the rate-limiting step in the oral absorption process,which has facilitated the exchange of information between experts involved in the overalldrug development process. In the future, this increased awareness of a proper
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biopharmaceutical characterization of new drugs may result in drug molecules withsufficiently high permeability, solubility and dissolution rate properties, that willautomatically help increase the importance of BCS as a regulatory tool.
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Appendix A:
FORMULAS DESCRIPTION
Single Dose Pharmacokinetics
General Disposition Parameters and Constants
Dose Amount D
Fraction of dose absorbedUsed to correct dose amount for someoral dose calculations. F
Exponential SummationExpression for sum of 1st orderkinetic terms. for n exponential terms
Y-InterceptCoefficient of each exponential term.Note the sign of the absorptioncoefficient is negative.
Slope
Rate constant
Elimination rate constant
Half-life
Descriptive Curve Parameters
CinitialInitial concentration extrapolated totime zero for i.v. dose.
Tmax (obs)Usually applies to oral doses only.
Cmax (calculated)For biexponential oral data only. where V is Vd (area).
Tmax (calculated)For biexponential oral data only.
where and are the apparent absorptionand elimination rate constants, respectively.
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Curve Area Calculations
AUC(0-t) (obs area)Trapezoid calculation of AUC usingobserved data points only. Usefulwhen final concentration values tendto exaggerate total AUC. where n is the number of data points.
AUC (area)Total AUC computed by combiningAUC(0-t) with an extrapolated value. where is the last concentration.
AUC (expo)Total AUC computed usingexponential terms.
% of AUC (expo)Percent each exponential termcontributes to the total AUC.
Statistical Moment Calculations
AUMC (area)Calculation of total area under thefirst-moment curve (plot of Ct vs t) bycombining trapezoid calculation ofAUMC(0-t) and extrapolated area. +
AUMC (expo)Total AUMC computed usingexponential terms.
% of AUMC (expo)Percent each exponential termcontributes to the total AUMC.
MRT (area)Mean Residence Time calculatedusing trapezoid area calculationsextrapolated to infinity. where both area terms use trapezoidalcalculations
MRT (expo)Mean Residence Time calculatedusing exponential terms.
Volume of Distribution Calculations
Vc (initial central compartment)Apparent volume of the centralcompartment for i.v. doses only.
Vd (obs area)Apparent volume of distributionbased on AUC(0-t) trapezoidcalculation and elimination rate. Usewhen total AUC (area) is exaggerateddue to high terminal concentrationvalues.
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Vd (area)Apparent volume of distributionbased on trapezoid AUC (area) andelimination rate. Applies mainly toi.v., but also to oral if completeabsorption (F=1) is assumed.
Vd (area) / kgApparent volume of distributionnormalized by animal weight. Usessame equation as Vd (area).
Vd (expo)Apparent volume of distributioncalculated from exponential terms.
where is the elimination rate
Vss (area)Apparent volume of distribution atsteady state estimated graphicallyfrom trapezoidal total areameasurements. Applies to iv dose.
Vss (expo)Apparent volume of distribution atsteady state estimated fromexponential terms. Applies only afteriv and assumes elimination fromcentral compartment.
Systemic Clearance Calculations
CL(sys) (obs area)Systemic clearance based on AUC(0-t)trapezoid calculation. Use when totalAUC (area) is exaggerated due to highlast concentration.
CL (area)Systemic clearance based ontrapezoid AUC (area). Applies mainlyto i.v. data. Limited to oral data only ifcomplete absorption (F=1) isassumed.
CL (area) / kgSystemic clearance normalized byanimal weight. Uses same equation asCL (area).
CL (expo)Systemic clearance calculated usingexponential terms.
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Half-life based on Vd and CLAlternate calculation of half-life usingVd (area) and CL (area). For i.v. dataonly.
Two-compartment Open Model Microconstants
k12Microconstant calculated usingexponentials. Applies to 2compartment i.v. dose data only.
k21Microconstant calculated usingexponentials. Applies to 2compartment i.v. dose data only.
Multiple Intravenous Dose Pharmacokinetics
General
Dose Interval (tau)Time span between dosing intervals.Distinguish from time after dose (t). tauAssume constant dose interval
First Dose Concentration Calculations
C1(max)Maximum concentration after firstdose interval (tau). Equal to Cinitial
C1(min)Minimum concentration at end of firstdose interval (tau).
C1(ave)Average concentration during firstdose interval (tau).
Prediction of Steady State Parameters
Css(min)Minimum concentration during anydosing interval at steady state.
Css(min)Minimum concentration during anydosing interval at steady state.Included on graph.
Css(max) - Css(min)Difference between peak and troughconcentration during steady state.
Css(ave)Average concentration at steady state.
Css(ave) (area)Average concentration at steady statecalculated from trapezoidal AUC datafor a single dose.
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Accumulation Factors
R based on Css(max)/C1(max)Accumulation ratio based onmaximum concentrations after firstdose and at steady state.
R based on Css(min)/C1(min)Accumulation ratio based onminimum concentrations after firstdose and at steady state.
R based on Css(ave)/C1(ave)Accumulation ratio based on averageconcentrations after first dose and atsteady state.
Time to Reach Percent of Steady State
To reach 95% Css(ave)Time required to reach 95% ofaverage steady state concentration.Assumes one-compartmentcharacteristics apply. where is the fraction of the steady stateconcentration.
To reach 99% Css(ave)Time required to reach 95% ofaverage steady state concentration.Assumes one-compartmentcharacteristics apply. where is the fraction of the steady stateconcentration.
General and Graphing Functions
Dose Interval (tau)Constant time span between dosingintervals. Distinguish from time afterdose (t).
(tau) Assumes equal dose intervals
Graphing FunctionThe graphing function is based on amathematical generalization of thegraphical superimposition principle.It involves the addition of a decayfunction (CN) to the initialconcentration (C1)at repeated timepoints for a progressive series ofdoses (N). Assumes constant doseintervals during the postdistributionphase.
where
and
First Dose Concentration Values
C1(max)Observed maximum concentrationtaken from data set.
C1(min)Minimum concentration at end of firstdose interval (tau).
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C1(ave)Average concentration during firstdose interval (tau).
Prediction of Steady State Parameters
Css(max)Computed from a simplification of thegraphing function to a steady stateform as shown. The Css(max) isevaluated as the maximumconcentration during the steady statedosing interval.
where
Css(min)Computed using same steady stateequation as Css(max) and evaluatingthe minimum concentration during asteady state dose interval.
Same as above.
Css(max) - Css(min)Difference between peak and troughconcentration during steady state.
Css(ave)Average concentration at steady state.
Css(ave) (area)Average concentration at steady statecalculated from trapezoidal AUC datafor a single dose.
Additional Oral Dose Calculations
Tmax (1st dose, observed)Observed time of largestconcentration value from data set.
Tmax (1st dose, calculated)Calculation of time at whichmaximum concentration occurs aftera single dose. Applies to 1-compartment characteristics, butcalculated also to illustrate magnitudefor 2-compartments.
where is the absorption rateand is the elimination rate.
Tmax(ss)Calculation of time at whichmaximum concentration occurs afterdosing during steady state. Applies to1-compartment characteristics, butcalculated also to illustrate magnitudefor 2-compartments. where is the absorption rateand is the elimination rate.
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Appendix B:
DEFINITIONS OF TERMS
Batch:A specific quantity of a drug or other material produced according to a single manufacturingorder during the same cycle of manufacture and intended to have uniform character andquality, within specified limits (21 CFR 210.3(b)(2)).
Batch formula (composition):A complete list of the ingredients and their amounts to be used for the manufacture of arepresentative batch of the drug product. All ingredients should be included in the batchformula whether or not they remain in the finished product.
Bioavailability:The rate and extent to which the active drug ingredient or therapeutic moiety is absorbedfrom a drug product and becomes available at the site of drug action.
Biobatch:A lot of drug product formulated for purposes of pharmacokinetic evaluation in abioavailability/bioequivalency study. This lot should be 10% or greater than the proposedcommercial production batch or at least 100,000 units, whichever is greater.
Bioequivalent drug products:Pharmaceutical equivalents or pharmaceutical alternatives whose rate and extent ofabsorption do not show a significant difference when administered at the same molar doseof the therapeutic moiety under similar experimental conditions, either single dose ormultiple dose. Some pharmaceutical equivalents or pharmaceutical alternatives may beequivalent in the extent of their absorption but not in their rate of absorption and yet maybe considered bioequivalent because such differences in the rate of absorption areintentional and are reflected in the labeling, are not essential to the attainment of effectivebody drug concentrations on chronic use, or are considered medically insignificant for theparticular drug product studied.
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Correlation:As used in this guidance, a relationship between in vitro dissolution rate and in vivo input(absorption) rate.
Development:Establishing an in vitro/in vivo correlation.
Drug product:A finished dosage form, e.g., tablet, capsule, or solution, that contains a drug substance,generally, but not necessarily, in association with one or more other ingredients.
Extended release dosage form:A dosage form that allows a reduction in dosing frequency as compared to that presented bya conventional dosage form, e.g., a solution or an immediate release dosage form.
Evaluation:In the context of in vitro/in vivo correlation, a broad term encompassing experimental andstatistical techniques used during development and evaluation of a correlation which aid indetermining the predictability of the correlation.
Formulation:A listing of the ingredients and composition of the dosage form.
In vitro/in vivo correlation:A predictive mathematical model describing the relationship between an in vitro propertyof an extended release dosage form (usually the rate or extent of drug dissolution orrelease) and a relevant in vivo response, e.g., plasma drug concentration or amount of drugabsorbed.
In vivo dissolution:The process of dissolution of drug in the gastro-intestinal tract.
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In vitro release:Drug dissolution (release) from a dosage form as measured in an in vitro dissolutionapparatus.
In vivo release:In vivo dissolution of drug from a dosage form as determined by deconvolution of dataobtained from pharmacokinetic studies in humans (patients or healthy volunteers).
Level A correlation:A predictive mathematical model for the relationship between the entire in vitrodissolution/release time course and the entire in vivo response time course, e.g., the timecourse of plasma drug concentration or amount of drug absorbed.
Level B correlation:A predictive mathematical model for the relationship between summary parameters thatcharacterize the in vitro and in vivo time courses, e.g., models that relate the mean in vitrodissolution time to the mean in vivo dissolution time, the mean in vitro dissolution time tothe mean residence time in vivo, or the in vitro dissolution rate constant to the absorptionrate constant.
Level C correlation:A predictive mathematical model of the relationship between the amount dissolved in vitroat a particular time (or the time required for in vitro dissolution of a fixed percent of thedose, e.g., T %) and a summary parameter that characterizes the in vivo time 50 course (e.g.,C or AUC).
Lot:A batch, or a specific identified portion of a batch, having uniform character and qualitywithin specified limits or, in the case of a drug product produced by continuous process, aspecific identified amount produced in a unit of time or quantity in a manner that assures itshaving uniform character and quality within specified limits.
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Mean absorption time:The mean time required for drug to reach systemic circulation from the time of drugadministration. This term commonly refers to the mean time involved in the in vivo releaseand absorption processes as they occur in the input compartment and is estimated asMAT = MRT - MRT oral i.v.
Mean in vitro dissolution time:The mean time for the drug to dissolve under in vitro dissolution conditions.
Mean in vivo dissolution time:For a solid dosage form: MDT = MRT - MRT . This solid solution reflects the mean time fordrug to dissolve in vivo.
Mean residence time:The mean time that the drug resides in the body. MRT may also be the mean transit time.MRT = AUMC/AUC.
Narrow therapeutic index drugs:Drugs having, for example, less than a two-fold difference in the minimum toxicconcentrations and the minimum effective concentrations.
Nonrelease controlling excipient (noncritical compositional variable):An inactive ingredient in the final dosage form that does not significantly affect the releaseof the active drug substance from the dosage form.
Release mechanism:The process by which the drug substance is released from the dosage form.
Release rate:Amount of drug released per unit of time as defined by in vitro or in vivo testing.
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Statistical moments:Parameters that describe the characteristics of the time courses of plasma concentration(area, mean residence time, and variance of mean residence time) and of urinary excretionrate.
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